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Summary	  
Mycobacterium	  tuberculosis	  (Mtb)	  is	  a	  pervasive	  human	  pathogen	  that	  continues	  to	  kill	   1.8	  million	  people	   every	  year.	  Acquisition	  of	   iron	  within	   the	  host	   is	   vital	   to	   the	  pathogenicity	   of	   Mtb	   and	   to	   accomplish	   this	   it	   produces	   siderophores	   called	  mycobactins	   and	   carboxymycobactins.	   This	   dissertation	   has	   sought	   to	   build	   a	   simple	  assay	  for	  detection	  and	  quantification	  of	  mycobacterial	  siderophores	  that	  has	  potential	  applications	   in	   tuberculosis	   (TB)	   diagnosis.	   This	   assay	   has	   been	   tested	   and	   was	  successfully	  able	  to	  detect	  mycobactin	  spiked	   into	  a	  biological	  specimen.	  Furthermore,	  the	   theoretical	   level	   of	   mycobactin	   production	   that	   occurs	   in	   the	   lungs	   of	   infected	  patients	  was	  estimated.	  Samples	  were	  obtained	  from	  infected	  animal	  models	  of	  TB	  and	  human	  patients	   and	   tested	   for	  presence	  of	  mycobactin	   and	   carboxymycobactin.	  These	  data	   provided	   information	   regarding	   the	   potential	   use	   of	   siderophores	   as	   diagnostic	  biomarkers	  for	  TB.	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  bovine	  serum	  FDG	   Fludeoxyglucose	  Fe(acac)3	   Ferric	  acetylacetonate	  Fe(CN)6	   Ferricyanide	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  mycobactin	  S	  FeSMT	   Ferric	  synthetic	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  transferred	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  Institute	  of	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  and	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  Diseases	  NIDDK	   National	  Institute	  of	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  Kidney	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  NIH	   National	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  NMR	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  magnetic	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  spectroscopy	  NTA	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  OD650	   Optical	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  PET	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R	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  RT	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  S/N	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  noise	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  SCM	   Synthetic	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  SDS-­‐PAGE	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  T	  SMT-­‐C6	   Synthetic	  mycobactin	  T	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  C6	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  tail	  
T	   Absolute	  temperature	  TB	   Tuberculosis	  disease	  THF	   Tetrahydrofuran	  TLC	   Thin	  layer	  chromatography	  TOF	   Time-­‐of-­‐flight	  UV	   Ultra-­‐violet	  WHO	   World	  Health	  Organization	  XPS	   X-­‐ray	  photoelectron	  spectroscopy	  
βII	   Formation	  constant	  for	  the	  complex	  with	  Fe2+	  
βIII	   Formation	  constant	  for	  the	  complex	  with	  Fe3+	  
βv	  and	  βw	   Apparent	  transfer	  coefficients	  ν	   Scan	  rate	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1 Introduction	  
Mycobactins	  are	  vital	  iron-­‐harvesting	  molecules	  secreted	  by	  mycobacteria.	  These	  unique	  natural	  products	  have	  garnered	  much	  attention	  over	  the	  past	  100	  years	  because	  of	   their	   importance	   to	   the	   growth	   and	   pathogenesis	   of	   Mycobacterium	   tuberculosis	  (Mtb),	   the	   etiological	   agent	   of	   tuberculosis	   (TB).	   Despite	   this,	   there	   is	   currently	   no	  simple	  assay	  for	  detection	  and	  quantification	  of	  mycobactin.	  The	  research	  described	  in	  this	  dissertation	  has	  been	  directed	  toward	  the	  development	  of	  an	  electrochemical	  assay	  to	  detect	  these	  siderophores	  and	  investigation	  of	  its	  potential	  application	  and	  problems	  in	  TB	  diagnostics.	  
1.1 Tuberculosis	  TB	   has	   ravaged	   humanity	   from	   before	   the	   beginning	   of	   history	   and	   has	   been	  implicated	  in	  the	  deaths	  of	  millions,	  ranging	  from	  Homo	  erectus1	  and	  	  Neolithic	  settlers2	  to	   Immanuel	   Kant	   and	   Erwin	   Schrödinger.	   In	   the	  most	   highly	   developed	   areas	   of	   the	  word	  the	  incidence	  of	  TB	  has	  finally	  been	  reduced	  yet	  the	  bacterium	  continues	  to	  infect	  fully	   one-­‐third	   of	   the	   global	   population	   and	   kill	   1.8	  million	   people	   every	   year3.	   Areas	  with	  particularly	  high	  TB	  burdens	  include	  Sub-­‐Saharan	  Africa	  and	  Southeast	  Asia,	  as	  can	  be	  seen	  in	  Figure	  1.	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Figure	  1:	  Global	  incidence	  (bubble	  temperature	  map)	  and	  prevalence	  (bubble	  size)	  of	  TB	  by	  
country	  and	  population.	  Data	  from	  the	  World	  Health	  Organization	  (WHO,	  2007)	  visualised	  by	  
Gapminder	  World,	  powered	  by	  Trendalyzer	  from	  www.gapminder.org.	  
1.1.1 Anatomy	  of	  the	  Infection	  TB	  is	  a	  lung	  disease	  spread	  by	  expulsion	  (often	  exacerbated	  by	  coughing)	  of	  fine	  droplets	   containing	   Mtb	   organisms,	   which	   can	   be	   inhaled	   by	   nearby	   individuals4.	  Typically	   TB	   is	   spread	   to	   other	   individuals	  who	   spend	   time	   in	   close	   proximity	   to	   the	  initially	   infected	  person.	  Once	   infection	   is	   established,	   it	  may	   either	   be	   cleared	  by	   the	  immune	  system,	  progress	  to	  active,	  clinically	  symptomatic	  TB,	  or	  remain	  asymptomatic	  as	  a	  so-­‐called	  ‘latent’	  infection5.	  It	  is	  estimated	  that	  there	  is	  a	  10	  percent	  chance	  of	  latent	  infection	   progressing	   to	   symptomatic	   TB	   over	   the	   course	   of	   a	   lifetime,	   with	   the	   risk	  decreasing	  with	  time	  after	  initial	  infection.	  However,	  weakening	  of	  the	  immune	  system,	  such	  as	  that	  which	  occurs	  during	  HIV	  progression,	  can	  lead	  to	  a	  greatly	  increased	  risk	  of	  the	  Mtb	  infection	  ‘reactivating’5.	  This	  has	  led	  to	  a	  great	  number	  of	  clinical	  TB	  cases	  and	  deaths	  in	  populations	  that	  have	  high	  rates	  of	  Mtb	  and	  HIV	  coinfection	  and	  contributed	  to	  a	   global	   resurgence	   of	   TB3.	   Symptoms	   of	   TB	   include	   persistent	   cough,	   night	   sweats,	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weight	   loss,	   and	   fever6.	   Progressive	   destruction	   of	   lung	   tissue	   can	   ultimately	   lead	   to	  death.	  
Mtb	  cells	  living	  within	  the	  lung	  are	  typically	  characterised	  as	  residing	  in	  alveolar	  macrophages,	   which	   as	   adaptive	   immunity	   develops,	   are	   surrounded	   by	   infiltrating	  inflammatory	   cells	   forming	   a	   granulomatous	   structure	   as	   the	   host	   immune	   system	  attempts	   to	   eliminate	   or	   wall	   off	   the	   infection.	   Recent	   advances	   in	   biomedicine	   have	  enabled	   a	  much	   greater	   understanding	   of	   the	  microenvironment	   of	   the	   host	   in	  which	  
Mtb	   lives,	   and	   it	   is	   now	   thought	   that	   Mtb	   inhabits	   a	   variety	   of	   different	  microenvironments	   within	   the	   lung	   associated	  with	   different	   types	   of	   granulomatous	  tissue5.	  This	  also	  brings	  into	  question	  the	  dichotomy	  of	  ‘latent’	  and	  ‘active’	  clinical	  TB.	  In	  fact	  there	  is	  growing	  evidence	  that	  Mtb	  infecting	  the	  human	  lung	  creates	  a	  spectrum	  of	  disease	   from	   aggressively	   progressing	   clinical	   disease,	   through	   a	   slowly	   dividing	  community	  of	  organisms	  at	  the	  subclinical	  level,	  to	  an	  infection	  that	  has	  been	  completely	  cleared	  from	  a	  calcified	  lesion5.	  The	  immunology	  of	  TB	  is	  complex.	  Mtb	  produces	  some	  of	  the	  most	  inflammatory	  compounds	   that	   are	   known;	   so	   powerful	   that	   they	   are	   often	   used	   as	   immunologic	  adjuvants	   for	   the	  administration	  of	  vaccines	  and	  other	   treatments7.	  There	   is	  mounting	  evidence	  that	  Mtb	  uses	  the	  host	  immune	  system	  to	  its	  advantage8	  by	  using	  its	  own	  lipids	  and	   proteins	   to	  modulate	   the	   host	   immune	   response9.	  Mtb	   may	   seek	   to	   use	   the	   host	  response	   to	   wall	   itself	   off	   within	   granulomas	   where	   it	   can	   maintain	   a	   persistent	  population	  for	  long	  periods	  of	  time10.	  It	  is	  noteworthy	  that	  the	  immunological	  response	  to	  Mtb	   is	   almost	   exclusively	   cellular;	   few	   antibodies	   are	   raised	   against	   the	   bacterium,	  and	   when	   they	   are	   they	   tend	   to	   come	   in	   the	   later	   stages	   of	   infection	   against	   a	  heterogeneous	   range	   of	   antigens11.	   This	   makes	   the	   development	   of	   antibody-­‐based	  diagnostics	  difficult.	  The	  mycobacterial	  cell	  wall	  of	  Mtb	   is	  particularly	  thick	  and	  waxy;	  having	  a	  thick	  layer	  of	  mycolic	  acids	  outside	  of	  the	  peptidoglycan	  and	  other	  polysaccharide	  layers12	  as	  illustrated	   in	   Figure	   2.	   This	   formidable	   cell	   wall	   makes	   Mtb	   a	   hardy	   organism	   and	  prevents	  many	  drugs	  and	  other	  compounds	  from	  entering	  into	  the	  cytosol	  of	  the	  cell.	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Figure	  2:	  Schematic	  diagram	  of	  the	  mycobacterial	  cell	  wall.	  
1.1.2 Treatment	  TB	   is	   usually	   treatable	   if	   properly	   diagnosed.	   The	   World	   Health	   Organization	  (WHO)	   directly	   observed	   treatment,	   short-­‐course	   (DOTS)	   strategy	   for	   tuberculosis	  control	   calls	   for	   two	  months	   of	   combination	   chemotherapy	  with	   isoniazid,	   rifampicin,	  pyrazinamide,	   and	   ethambutol	   followed	   by	   continuation	   treatment	   for	   either	   four	  months	  with	   isoniazid	   and	   rifampicin	   or	   six	  months	  with	   isoniazid	   and	   ethambutol13.	  This	   prolonged	   treatment	   period	   combined	   with	   what	   can	   be	   a	   high	   and	   nausea-­‐inducing	   pill	   burden,	   as	   well	   as	   the	   potential	   for	   drug	   supply	   interruptions	   over	   the	  extended	   time	   frame	   can	   often	   lead	   to	   inadequate	   or	   incomplete	   treatment.	   Initial	  treatment	   failure,	   in	   turn,	   gives	   rise	   to	  drug-­‐resistant	   strains	  of	  Mtb	   that	   can	  be	  more	  difficult	  to	  treat13.	  
1.1.3 Diagnostics	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settings	   because	   of	   its	   low	   cost15.	   However,	   smear	   microscopy	   is	   time	   and	   labour	  intensive	   and	   produces	   highly	   variable	   results	   with	   an	   estimated	   sensitivity	   of	   31-­‐80	  percent16.	   The	   growing	   prevalence	   of	   smear-­‐negative	   TB	   in	   HIV-­‐positive	   patients	   and	  children	   also	   contribute	   to	   the	   poor	   performance	   and	   variability	   of	   this	   diagnostic	  method15.	  The	   tuberculin	   skin	   test,	   another	   commonly	   used	   indicator	   of	  Mtb	   exposure,	   is	  complicated	  by	  various	   factors	   including	  Bacillus	  Calmette-­‐Guérin	   (BCG)	  vaccine	  cross	  reactivity	  and	  failure	  to	  differentiate	  between	  latent	  and	  active	  TB17.	  It	  is	  vital	  to	  be	  able	  to	  make	  this	  differentiation	  in	  order	  to	  prioritise	  the	  treatment	  of	  clinically	  progressive	  TB13.	  More	  advanced	  tests	  include	  interferon-­‐γ	  release	  assays,	  which	  require	  incubation	  of	  the	  patient’s	  cells	  with	  Mtb	  components	  and	  measurement	  of	  any	  resulting	  interferon-­‐γ	   release	   to	   gauge	   prior	   exposure18.	   These	   assays	   also	   do	   not	   differentiate	   active	   TB	  cases	   from	   ‘latent’	  cases	  or	  other	  previous	  exposure19	  and	  are	   too	  costly	   to	  be	  used	   in	  resource-­‐poor	  settings,	  thus	  leaving	  these	  communities	  with	  no	  adequate	  means	  for	  TB	  diagnosis.	  The	  recent	  WHO	  endorsement	  of	  nucleic	  acid	  amplification	  tests	  (NAATs)	  such	  as	  the	  Xpert	  MTB/RIF	  assay	  has	  signalled	  the	  biggest	  advance	  in	  TB	  diagnostics	  for	  many	  years,	  however	  the	  assay	  still	  fails	  to	  meet	  the	  requirements	  of	  point-­‐of-­‐care	  diagnostic	  for	   the	   developing	   world.	   It	   is	   still	   relatively	   expensive	   and	   requires	   sophisticated	  equipment	  and	   trained	   technical	  personnel	   to	  operate,	   thus	   it	   is	  not	  suitable	   for	  assay	  delivery	  at	  the	  community	  level20.	  
1.1.3.2 Future	  Techniques	  and	  Potential	  Biomarkers	  One	   of	   the	   most	   difficult	   obstacles	   to	   overcome	   is	   the	   unattractiveness	   of	   the	  market	   in	   the	   low-­‐cost	   sector	   and	   the	   reluctance	   of	   private	   industry	   to	   expend	  significant	   resources	   in	  development	   and	   regulatory	   approval	  processes	   for	   a	  product	  aimed	  for	  delivery	  to	  impoverished	  settings21.	  This	  is	  in	  spite	  of	  the	  fact	  that	  the	  global	  market	   for	  TB	  diagnostics	   is	   estimated	   at	   $1	  billion,	   and	  $326	  million	  of	   that	   is	   spent	  outside	   of	   established	   market	   economies,	   where	   73	   percent	   of	   TB	   diagnostic	   testing	  currently	  takes	  place22.	  Fluorescent	  reporters	  for	  β-­‐lactamase	  detection	  have	  been	  used	  to	  visualise	  Mtb	  infections	   in	   vivo	   within	   living	   mice23	   and	   could	   hold	   promise	   for	   improving	   the	  sensitivity	  of	  fluorescent	  microscopy-­‐based	  diagnoses.	  More	  interesting,	  is	  the	  potential	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for	   this	   strategy	   to	   produce	   a	   point-­‐of-­‐care	   assay	   that	   does	   not	   require	   the	   use	   of	  expensive	  and	  bulky	  fluorescent	  technology	  in	  the	  field.	  This	  might	  be	  achieved	  through	  future	   development	   of	   new	   substrates	   for	   β-­‐lactamase	   that	   utilise	   chemiluminescence	  rather	  than	  fluorescence	  detection.	  Recently	   there	   has	   been	   a	   great	   deal	   of	   interest	   in	   detection	   of	  lipoarabinomannan	   (LAM)	   in	   the	   urine	   of	   TB	   patients	   for	   diagnostic	   use.	   LAM	   is	   a	  glycolipid	  antigen	  produced	  by	  Mtb24	  and	  exported	  into	  its	  environment	  within	  the	  host8	  perhaps	   for	   the	  purpose	  of	   inhibiting	  macrophage	  activation	  and	  T	  cell	  proliferation25.	  This	  would	  allow	  the	  bacterium	  to	  extend	  its	  inhabitation	  of	  the	  host	  cell.	  Recent	  studies	  of	   LAM	  detection	   by	   enzyme-­‐linked	   immunosorbent	   assay	   (ELISA)	   showed	   promising	  results	   in	   the	   prediction	   of	   mortality	   in	   HIV-­‐infected	   individuals	   with	   low	   CD4	   cell	  counts26.	   This	   could	   be	   useful	   in	   that	   these	   patients	   are	   difficult	   to	   diagnose	   by	   other	  methods,	   thus	   providing	   additive	   utility,	   however	   detection	   of	   LAM	   in	   patients	   with	  normal	   CD4	   counts	   was	   less	   promising.	   LAM	   detection	   by	   other	   means	   remains	   a	  hopeful	  target	  for	  the	  development	  of	  TB	  diagnostics	  and	  there	  is	  work	  currently	  being	  done	  to	  develop	  a	  lateral	  flow	  point	  of	  care	  diagnostic	  based	  on	  direct	  detection	  of	  this	  lipidic	  Mtb	  antigen27.	  Siderophores	  are	  another	  class	  of	  lipidic	  Mtb	  products	  that	  have	  been	  heretofore	  unexplored	   as	   potential	   diagnostic	   biomarkers	   for	   TB.	   They	   are	   also	   produced	  specifically	  for	  excretion	  in	  that	  they	  must	  collect	  extracellular	  iron	  and	  return	  it	  to	  the	  bacterium24.	  Because	  of	  their	  iron-­‐binding	  ability	  and	  potential	  for	  redox	  chemistry,	  they	  provide	  an	  interesting	  and	  promising	  analyte	  to	  explore	  by	  electrochemical	  methods.	  An	  electrochemistry-­‐based	  sensor	   for	  mycobactin	  would	  be	  well	  suited	   for	  deployment	   to	  the	  developing	  world	  due	  to	  its	  low	  cost	  and	  potential	  for	  point-­‐of-­‐care	  use	  by	  untrained	  operators	  and	  such	  an	  assay	  could	  open	   the	  door	   for	  an	  exciting	  new	  modality	   for	  TB	  diagnosis.	  
1.2 Siderophores	  and	  Mycobactin	  Iron	  is	  a	  vital	  nutrient	  for	  the	  growth	  of	  mycobacteria,	  just	  as	  it	  is	  for	  other	  fungi	  and	  bacteria.	   It	   is	  necessary	   for	  the	   function	  of	  many	  essential	  enzymes	  and	  metabolic	  processes	  vital	  to	  the	  survival	  and	  growth	  of	  the	  organism.	  The	  advent	  of	  oxygen	  on	  our	  planet	  facilitated	  the	  easy	  oxidation	  of	  iron	  into	  its	  insoluble	  ferric	  form.	  This	  new	  state	  of	  insolubility	  turned	  iron	  into	  a	  rare	  and	  growth-­‐limiting	  resource28.	  To	  overcome	  this	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deficiency,	  fungi	  and	  bacteria	  have	  evolved	  high-­‐affinity	  iron-­‐chelating	  molecules	  called	  siderophores	  to	  harvest	  the	  iron	  that	  they	  require	  from	  their	  environment29.	  The	   lipidic	   siderophores	   of	   the	   mycobacteria	   are	   known	   as	   mycobactins.	  Extensive	  research	  has	  been	  conducted	  on	   them	  since	   their	   initial	  discovery	   in	  191230	  and	  isolation	  in	  195331.	  Subsequent	  to	  their	  discovery	  it	  was	  postulated	  that	  mycobactin	  analogues	   could	   serve	   as	   vehicles	   for	   drug	   delivery	   to	   pathogenic	   mycobacteria.	  Mycobactins	   were	   among	   the	   first	   examples	   of	   microbial	   growth	   factors,	   allowing	   in	  
vitro	   culture	  of	  Mycobacterium	  avium	   subsp.	  paratuberculosis	   for	   the	   first	   time.	  For	  25	  years	  scientists	  at	   Imperial	  Chemical	   Industries	   led	  by	  Alan	  Snow	  worked	   to	  elucidate	  the	   properties	   of	   these	   compounds.	   The	   culmination	   of	   this	   work	   was	   an	   exacting	  analysis	  of	  mycobactins	   from	  many	  different	  species	  of	  mycobacteria;	   the	  methods	   for	  their	   production	   and	   purification;	   and	   ascertainment	   of	   their	   physical	   and	   chemical	  properties32.	  Interest	  in	  mycobactin	  and	  mycobactin	  biosynthesis	  intensified	  after	  mycobactin	  was	  determined	  to	  be	  essential	  for	  the	  pathogenicity	  of	  Mtb33.	  Mycobactin	  biosynthesis	  is	  now	  one	  of	  the	  best-­‐characterised	  nonribosomal	  polypeptide/polyketide	  syntheses	  in	  nature.	   A	   host	   of	   structurally	   related	   siderophores	   have	   since	   been	   discovered,	   as	  summarised	   in	   Table	   1.	   This	   dissertation	   focuses	   the	   siderophores	   produced	   by	  Mtb,	  which	  are	  most	  closely	  related	  to	  those	  of	  other	  mycobacteria	  and	  nocardiae,	  both	  of	  the	  suborder	  corynebacterineae.	  
Table	  1:	  Siderophore	  classes	  isolated	  from	  different	  organisms	  of	  the	  Actinobacteria	  and	  
Proteobacteria	  phylums.	  
Organism	   Siderophore	  Class	  Mycobacteria	   Mycobactin,	  carboxymycobactin	  (also	  called	  exomycobactin)	  Mycobacteria	  (saprophytic	  sp.)	   Exochelin34	  Nocardiae	   Nocobactin35,	  nocardichelins36	  
Pseudomonas	  aeruginosa	   Pyochelin37	  
Agrobacterium	  tumefaciens	   Agrobactin38	  
Vibrio	  cholerae	   Vibriobactin39	  
Vibrio	  anguillarum	   Anguibactin40	  Yersiniae	   Yersiniabactin41	  Marinobacteria	   Marinobactin42	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1.2.1 Structure	  The	   core	   structure	   of	   mycobactin	   is	   shown	   in	   Figure	   3A.	   The	   core	   consists	   of	  salicylate	  linked	  to	  an	  oxazoline	  ring,	  followed	  by	  a	  linear	  lysine	  residue	  and	  a	  butyrate	  capped	  with	  a	  seven-­‐membered	  ring	  formed	  out	  of	  a	  cyclised	  lysine.	  The	  linear	  lysine	  is	  acylated	   at	   R1;	   this	   is	   the	   position	   of	   the	   long	   alkyl	   chain	   in	   most	   mycobactins.	   The	  butyrate	   subunit	   is	   the	  most	   diversely	   substituted	   and	   chirally	   variable	   section	   of	   the	  molecule	  and	  is	  the	  only	  subunit	  not	  derived	  directly	  from	  an	  amino	  acid.	  Both	  the	  cyclic	  and	   linear	   lysine	   residues	   are	   N6-­‐hydroxylated	   to	   form	   the	   two	   hydroxamate	   metal	  coordination	  sites.	  These,	  together	  with	  an	  oxazoline-­‐phenolate	  coordination	  site,	  serve	  to	  make	  mycobactin	  a	  hexadentate	  metal	  coordinator	  with	  an	  extremely	  high	  formation	  constant	   for	   complexation	   of	   Fe3+	   (4×1026	  M-­‐1)43.	   Each	   species	   of	   mycobacteria	   has	   a	  defined	  set	  of	  R2-­‐6	  substituents,	  while	  the	  alkyl	  chain	  at	  R1	  can	  vary	  in	  length	  (C14-­‐20)	  and	  degree	  of	  unsaturation.	  It	  is	  common	  for	  the	  alkyl	  chain	  to	  contain	  a	  cis	  double	  bond	  in	  the	   α-­‐β	   position32.	   Figure	   3B	   shows	   an	   example	   of	   a	   fully	   substituted	   molecule	   of	  mycobactin	  T	  from	  Mtb.	  Mycobactin	   complexes	   are	   stable	   when	   bound	   to	   iron,	   but	   dissociate	   in	   acidic	  conditions44.	  The	  desferri	  form	  of	  mycobactin	  is	  moderately	  stable	  to	  acid,	  but	  degrades	  easily	  when	  exposed	  to	  base32.	  The	   configuration	   of	   the	   alkyl	   tail	   is	   critical	   for	   utilisation	   of	   mycobactins	   by	  mycobacteria45.	   Carboxymycobactins	   have	   shorter	   alkyl	   chains	   at	   R1	   (C2-­‐13)	   that	  terminate	   in	   either	   a	   carboxylic	   acid46	   or	   a	   methyl	   ester47.	   Carboxymycobactins	   are	  much	  more	  water-­‐soluble	  than	  mycobactins,	  but	  the	  distinct	  functional	  role	  of	  these	  two	  forms	   is	   still	   unknown.	   Carboxymycobactins	   were	   once	   thought	   to	   occur	   only	   in	  pathogenic	   mycobacteria,	   but	   have	   since	   been	   isolated	   from	   the	   non-­‐pathogenic	   M.	  
smegmatis48.	  The	   siderophores	  of	  M.	  marinum	   and	  most	  nocardiae	  possess	   their	  major	   alkyl	  chain	  at	  R5	  instead	  of	  R1,	  and	  those	  of	  nocardiae	  may	  have	  an	  additional	  double	  bond	  in	  the	   oxazoline	   ring	   between	   a	   and	   b.	   The	   stereochemistry	   of	   the	   chiral	   centres	  investigated	  thus	  far	  have	  conformed	  to	  the	  naturally	  occurring	  L-­‐series	  of	  amino	  acids	  from	  which	  mycobactin	  is	  derived.	  The	  chiral	  centres	  d	  and	  e	  result	  from	  the	  action	  of	  a	  polyketide	  synthase,	  allowing	  their	  chiralities	  to	  fluctuate	  from	  species	  to	  species.	  Table	  2	  lists	  species	  of	  mycobacteria	  and	  nocardia	  that	  produce	  mycobactin-­‐like	  siderophores	  and	  the	  details	  of	  their	  molecular	  substituents	  that	  have	  been	  reported	  in	  the	  literature.	  





Figure	  3A:	  Structure	  of	  mycobactin	  with	  coordination	  ligands	  shown	  in	  red49,	  and	  chiral	  centres	  in	  blue.	  B:	  Mycobactin	  T	  from	  M.	  tuberculosis.	  
Table	  2:	  Mycobactins	  and	  nocardial	  siderophores	  with	  similar	  known	  structures.	  The	  substituents	  are	  given,	  as	  well	  as	  the	  chirality	  of	  each	  stereo	  centre	  
denoting	  either	  the	  D/L	  configuration	  of	  its	  parent	  amino	  acid,	  or	  the	  R/S	  absolute	  configuration	  where	  appropriate	  and	  known.	  
Species	   Siderophore	  Name	   R1	  
R1	  Unsat.	  
Pos.	   R2	   R3	   R4	   R5	   R6	   a	   b	   c	   d	   e	   f	  
Mycobacterium	  africanum	   Mycobactin	  T50	  (see	  below)	  
M.	  aurum	   Mycobactin	  A44	   C14	   2	  ×	   CH3	   H	   	   CH3	   H	   -­‐	   	   	   	   -­‐	   	  
M.	  avium	  subsp.	  avium	   Mycobactin	  Av51,	   C15,C18	  C14-­‐17	   Sat	  α-­‐β	   H	   CH3	   	   C2H5	   CH3	   	   	   	   	   	   	  
	   Carboxymycobactin	  MA46,	  51	   (CH2)1-­‐11	  COOH	  (CH2)2-­‐6	  COOCH3	   Sat	  and	  unsat	   H	   CH3	   	   C2H5	   CH3	   	   	   	   	   	   	  
M.	  avium	  subsp.	  
paratuberculosis*	  
Mycobactin	  J52-­‐54	   C15	   α-­‐β	   H	   CH3	   	   C2H5	   CH3	   R	   S	   S	   R	   S	   S	  
M.	  bovis	   Mycobactin	  T50	  (see	  below)	  
	   Carboxymycobactin55	   (CH2)3-­‐9	  COOH	  (CH2)3-­‐6	  COOCH3	   Sat	  and	  unsat	   H	   H,	  CH3	   	   CH3	   H	   	   	   	   	   -­‐	   	  
M.	  farcinogenes	   Mycobactin	  F44,	  56	   C10-­‐18	   Unspecified	   H	   CH3	   	   CH3	   H	   	   	   	   S	   -­‐	   L	  
M.	  fortuitum	   Mycobactin	  H57	   C18,	  C20	   Unspecified	   CH3	   CH3	   H	   CH3	   H	   R	   L	   L	   S	   -­‐	   L	  
	   (also	  produces	  mycobactin	  F,	  above44,	  56)	  
M.	  intracellulare	   Mycobactin53	   Unsat	  alkyl	   α-­‐β	   H	   CH3	   H	   Sat.	  alkyl	   CH3	   	   	   	   	   	   	  
M.	  kansasii	   Mycobactin	  K44	   Not	  reported	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Species	   Siderophore	  Name	   R1	  
R1	  Unsat.	  
Pos.	   R2	   R3	   R4	   R5	   R6	   a	   b	   c	   d	   e	   f	  
M.	  marinum	   Mycobactin	  M44	   C2	   None	   H	   CH3	   H	   C15-­‐18	   CH3	   	   	   	   erythro	   	  
	   Mycobactin	  N44	   C3	   None	   H	   CH3	   H	   C15-­‐18	   CH3	   	   	   	   	   	   	  
M.	  phlei	   Mycobactin	  P57	   C14,	  C16,	  C18,	  C20	   2	  ×	  cis	   CH3	   H	   H	   C2H5	   CH3	   -­‐	   L	   L	   S	   R	   L	  
M.	  scrofulaceum	   Mycobactin53	   Unsat	  alkyl	   Unspecified	   H	   H	   H	   Sat.	  alkyl,	  CH3	   CH3	   -­‐	   	   	   	   	   	  
M.	  senegalense	   Mycobactin	  F44,	  56	  (see	  above)	  
M.	  smegmatis	   Mycobactin	  S57	   C14,	  C16,	  C18,	  C20	   2	  ×	  cis	   H	   H	   H	   CH3	   H	   -­‐	   L	   L	   S	   -­‐	   L	  
	   Carboxymycobactin	  MS48	   (CH2)5-­‐12	  COOH	   None	   H	   H	   H	   CH3	   H	   -­‐	   	   	   	   -­‐	   	  
M.	  terrae	   Mycobactin	  R44	   C20	   2	  ×	   H	   H	   H	   C2H5	   CH3	   -­‐	   L	   L	   R	   S	   L	  
M.	  thermoresistibile	   Mycobactin	  H57	  (see	  above)	  
M.	  tuberculosis	   Mycobactin	  T47,	  57,	  58	   C16-­‐21	   Sat	  and	  unsat	   H	   H	   H,	  CH3	   CH3	   H	   -­‐	   	   	   R	   -­‐	   L	  
	   Carboxymycobactin	  MT47	   (CH2)1-­‐7	  COOCH3	   Sat	  and	  unsat	   H	   H,	  CH3	   H	   CH3	   H	   	   	   	   	   -­‐	   	  
Nocardia	  asteroides	   Nocobactin	  NA59	   CH3	   None	   CH3	   H,	  oxazole	   H	   C9-­‐11	   CH3	   	   	   	   	   	   	  
	   Amamistatin	  B60,	  61	   H	   None	   CH3	   CH3,	  oxazole	   H	   C7	   (CH3)2	   -­‐	   -­‐	   	   	   -­‐	   	  
	   Asterobactin62	   H	   None	   H	   No	  oxazoline	   H	   C8	   CH3	   	   	   	   	   	   	  
N.	  brasiliensis	   Nocobactin	  NB63	   Alkyl	   None	   H	   H	   H	   Alkyl	   CH3	   	   	   	   	   	   	  
	   Brasilibactin	  A64,	  65	   H	   None	   H	   H	   H	   C15	   CH3	   -­‐	   	   	   	   	   	  
N.	  caviae,	  N.	  phenotolerans	   Nocobactin	  NC63	   Alkyl	   Sat	  and	  unsat	   H	   H,	  CH3	   H	   H,	  CH3	   H	   	   	   	   	   	   	  
N.	  sp.	  A32030	   BE-­‐3203066	   C12-­‐16	   Varies	   H	   H	   CH3	   CH3	   H	   	   	   	   	   -­‐	   	  
N.	  sp.	  ND20	   Formobactin67	   H	   None	   H	   CH3,	  oxazole	   H	   C9	   (CH3)2	   -­‐	   -­‐	   	   	   -­‐	   	  
N.	  sp.	  TP-­‐A0674	   Nocardimicin68	   CH3	   None	   H	   H,	  oxazole	   H	   C9-­‐15	   CH3	   -­‐	   -­‐	   	   	   	   	  *Mycobactin	  production	  by	  M.	  avium	  subsp.	  paratuberculosis	  is	  contingent	  upon	  selection	  for	  survival	  in	  iron-­‐free	  media69;	  thus	  several	  variations	  of	  mycobactin	  J	  have	  been	  observed.	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It	   should	   be	   noted	   that	   mycobactin	   J	   is	   the	   only	   mycobactin	   that	   is	   currently	  available	  commercially.	  Mycobactin	  J	  is	  named	  as	  such	  because	  the	  originating	  organism	  was	  known	  as	  M.	  johnei	  (now	  known	  as	  M.	  avium	  subsp.	  paratuberculosis)	  at	  the	  time	  of	  its	   discovery31.	   It	   is	   a	   somewhat	   curious	   phenomenon	   in	   that	   M.	   avium	   subsp.	  
paratuberculosis	   does	   not	   produce	   mycobactin	   in	   vitro	   and	   is	   dependent	   upon	  supplementation	  of	  the	  medium	  by	  mycobactin	  J.	  Mycobactin	  J	  was	  isolated	  from	  certain	  strains	   of	  M.	   avium	   subsp.	  paratuberculosis	   that	  were	   selected	   for	   survival	   in	  media69	  and	  its	  widespread	  use	  in	  culturing	  for	  the	  organism	  that	  causes	  Jöhne’s	  disease	  is	  the	  reason	   why	   it	   is	   now	   produced	   on	   a	   commercial	   scale.	   This	   availability	   makes	  mycobactin	  J	  useful	  for	  mycobactin	  research.	  Despite	   its	   long,	   lipophilic	   tail,	  mycobactin	  has	   a	   strong	   amphipathic	   character.	  All	  of	  the	  hydrophilic	  components	  of	  the	  molecule	  are	  concentrated	  in	  its	  peptidic	  head,	  while	  the	  alkyl	  tail	  provides	  the	  lipophilic	  counterpoint.	  Upon	  binding	  iron,	  many	  of	  the	  hydrophilic	  ligands	  are	  turned	  inward	  to	  coordinate	  the	  central	  iron	  atom49.	  This	  causes	  the	   molecule	   to	   transition	   into	   a	   more	   compact,	   less	   flexible	   conformation	   and	   the	  external	   surface	   to	   become	   dominated	   by	   the	   lipophilic	   character	   of	   the	   alkyl	   chain.	  Figure	   4	   shows	   space-­‐filling	   models	   of	   mycobactin	   T	   before	   and	   after	   binding	   Fe3+.	  Research	  on	  related	  siderophores,	  the	  marinobactins,	  has	  shown	  that	  the	  desferri	  form	  of	   the	   siderophore	   is	   capable	   of	   forming	   micelles42.	   The	   marinobactins	   have	   a	   more	  overall	  hydrophilic	  character	  than	  mycobactins,	  but	  share	  the	  attribute	  of	  a	  single	  C12-­‐16	  alkyl	   chain,	   making	   them	   highly	   amphipathic.	   This	   gives	   rise	   to	   a	   conical	   molecular	  shape	  in	  which	  the	  hydrophilic	  iron-­‐coordinating	  ligands	  are	  spread	  out	  on	  the	  surface	  of	   the	   micelle.	   Upon	   binding	   iron,	   marinobactins	   undergo	   a	   phase	   change	   to	   form	  bilayered	   vesicles42.	   These	   vesicles	   can	   form	   aggregates	   that	   traffic	   back	   to	   the	  organism.	  The	  length	  and	  degree	  of	  unsaturation	  of	  the	  lipophilic	  tail	  plays	  a	  major	  role	  in	   determining	   the	   lipophilicity	   and	   membrane	   permeability	   of	   the	   marinobactins,	  thereby	   affecting	   the	   critical	   concentration	   at	   which	   micelles	   of	   marinobactin	  spontaneously	  form	  and	  bud	  off	  from	  the	  membrane70.	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Figure	  4:	  Mycobactin	  T	  before	  and	  after	  binding	  iron.	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8. The	  fatty	  acid	  is	  transferred	  to	  MbtL	  and	  MbtN	  dehydrogenates	  the	  alkyl	  chain	  while	  it	  is	  bound	  to	  MbtL74.	  9. MbtK	  acylates	  the	  linear	  lysine	  residue,	  attaching	  the	  lipophilic	  alkyl	  chain82.	  10. MbtG	  is	  thought	  to	  hydroxylate	  the	  lysine	  residues	  as	  the	  final	  step	  in	  mycobactin	  synthesis.	  This	  hypothesis	  is	  supported	  by	  evidence	  that	  N6-­‐hydroxylysine	  is	  not	  incorporated	  into	  mycobactin81	  nor	  is	  it	  a	  substrate	  for	  acylation	  by	  MbtK82.	  It	  is	  further	  supported	  by	  the	  discovery	  of	  dideoxymycobactin	  (DDM)83,	  84,	  which	  is	  presumed	  to	  be	  an	  intermediate	  in	  mycobactin	  synthesis.	  Study	  of	  a	  recombinant	  homologue	  of	  MbtG	  has	  also	  demonstrated	  its	  ability	  to	  hydroxylate	  lysine85.	  	   Note	   that	   MbtB,	   D,	   E,	   F	   and	   L	   must	   be	   activated	   with	   4'-­‐phosphopantetheinyl	  cofactors	  before	  they	  can	  participate	  in	  biosynthesis72,	  74.	  The	  precise	  functions	  of	  mbtH	  and	  mbtJ	   are	   still	   unknown,	   but	  mbtH-­‐like	   genes	   in	  Streptomyces	   coelicolor	   have	  been	  found	  necessary	  for	  production	  of	  aminocoumarin86.	  Furthermore,	  genetic	  analysis	  has	  revealed	   that	  MbtH-­‐like	   proteins	   interact	  with	   nonribosomal	   peptide	   synthetases	   that	  contain	  adenylation	  domains87.	  The	  branch	  point	  at	  which	  the	  biosynthetic	  pathways	  of	  mycobactin	  and	  carboxymycobactin	  bifurcate	  is	  also	  unknown.	  Both	   mbt	   operons	   are	   regulated	   by	   IdeR,	   an	   essential	   iron	   regulator	   that	  suppresses	  mycobactin	  synthesis	  both	  in	  the	  presence	  of	  iron	  and	  upon	  exposure	  of	  cells	  to	   oxidative	   stress88.	   During	   oxidative	   stress	   mycobactin	   synthesis	   is	   proposed	   to	   be	  downregulated	  to	  limit	  the	  iron-­‐catalysed	  production	  of	  reactive	  oxygen	  species	  through	  the	   Fenton	   reaction.	   IdeR	   also	   regulates	   other	   genes	   involved	   in	   iron	   acquisition	   and	  storage89,	  90.	  It	   has	   long	   been	   thought	   that	   the	   oxazoline	   ring	   is	   synthesised	   from	   serine	   or	  threonine.	  However,	  the	  antigen	  DDM	  from	  Mtb	  resembles	  mycobactin	  T,	  but	  lacks	  the	  N6-­‐hydoxyl	  groups	  and	  incorporates	  a	  methyl	  group	  in	  the	  R4	  position58,	  83.	  This	  suggests	  the	   involvement	   of	   the	   uncommon	   amino	   acid	   α-­‐methyl	   serine	   in	   mycobactin	  biosynthesis.	   Nuclear	   magnetic	   resonance	   spectroscopy	   (NMR)	   and	   tandem	   mass	  spectrometry	   (MS/MS)	   fragment	   analyses	   of	   DDM	   and	   synthetic	   analogues	   confirmed	  the	  presence	  of	   the	  methyl	   group	   at	  R4.	   The	  only	   other	   report	   of	   a	   substituent	   at	   this	  position	  can	  be	  found	  in	  the	  siderophores	  isolated	  from	  Nocardia	  sp.	  A32030	  that	  also	  exhibit	  a	  methyl	  group	  at	  R4.	  It	  is	  possible	  that	  this	  methyl	  group	  is	  cleaved	  to	  form	  the	  finished	  mycobactin	  T	  structure,	  but	  this	  seems	  unlikely.	  Both	  of	  these	  structures	  were	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elucidated	  using	  modern	  NMR	  technology	  not	  available	  during	  the	  initial	  determination	  of	  the	  mycobactin	  T	  structure91.	  An	   mbtM	   orthologue	   deletion	   (fadD33	   in	   M.	   smegmatis)	   produced	   90%	   less	  mycobactin	  than	  the	  wild	  type,	  and	  only	  produced	  mycobactins	  containing	  the	  saturated	  alkyl	   chain92.	  This	   suggests	   that	  MbtK	   is	   capable	  of	   attaching	  alternative	   substrates	   to	  mycobactin	   that	  do	  not	  result	  directly	   from	  the	  mbt-­2	  pathway.	  However,	   it	   should	  be	  noted	   that	   complementation	  with	   the	  mbtM	   gene	   from	  Mtb	   failed	   to	   restore	  wild-­‐type	  mycobactin	   production	   in	  M.	   smegmatis,	   so	   the	   two	   orthologues	   may	   have	   different	  functions92.	  
Para-­‐aminosalicylic	   acid	   (PAS)	   was	   one	   of	   the	   standard	   drugs	   used	   to	   treat	  tuberculosis	  before	  the	  introduction	  of	  rifampicin	  and	  pyrazinamide93.	  PAS	  is	  thought	  to	  act	  in	  part	  by	  inhibiting	  mycobactin	  synthesis94,	  95.	  While	  shown	  to	  decrease	  mycobactin	  production,	   PAS	   confoundingly	   increases	   production	   of	   carboxymycobactin	   in	   M.	  
smegmatis96.	  The	  mechanism	  through	  which	  this	  occurs	  is	  unknown	  and	  invites	  further	  investigation.	   PAS	   may	   interact	   with	   an	   enzyme	   involved	   with	   the	   differentiation	  between	  mycobactin	  and	  carboxymycobactin.	  Wild	   type	   M.	   avium	   subsp.	   paratuberculosis	   is	   dependent	   on	   exogenous	  mycobactin	  for	  growth	  in	  the	  laboratory.	  Interestingly,	  when	  an	  IS900	  gene	  repeat	  was	  transformed	  into	  M.	  smegmatis,	  the	  property	  of	  mycobactin	  dependence	  was	  conferred	  unto	  the	  recombinant	  strain97.	   IS900	  encodes	  p43,	  a	  protein	  of	  unknown	  function.	  The	  mechanism	  through	  which	  exogenous	  mycobactin	  dependence	  is	  conferred	  is	  unknown,	  but	  merits	   further	   investigation	   as	   a	   route	   toward	  mycobactin	   inhibition.	   p43	  may	  be	  responsible	   for	   the	  mycobactin	   dependence	   and	   slow	   growth	   rate	   of	  M.	   avium	   subsp.	  
paratuberculosis97.	  
1.2.3 Function	  in	  Iron-­acquisition	  by	  Mtb	  Bacteria	  use	  siderophores	  to	  acquire	  iron	  when	  it	  is	  otherwise	  too	  scarce	  in	  the	  surrounding	   environment.	   In	   the	   case	   of	   pathogenic	   mycobacteria,	   the	   scarcity	   is	  compounded	  by	  two	  factors:	  first,	  that	  Fe3+	  has	  very	  low	  solubility	  at	  physiological	  pH98,	  and	   second,	   that	   the	   natural	   host	   response	   to	   infection	   includes	   sequestration	   of	  available	   iron.	   Sequestration	   is	   accomplished	   by	   upregulation	   of	   the	   iron-­‐binding	  proteins	   transferrin,	   lactoferrin,	   and	   ferritin,	   as	  well	   as	   internalisation	  of	   iron	  by	  host	  cells99.	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Mycobactins	  can	  pilfer	  iron	  directly	  from	  all	  three	  of	  these	  proteins	  to	  overcome	  host	   sequestration100.	   There	   is	   also	   evidence	   to	   suggest	   the	   pathogenic	   mycobacteria	  manipulate	  the	  host	  to	  traffic	  iron	  into	  infected	  cells101,	  102.	  Aside	  from	  being	  an	  essential	  cofactor	   in	   many	   metabolic	   processes,	   iron	   is	   especially	   important	   for	   production	   of	  many	   mycobacterial	   lipids.	   Testament	   to	   this	   is	   the	   requirement	   of	   iron	  supplementation	   for	   the	   formation	   of	  M.	   smegmatis	   biofilms103.	   The	   aforementioned	  
mbtB	   deletion	   mutant	   showed	   attenuated	   growth	   in	   low-­‐iron	   conditions	   and	   in	  macrophages33.	  Another	  mutant	   that	   constitutively	  expressed	  a	  homologue	  of	   the	   iron	  repressor	  IdeR	  also	  showed	  attenuated	  growth	  in	  BALB/C	  mice104.	  Gene	  expression	  data	  has	  shown	  that	  mycobacteria	  are	  exposed	  to	  iron-­‐restriction	  in	  human	  macrophages105;	  similar	  data	  supporting	  this	  hypothesis	  have	  been	  reviewed	  by	  Waddell	  and	  Butcher106.	  Furthermore,	   iron	   overload	   has	   long	   been	   associated	   with	   exacerbation	   of	  mycobacterial	   and	   other	   infections	   in	   both	   experimental	   models107,	   108	   and	   clinical	  practice109-­‐111.	   A	   reanalysis	   of	   data	   from	   a	   pre-­‐HIV	   1929	   study	   indicated	   that	   iron	  overload	  significantly	  increased	  the	  risk	  of	  death	  from	  tuberculosis112.	  Most	  compelling	  was	   the	  discovery	   that	   transcripts	   of	  mycobactin	   biosynthesis	   gene	  mbtB	  were	  highly	  elevated	   in	  mice	   and	   to	   a	  more	  moderate	   extent	   in	   human	   clinical	   tissue	   samples113.	  Transcriptional	  analysis	  of	  human	  clinical	   samples	  has	  been	  highly	  variable	   113,	   114.	  All	  these	   data	   support	   that	   iron	   availability	   is	   a	   limiting	   factor	   for	   the	   progression	   of	  mycobacterial	   infections	   and	   the	   idea	   that	   Mtb	   actively	   produces	   mycobactin	   while	  inhabiting	  the	  infected	  lung.	  Despite	   this	   compelling	   evidence	   for	   the	   importance	   of	   mycobactin,	   the	  mbtB	  mutant	   is	   still	   able	   to	   grow	   in	   culture	  medium	   supplemented	   with	   exogenous	   iron33,	  suggesting	   the	   existence	   of	   an	   alternative	   iron	   acquisition	   pathway	   that	   has	   yet	   to	   be	  characterised.	   There	   is	   evidence	   that	   the	   xenosiderophore	   fericrocin	   and	   fungal	  siderophore	   rhizoferrin	   are	   internalised	   by	   M.	   smegmatis115.	   It	   is	   also	   possible	   that	  mycobacteria	  can	  take	  up	  iron	  from	  other	  common	  xenosiderophores	  and	  coordination	  compounds	  that	  might	  be	  found	  in	  their	  immediate	  environment,	  however	  this	  does	  not	  seem	   to	   be	   as	   effective	   as	   mycobactin-­‐mediated	   iron	   acquisition	   in	   iron-­‐restricted	  environments.	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1.2.3.1 Current	  Model	  of	  Mycobacterial	  Iron	  Trafficking	  Conventionally,	  mycobactins	  were	  thought	  to	  be	  associated	  with	  the	  cell	  wall	  and	  membrane	  of	  the	  mycobacteria.	  They	  have	  low	  solubility	  in	  water	  (5-­‐10	  µg/mL)	  and	  are	  typically	  extracted	  from	  the	  cell	  pellet,	  not	  from	  culture	  supernatants32.	  They	  have	  been	  reported	   to	   be	   entirely	   cell-­‐associated	   when	   grown	   in	   the	   absence	   of	   the	   detergent	  Tween,	  but	   can	  be	   found	   in	  culture	   supernatants	  when	  Tween	   is	  added	   to	   the	  growth	  medium116.	  They	  have	  also	  been	  observed	  by	  electron	  microscopy	  to	  exist	  within	  the	  cell	  wall	  near	  the	  cytoplasmic	  membrane117.	  Accordingly,	  mycobactin	  was	  initially	  presumed	  to	   function	  simply	  as	  a	  means	  of	   ferrying	   iron	  across	   the	   thick	  mycobacterial	   cell	  wall	  and	  membrane118.	  ‘Exochelins,’34	   were	   discovered	   in	   1975.	   This	   group	   of	   water-­‐soluble	  siderophores	   is	   now	   known	   to	   consist	   of	   two	   types:	   the	   true	   exochelins	   of	   the	  saprophytic	   mycobacteria,	   which	   are	   structurally	   unrelated	   to	   mycobactins,	   and	   the	  chloroform-­‐extractable	  carboxymycobactins.	  The	  structures	  of	  the	  carboxymycobactins	  were	   elucidated	   in	  both	  M.	  avium46	   and	  Mtb47	   simultaneously	   and	  determined	   to	  be	   a	  variation	   of	   the	   mycobactins.	   To	   date,	   only	  M.	   smegmatis	   is	   known	   to	   produce	   both	  exochelins	  and	  carboxymycobactins119.	  The	   discovery	   of	   extracellular	   siderophores	   brought	   into	   question	   the	  importance	   of	   lipophilic	   mycobactin116.	   Models	   began	   to	   emerge	   in	   which	  carboxymycobactins/exochelins	   scavenged	   iron	   in	   the	   extracellular	   milieu,	   then	  transferred	  it	   into	  the	  cell	  by	  means	  of	  a	  putative	  membrane-­‐spanning	  reductase120.	   In	  the	   case	   of	   excess	   iron	   and	   high	   concentrations	   of	   ferric	  carboxymycobactins/exochelins,	   the	   surplus	   iron	   may	   be	   donated	   to	   mycobactin	  residing	  in	  the	  cell	  membrane	  simply	  as	  a	  type	  of	  reservoir120,	  121.	  However,	  the	  growth	  promoting	   effect	   of	   mycobactin	   could	   not	   be	   ignored,	   and	   more	   recent	   studies	   have	  shown	  that	  mycobactins	  are	  more	  vital	  to	  iron	  acquisition	  than	  are	  exochelins.	  This	  was	  demonstrated	   by	   a	  mycobactin-­‐deficient	  M.	   smegmatis	  mutant	   that	  was	   fivefold	  more	  susceptible	   to	   growth	   inhibition	   by	   the	   iron	   chelator	   ethylenediamine-­‐N,N’-­‐di(2-­‐hydroxyphenylacetic	   acid)	   (EDDA)	   than	   either	   the	   wild	   type	   or	   exochelin-­‐deficient	  mutant92.	  Recently	  an	  ABC	  transporter	  system	  consisting	  of	  two	  proteins,	  IrtA	  and	  IrtB,	  was	  found	   to	   be	   required	   for	   effective	   utilisation	   of	   ferric	   carboxymycobactin	   but	   not	   for	  secretion122.	  The	  same	  study	  also	  found	  that	  mycobactin	  is	  not	  required	  for	  iron	  uptake	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from	  ferric	  carboxymycobactin,	  but	  this	  was	  based	  on	  uptake	  from	  culture	  filtrates,	  not	  purified	   carboxymycobactin.	   Another	   study	   concluded	   that	   IrtA	   specifically	   exports	  siderophores	  and	  IrtB	  in	  conjunction	  with	  Rv2895c	  imports	  ferric	  siderophores123,	  but	  more	   recent	   evidence	   has	   called	   the	   role	   of	   Rv2895c	   into	   question124.	   It	   is	   unknown	  whether	   the	   IrtAB	   system	   transports	   lipophilic	   mycobactins	   in	   addition	   to	  carboxymycobactins.	   Likewise,	   the	   esx-­‐3	   secretory	   system	   has	   recently	   been	  demonstrated	  to	  be	  essential	  for	  iron	  acquisition	  from	  exogenous	  mycobactin125.	  Is	  not	  currently	  known	  whether	   esx-­‐3	   interacts	  directly	  with	  mycobactin,	   or	  may	  export	   the	  machinery	   necessary	   for	   effective	   utilisation	   of	   the	   siderophore,	   such	   as	   a	   putative	  reductase	  or	  other	  iron-­‐trafficking	  entity.	  Figure	   6	   depicts	   a	   model	   of	   conventional	   carboxymycobactin-­‐mediated	   iron	  acquisition.	   Carboxymycobactins	   are	   transported	   out	   of	   the	   bacterium	   by	   means	   of	  IrtAB	  and	  a	  putative	  porin-­‐based	  mechanism120	  or	  other	  as-­‐yet	  undefined	  method.	  The	  carboxymycobactins	  then	  scavenge	  iron	  from	  host	  iron-­‐binding	  proteins,	  either	  within	  a	  macrophage	  or	  in	  the	  relatively	  aqueous	  extracellular	  milieu.	  Ferric	  carboxymycobactins	  are	  then	  either	  transported	  back	  into	  the	  cell	   through	  IrtAB,	  are	  relieved	  of	   iron	  by	  an	  undetermined	  reductive	  process	  in	  the	  periplasm,	  or	  hand	  excess	  iron	  off	  to	  mycobactin.	  Mycobactins	   in	   the	   cytoplasmic	   membrane	   creating	   a	   reservoir	   of	   readily	   accessible	  mycobactin-­‐bound	  ferric	  iron117.	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1.2.3.2 Immunology	  of	  Mycobactin	  It	   was	   not	   known	  whether	  mycobactins	   played	   a	   role	   in	   the	   adaptive	   immune	  response	   until	   the	   discovery	   of	   the	   antigen	   DDM,	   which	   is	   an	   incomplete	   form	   of	  mycobactin.	  Moody	  and	  colleagues	  showed	  that	  DDM	  is	  recognised	  by	  the	  CD1a	  antigen	  display	  protein	  and	  serves	  as	  a	  potent	  T	  cell	  activator58,	   83.	  Natural	  mycobactin	  did	  not	  activate	  T	   cells,	   and	  T	   cell	   activation	   seemed	   to	  be	   sensitive	   to	   the	   length	  of	   the	   alkyl	  chain	   at	  R1.	   T	   cell	   activation	  by	  DDM	  may	  play	   an	   important	   role	   in	   the	  host	   immune	  response	   to	  Mtb	   and	   the	   formation	   of	   granulomas.	   CD1a	   has	   subsequently	   been	   co-­‐crystallised	  with	  a	  synthetic	  DDM	  analogue126.	  The	  crystal	  structure	  of	  this	  analogue	  in	  the	  binding	  pocket	  of	  CD1a	   is	   shown	   in	  Figure	  7.	  The	  DDM	  analogue	   sits	   in	   a	  deep	  A’	  binding	  pocket	  that	  is	  a	  connected	  to	  a	  shallower	  F’	  pocket	  near	  the	  surface	  of	  the	  CD1a	  protein	  and	  allows	  presentation	  of	   the	  peptidic	  portion	  of	  DDM	  to	  T	  cells.	  The	  binding	  pocket	  is	  quite	  rigid	  and	  the	  primary	  interactions	  with	  DDM	  are	  through	  van	  der	  Waals	  forces.	  Hydrogen	  bonding	  also	  occurs	  between	  arginine	  73	  and	  the	  oxazoline	  ring	  of	  the	  molecule,	  and	  between	  serine	  77	  in	  the	  F’	  pocket	  and	  the	  cyclised	  lysine	  moiety.	  	  
	  
Figure	  7:	  DDM	  analogue	  shown	  bound	  to	  the	  CD1a	  T	  cell	  antigen	  display	  protein.	  Lipocalin	   2	   (Lcn2,	   also	   called	   siderocalin127,	   neutrophil	   gelatinase-­‐associated	  lipocalin128,	  and	  other	  names129,	  130)	  is	  a	  secreted	  human	  neutrophil	  granule	  protein131.	  It	  is	  secreted	  during	  bacterial	  infection	  as	  part	  of	  innate	  immunity132	  and	  binds	  several	  bacterial	   siderophores	   including	   the	   carboxymycobactins	   of	  Mtb	   and	  M.	   smegmatis127,	  enterobactin	  from	  Escherichia	  coli	  (E.	  coli)133,	  and	  parabactin	  from	  Paracoccus127.	  In	  this	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way,	   Lcn2	   sequesters	   siderophore-­‐bound	   iron	   to	   prevent	   harvest	   by	   the	   bacterium.	  Figure	  8	  shows	  the	  crystal	  structure	  of	  Lcn2	  bound	  to	  ferric	  carboxymycobactin	  T.	  	  
	  
Figure	  8:	  Lcn2	  bound	  to	  ferric	  carboxymycobactin	  T;	  rendered	  from	  Protein	  Data	  Bank	  (PDB)	  
accession	  code	  1X8U127	  using	  Chimera134.	  Lcn2	   is	   released	   from	   neutrophil	   granules	   as	   a	   monomer,	   a	   disulfide-­‐linked	  homodimer,	  or	  a	  heterodimer	  with	  neutrophil	  gelatinase-­‐B128,	  135.	  Neutrophil	  gelatinase-­‐B	   is	  also	  known	  as	  matrix	  metalloproteinase-­‐9	  (MMP-­‐9),	  which	   interestingly,	  has	  been	  shown	  to	  play	  a	  role	  in	  granuloma	  development	  to	  resist	  tuberculosis	  disease136.	  Serum	  concentrations	   of	   Lcn2	   have	   been	   recorded	   as	   high	   as	   404	   ng/mL	   during	   bacterial	  infection	  and	  can	  be	  used	  to	  differentiate	  between	  bacterial	  and	  viral	  infections137.	  Lcn2	   binds	   the	   species	   of	   carboxymycobactin	   that	   contains	   eight	   methylene	  groups	   in	   its	   carboxylated	   alkyl	   chain	   at	   R1.	   Lcn2	   may	   also	   be	   able	   to	   bind	  carboxymycobactins	   of	   slightly	   differing	   chain	   lengths,	   but	   with	   reduced	   affinity127.	  Previously,	  only	  chains	  containing	  up	  to	  seven	  methylene	  groups	  had	  been	  reported	  in	  carboxymycobactin47.	   Lcn2	   knockout	   mice	   have	   greater	   susceptibility	   to	   infection	   by	  
Escherichia	   coli132	   and	   Mtb.138	   Intratracheal	   infection	   with	   Mtb	   yielded	   significantly	  increased	  Mtb	   growth	   in	   alveolar	   epithelium,	   but	   not	   inside	   macrophages.	   The	   Lcn2	  knockout	  mice	  also	  died	  more	  quickly	  than	  wild	  type	  mice.	  It	  has	  been	  suggested	  that	  bacteria	  may	  modify	  their	  siderophores	  specifically	  to	  elude	  capture	  by	  Lcn2139,	  140.	  Although	  this	  has	  yet	  to	  be	  experimentally	  demonstrated,	  it	  could	  account	  for	  the	  diverse	  structural	  variability	  of	  mycobactins,	  even	  within	  a	  single	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species.	  Enterobactin,	  another	  bacterial	  siderophore,	  undergoes	  a	  shift	   in	  coordination	  chemistry	  upon	  acidification	   that	   results	   in	   a	   conformational	   change	  of	   the	  molecules.	  This	  shift	   is	  sterically	   incompatible	  with	  the	  Lcn2	  binding	  pocket,	   leading	  to	  release	  of	  the	   iron	  and	  degraded	  siderophore141.	   It	  has	  yet	   to	  be	  shown	  whether	  or	  not	  a	  similar	  release	   of	   iron	   occurs	   with	   carboxymycobactin.	   There	   is	   no	   evidence	   that	  carboxymycobactin	  undergoes	  a	  similar	  structural	  change,	  but	  carboxymycobactin	  does	  dissociate	   from	   iron	  at	   low	  pH44.	  A	   recent	   study	  examined	   the	   role	  of	  electrostatics	   in	  siderophore	   capture	   by	   Lcn2.	   The	   authors	   concluded	   that	   electrostatic	   attraction	  between	  the	  siderophore	  and	  Lcn2	  binding	  pocket	  is	  important	  for	  siderophore	  binding	  and	  that	  because	  of	   this,	  catecholate	  siderophores	  are	  the	  natural	  prey	  for	  Lcn2,	  while	  hydroxamate	   siderophores	   do	   not	   bind	   as	   well	   because	   the	   complex	   forms	   a	   neutral	  molecule142.	   Conversely,	   mycobactin	   utilises	   a	   primarily	   hydroxamate	   chelation	  modality	   and	   forms	   a	   neutral	   complex	   with	   Fe3+.	   Nevertheless,	   Lcn2	   binds	  carboxymycobactins	  S	  and	  T	  with	  a	  high	  affinity,	  and	  the	  Lcn2	  binding	  pocket	   is	  more	  completely	  filled	  by	  carboxymycobactin	  than	  by	  the	  catecholate	  enterobactin127.	  
1.3 Therapeutic	  Applications	  of	  Mycobactins	  Not	   only	   are	   mycobactins	   vitally	   important	   to	   the	   understanding	   of	  mycobacterial	  diseases,	   such	  as	  TB,	  but	   these	  unique	  natural	  products	  have	  also	  been	  investigated	  for	  a	  variety	  of	  therapeutic	  applications	  that	  span	  the	  gambit	  from	  chelation	  therapy	  agents	  and	  anti-­‐cancer	  agents	  to	  antimicrobials.	  
1.3.1 Chelation	  Therapy	  Chelation	   therapy	   is	   used	   to	   treat	   conditions	   that	   arise	   due	   to	   undesirable	   or	  excess	  quantities	  of	  metal	  within	  the	  body.	  These	  can	  include	  therapies	  for	  heavy	  metal	  toxicity143	   and	   the	   removal	   of	   internal	   radioactive	   contamination.	   Treatment	   for	   the	  removal	  of	  excess	   iron	   is	   the	  most	  common	   type	  of	   chelation	   therapy	  and	   is	   routinely	  carried	  out	  for	  the	  treatment	  of	  acute	  iron	  poisoning	  and	  chronic	  iron	  overload,	  such	  as	  hemochromatosis144.	  Deferoxamine,	  deferasirox,	  and	  deferiprone	  are	  all	  pharmaceutical	  agents	  in	  use	  for	  iron-­‐specific	  chelation	  therapy.	  The	  first	  of	  these	  agents,	  deferoxamine,	  was	  originally	  discovered	  as	   the	  siderophore	  of	  Streptomyces	  pilosus.	  Mycobactin	   is	  an	  excellent	  candidate	  as	  a	  potential	   chelation	   therapeutic	  because	  of	   its	  high	  association	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constant	  for	  iron,	  allowing	  more	  efficient	  use	  of	  the	  agent	  at	  lower	  doses,	  coupled	  with	  its	  high	  degree	  of	  specificity	  for	  iron,	  which	  would	  prevent	  complications	  of	  undesirable	  chelation	  and	  excretion	  of	  other	  metals	  such	  as	  copper	  and	  zinc.	  The	  only	  other	  metals	  that	   mycobactin	   binds	   effectively	   are	   heavy	   metals	   and	   those	   not	   commonly	   found	  within	   the	   body,	   such	   as	   gallium.	   However	   there	   is	   one	   caveat:	   if	   the	   version	   of	  mycobactin	  that	  is	  used	  therapeutically	  is	  able	  to	  be	  taken	  up	  by	  mycobacteria,	  then	  care	  must	  be	  taken	  not	  to	  administer	  mycobactin	  to	  patients	  who	  may	  have	  a	  mycobacterial	  infection.	  This	  could	  risk	  exacerbating	  the	  infection.	  
1.3.2 Mycobactins	  as	  Anti-­Cancer	  Agents	  Iron-­‐chelating	   compounds	   have	   also	   been	   investigated	   for	   their	   anti-­‐cancer	  activities.	   Because	   iron	   plays	   a	   key	   role	   in	   the	   rate-­‐limiting	   step	   of	   DNA	   synthesis	  performed	  by	  ribonucleotide	  reductase,	  cancer	  cells	  have	  an	  increased	  requirement	  for	  iron	  as	  they	  rapidly	  proliferate144.	  Deferoxamine	  and	  other	  conventional	  pharmaceutical	  iron	   chelators	   have	   been	   investigated	   for	   cancer	   treatment145,	   but	   attention	   has	   also	  been	  directed	  at	  mycobactins	  and	  related	  compounds	  for	  this	  purpose.	  The	  lipophilicity	  of	  mycobactin	  makes	  it	  a	  good	  candidate	  to	  enter	  cells	  and	  deplete	  the	  intracellular	  iron	  pools	  of	  cancerous	  cells144.	  Additionally,	  the	  nature	  of	  mycobactin’s	  lipophilic	  tail	  makes	  tailoring	   the	   lipophilic	   character	   of	   mycobactin	   a	   relatively	   simple	   alteration	   in	   the	  synthetic	   process,	   enabling	   the	   siderophore	   to	   be	   tuned	   to	   the	   optimal	   level	   of	  lipophilicity.	  Carboxymycobactins146,	   147	  and	  their	  close	  cousins	   the	  nocardial	  siderophores66,	  148	   have	   been	   repeatedly	   examined	   for	   use	   as	   antitumor	   agents,	   chiefly	   because	   their	  strong	   iron-­‐chelating	   activity	   is	   able	   to	  deprive	   cancer	   cells	   of	   iron.	  This	   inhibits	  DNA	  replication	   by	   limiting	   iron	   availability	   to	   ribonucleotide	   reductase147.	  Carboxymycobactin	   T	   (referred	   to	   as	   exochelin	   in	   the	   study)	   was	   able	   to	   induce	  apoptosis	   of	   human	   breast	   cancer	   cells	   without	   harming	   normal	   breast	   tissue146.	  Carboxymycobactin	   T	   outperformed	   desferoxamine	   as	   a	   ribonucleotide	   reductase	  inhibitor;	   the	   greater	   effect	   was	   attributed	   to	   the	   lipophilicity	   of	   carboxymycobactin	  enabling	   it	   to	   penetrate	   the	   cell	   membrane	   and	   scavenge	   intracellular	   iron,	   whereas	  desferoxamine	  was	  only	   able	   to	   chelate	   extracellular	   iron147.	   Practically	   speaking,	   this	  would	   require	   local	   delivery	   of	   carboxymycobactin,	   since	   any	   carboxymycobactin	  
	  	   38	  
delivered	   systemically	  would	   almost	   certainly	   have	   chelated	   iron	   before	   reaching	   the	  target	  tumour	  cells.	  The	   amamistatins	   of	   N.	   asteroides	   were	   also	   investigated	   for	   their	   antitumor	  activity60,	  61.	  Several	  analogues	  of	  these	  were	  subsequently	  synthesised	  and	  tested149-­‐151.	  Interestingly,	   the	   amamistatin	   fragment	   mentioned	   earlier	   also	   showed	   antitumor	  activity	  and	  histone	  deacetylase	  inhibition,	  which	  did	  not	  seem	  to	  be	  related	  to	  its	  iron	  chelation	  activity150.	  
1.3.3 Antimicrobial	  Potential	  of	  Mycobactins	  and	  Their	  Analogues	  Mycobactin	   analogues	   have	   been	   contemplated	   for	   use	   as	   either	   mycobactin	  synthesis	   inhibitors	   or	   vehicles	   for	   infiltrating	   the	   mycobacterial	   cell	   wall	   to	   deliver	  drugs	   since	   194532.	  Hu	   and	   collaborators	   synthesised	  mycobactin	   S	   and	   unexpectedly	  found	  that	  it	  inhibited	  Mtb	  growth	  with	  99%	  growth	  inhibition	  (MIC99)	  at	  12.5	  µg/mL152.	  This	  inhibition	  was	  not	  due	  simply	  to	  the	  chelation	  effect	  of	  the	  synthesised	  compound	  because	   medium	   iron	   concentrations	   were	   higher	   than	   those	   of	   the	   synthetic	  mycobactin	   S.	   The	   remarkable	   facet	   to	   this	   story	   is	   that	   mycobactin	   S	   is	   identical	   to	  mycobactin	  T	  except	  for	  the	  chiral	  centre	  at	  d	  (see	  Figure	  3).	  It	  should	  be	  noted	  that	  this	  inhibitory	   activity	   has	   not	   been	   confirmed	   with	   naturally	   produced	   mycobactin	   S.	  Spurred	   on	   by	   this	   success,	   Marvin	   Miller’s	   laboratory	   synthesised	   more	   mycobactin	  analogues,	   the	  most	   active	   of	  which	   included	   a	   boc-­‐protected	   amino	   group	   at	   R5	   and	  demonstrated	  a	  MIC99	  of	  less	  than	  0.2	  µg/mL153.	  Transvalencin	  Z	  is	  a	  compound	  that	  was	  isolated	  from	  Nocardia	  transvalensis.	   It	  resembles	  the	  salicyl-­‐oxazoline	  moiety	  of	  mycobactin	  up	  to	  the	  ester	  bond	  but	  lacks	  the	  long	  acyl	  chain.	  This	  compound	  was	  shown	  to	  have	  antimicrobial	  activity154	  and	  may	  act	  by	   interfering	   with	   the	   siderophore	   pathways	   on	   organisms	   with	   siderophores	  containing	   salicyl-­‐oxazoline	   or	   salicyl-­‐thiazoline	   moieties.	   Cross	   reactivity	   of	   this	  structural	   feature	   is	   tentatively	   supported	   by	   the	   finding	   that	   mycobactin	   S	   and	  carboxymycobactin	   S	   induce	   the	   expression	   of	   Pseudomonas	   aeruginosa	  extracytoplasmic	   function	  sigma	   factor	  PA1910155.	  Although	   the	   function	  of	  PA1910	   is	  not	   fully	   understood,	   the	   Pseudomonas	   siderophore	   pyochelin	   also	   contains	   a	   salicyl-­‐thiazoline37.	  This	  suggests	  the	  possibility	  of	  siderophore	  cross	  reactivity	  or	  inhibition.	  The	   idea	   of	   a	   siderophore	   ‘Trojan	   Horse’	   has	   also	   gained	   traction	   as	   a	   way	   to	  transport	   drugs	   that	   would	   otherwise	   fail	   to	   penetrate	   the	  mycobacterial	   cell	   wall.	   A	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number	  of	  these	  compounds	  coupled	  to	  β-­‐lactams	  have	  successfully	  been	  synthesised156.	  Efforts	   to	   create	   therapeutic	   mycobactin	   analogues	   have	   also	   focused	   on	   creating	  competitive	  iron	  chelators	  to	  starve	  the	  bacteria	  of	  iron157.	  Elucidation	   of	   the	   mycobactin	   biosynthetic	   pathway	   kick-­‐started	   the	   hunt	   for	  inhibitors	  against	  enzymes	  within	  this	  system.	  In	  the	  quest	  for	  an	  inhibitor	  of	  salicylate-­‐activating	   enzymes	   (examples	   include	   MbtA	   in	  Mtb	   and	   YbtE	   in	   Yersinia	   pestis),	   two	  independent	  research	  groups	  generated	  the	  same	  bisubstrate	  inhibitor:	  salicyl-­‐5’-­‐O-­‐(N-­‐salicylsulfamoyl)adenosine	  (salicyl-­‐AMS),	  as	  depicted	  in	  Figure	  9B158,	   159.	  This	  inhibitor	  is	  a	  modification	  of	  activated	  salicyl-­‐AMP,	  the	  natural	  product	  of	  MbtA	  (Figure	  9A),	  and	  mimics	   both	   substrates	  while	   occupying	   both	   binding	   pockets	   of	   the	   enzyme.	   Salicyl-­‐AMS	  showed	  inhibitory	  activity	  against	  both	  Mtb	  and	  Y.	  pestis	  under	  low-­‐iron	  conditions,	  but	  only	  against	  Mtb	  under	  iron-­‐supplemented	  conditions158.	  Following	  the	  design	  of	  salicyl-­‐AMS,	  Courtney	  Aldrich	  and	  coworkers	  embarked	  on	   a	   systematic	   exploration	   of	   the	   salicyl-­‐AMS	   structure-­‐activity	   relationship.	   They	  synthesised	  a	  multitude	  of	  analogues	  with	  different	  modifications	  to	  the	  salicyl-­‐glycosyl	  linker159,	   160,	   glycosyl	   subunit161,	   salicyl	   subunit162,	   and	   adenosine	   subunit163,	   164	   of	  salicyl-­‐AMS.	   Luis	   Quadri	   and	   associates	   have	   also	   examined	   analogues	   of	   this	  compound158,	  165.	  The	  results	  suggested	  that	  the	  ribose	  subunit	  is	  critical	  for	  recognition	  by	  a	  putative	  transporter161.	  This	  could	  explain	  the	  ability	  of	  this	  compound	  to	  overcome	  the	   membrane	   permeability	   problem	   that	   has	   plagued	   other	   acyl	   adenylate-­‐based	  inhibitors166.	   Salicyl-­‐AMS	   analogues	   were	   designed	   rationally	   with	   the	   help	   of	   a	  complete	  homology	  model	  of	  MbtA	  based	  on	  the	  crystal	  structure	  of	  DhbE	  from	  Bacillus	  
subtilis	   in	   complex	  with	   an	   adenylated	   2,3-­‐dihydroxybenzoic	   acid.	   This	   epic	   conquest	  came	  to	   its	  dénouement	   in	  a	  compound	  exhibiting	  an	  MIC99	  of	  0.39	  µM	  in	   iron-­‐replete	  conditions	  and	  0.049	  µM	   in	   iron-­‐deficient	   conditions163.	  This	   compound	   is	  depicted	   in	  Figure	  9C.	  The	  potency	  of	  this	  compound	  and	  activity	  under	  both	  iron-­‐replete	  and	  iron-­‐deficient	  conditions	  suggests	  that	  it	  may	  be	  active	  in	  additional	  pathways	  beyond	  MbtA.	  Salicyl-­‐AMS	  has	  also	  been	  tested	  for	  stability	  for	  up	  to	  24	  hours	  in	  human	  plasma	  and	  1	  hour	  in	  human	  liver	  microsomes167.	  	  







Figure	  9A:	  Salicyl-­AMP,	  the	  natural	  product	  of	  MbtA.	  B:	  Salicyl-­AMS,	  the	  MbtA	  bisubstrate	  inhibitor.	  
C:	  2-­Phenyl-­salicyl-­AMS,	  optimised	  inhibitor163.	  Some	  mycobactin	   analogues	   have	   also	   been	   found	   to	   have	  monoamine	   oxidase	  (MAO)	  inhibitory	  properties	  as	  well	  as	  some	  antitubercular	  activity168.	  This	  was	  cited	  as	  a	   possible	   complicating	   factor	   for	   the	   development	   of	   antimicrobials	   based	   on	   these	  scaffolds.	   Siderophores	   from	   Nocardia	   sp.	   TP-­‐A0674	   showed	   inhibitory	   activity	   of	  muscarinic	  M3	  receptor,	  an	  important	  neurotransmitter68.	  The	  muscarinic	  M3	  receptor	  is	   a	   potential	   target	   for	   treatment	   of	   a	   variety	   of	   disorders	   including	   respiratory,	  gastrointestinal,	  and	  urinary	  tract	  disorders68.	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1.5 Use	  of	  Mycobactin	  to	  Detect	  and	  Identify	  Mycobacteria	  Given	   the	   quite	   specific	   structures	   of	   mycobactins	   from	   different	   species	   of	  mycobacteria,	  interrogation	  of	  their	  properties	  by	  thin	  layer	  chromatography	  (TLC)	  and	  NMR	  have	  been	  used	  to	  detect	  and	  differentiate	  mycobacterial	  species.	  Hall	  was	  able	  to	  use	  mycobactin	  as	  a	  specific	  chemotaxonomic	  marker	  to	  differentiate	  17	  closely	  related	  species	  of	  mycobacteria	   via	  TLC171.	   Similarly,	  Barclay	   and	   colleagues	  were	  able	   to	  use	  mycobactin	   TLC	   data	   to	   detect	   and	   identify	   organisms	   from	   the	   M.	   avium,	   M.	  
intracellulare,	  and	  M.	  scrofulaceum	  (MAIS)	  group	  of	  pathogenic	  mycobacterial	  species69,	  and	  Bosne	  and	  Lévy-­‐Frébault	  achieved	  similar	  results	  using	  TLC	  analysis	  of	  mycobactin	  to	  identify	  subspecies	  of	  the	  clinically	  important	  organisms	  M.	  fortuitum	  and	  M.	  chelonae	  from	   patient	   isolates	   and	   environmental	   samples172.	   NMR	   has	   also	   been	   used	   to	  interrogate	   the	   properties	   of	   mycobactins	   from	   different	   species173,	   but	   thus	   far	   no	  studies	  have	  addressed	  the	  potential	  to	  detect	  and	  identify	  mycobactin	  using	  relatively	  simple	   electrochemical	   techniques.	   Together,	   these	   studies	   demonstrate	   that	  mycobactins	  are	  useful	  as	  a	  unique	  marker	  for	  the	  organisms	  that	  produce	  them.	  Methods	  for	  accurate	  detection	  of	  mycobactin	  have	  been	  developed,	  but	  thus	  far	  have	  been	   limited	   in	   their	  utility	  by	  either	   their	   lack	  of	   sensitivity	  or	   the	   requirement	  that	  they	  be	  carried	  out	  in	  an	  analytical	  laboratory	  environment.	  The	  ferric	  mycobactins	  of	  Mtb	  can	  be	  detected	  experimentally	  by	  their	  characteristic	  absorbance	  at	  450	  nm,	  due	  to	   the	   ligand-­‐to-­‐metal	   charge	   transfer	   indicative	   of	   iron-­‐containing	   compounds;	   the	  desferri-­‐	  forms	  lack	  the	  450	  nm	  absorbance	  peak47.	  The	  mycobactins	  also	  have	  a	  major	  absorbance	  peak	  at	  220	  nm,	  indicative	  of	  amide	  and	  aromatic	  groups47.	  This	  allows	  for	  simple	  differentiation	  between	  the	  ferric	  and	  desferri-­‐	  forms.	  Gobin	  and	  coworkers	  used	  a	   combination	   of	   reverse-­‐phase	   high-­‐performance	   liquid	   chromatography	   (HPLC),	  simultaneous	  monitoring	  of	  absorbance	  at	  220	  nm	  and	  450	  nm,	  and	  mass	  spectrometry	  to	  purify	  and	  identify	  mycobactins100.	  A	   radiolabelling	   technique	   was	   first	   proposed	   by	   Snow174	   and	   later	   used	   by	  Ratledge	  &	  Marshall118,	  Barclay	  et	  al.69,	  and	  Raghu	  &	  Sarma175.	  Following	  growth	  of	  Mtb	  in	   iron-­‐deficient	   medium,	   the	   siderophores	   are	   labelled	   using	   55Fe,	   extracted	   using	  chloroform,	   and	   analysed	   using	   a	   liquid	   scintillation	   counter.	   In	   an	   alternative	  radiolabelling	   strategy,	  when	   14C-­‐containing	   salicylic	   acid	   is	   added	   to	  Mtb	   culture,	   the	  salicylic	  acid	   is	   incorporated	   into	  siderophore	  biosynthesis.	  Siderophores	  may	   then	  be	  extracted	   with	   chloroform,	   and	   analysed	   using	   TLC	   and	   PhosophoImager	   for	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quantification33,	   72.	   However,	   this	   technique	   would	   not	   be	   feasible	   for	   detecting	  siderophores	  produced	  in	  vivo.	  A	   chrome	   azurol	   S-­‐shuttle	   solution	   (CAS)	   is	   commonly	   used	   to	   detect	   the	  production	  of	  any	   iron-­‐chelating	  siderophores176.	  When	   the	  siderophores	  chelate	   iron,	  removing	   it	   from	   the	   dye	   complex,	   the	   dye	   changes	   from	   blue	   to	   orange.	   This	   can	   be	  observed	   as	   an	   absorbance	   extinction	   at	   630	  nm176.	   Another	   dye-­‐based	   method	   for	  catechol-­‐based	  siderophores	  is	  to	  use	  the	  Arnow	  assay177.	  Koedam	  et	  al.	  has	  suggested	  a	  method	   combining	   isoelectric	   focusing	   with	   CAS	   overlay	   for	   siderophore	   detection.	  These	   methods	   are	   useful	   for	   certain	   in	   vitro	   applications,	   however	   they	   lack	   the	  sensitivity	  and	  versatility	  required	  for	  many	  other	  uses.	  Lastly,	  a	  proposed	  bioassay	  based	  upon	  the	  growth	  of	  mycobactin-­‐dependent	  M.	  
avium	   subspecies	   paratuberculosis	   was	   developed	   by	   Lambrecht	   and	   Collins178.	   This	  assay	   failed	   to	   detect	   the	   presence	   of	   mycobactin	   in	   infected	   tissue	   samples	   with	   an	  estimated	   sensitivity	   of	   6	  nM	   and	   a	   readout	   time	   of	   21	   days.	   This	   is	   the	   only	   serious	  attempt	  that	  has	  ever	  been	  made	  to	  detect	  the	  presence	  of	  mycobactins	  in	  vivo.	  
1.6 Research	  Objectives	  Mycobactins	  have	  been	  studied	  extensively	  over	  the	  course	  of	  the	  last	  100	  years,	  yet	  many	  mysteries	  still	  surround	  their	  exact	  role	  and	  function	  in	  mycobacterial	  biology	  and	  disease.	  The	  importance	  of	  mycobactin	  in	  pathogenic	  mycobacterial	  diseases	  is	  well	  established,	  and	  the	  evidence	  of	  an	  arms	  race	  between	  pathogen	  and	  host	  is	  fascinating.	  In	  spite	  of	   this,	  mycobactin	  remains	  an	  elusive	  entity	   that	  has	  never	  successfully	  been	  detected	  in	  vivo.	  Given	   the	   necessity	   of	   mycobactin	   production	   and	   secretion	   for	   tuberculosis	  pathology,	   it	  bears	   investigation	  as	   to	  whether	  mycobactin	  might	  be	  used	   for	  a	  simple	  assay	   to	   detect	   and	   quantify	   the	   presence	   of	   mycobacterial	   species,	   particularly	   M.	  
tuberculosis.	  Additionally,	  mycobactin	  is	  an	  important	  natural	  product	  that	  has	  potential	  pharmaceutical	   uses	   for	   chelation	   and	   anti-­‐cancer	   therapy.	   As	   yet,	   there	   is	   no	   simple	  assay	  for	  the	  detection	  and	  quantification	  of	  mycobactin.	  Instead,	  most	  modern	  studies	  have	   relied	  on	  sophisticated	  and	  expensive	  HPLC	   techniques	   to	  detect	  mycobactin.	  An	  inexpensive	   sensor	   for	  mycobactin	  would	   open	   up	   exciting	   possibilities	   for	   a	   new	  TB	  diagnostic	   for	   the	   low-­‐cost	   market.	   Additionally,	   such	   a	   sensor	   would	   help	   to	   finally	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elucidate	   the	   role	   of	   mycobactin	   within	   an	   active	   Mtb	   infection	   by	   allowing	   in	   vivo	  detection	  for	  the	  first	  time.	  The	  goal	  of	  this	  dissertation	  is	  to	  combine	  facets	  of	  analytical	  and	  clinical	  science	  to	  develop	  a	  new	  electrochemical	  assay	  for	  mycobactin	  and	  to	  test	  the	  relevance	  of	  that	  assay	   to	   the	   measurement	   of	   Mtb	   infection.	   This	   would	   serve	   as	   a	   potential	   new	  diagnostic	   modality	   for	   TB.	   Thus,	   the	   objectives	   of	   this	   dissertation	   include	   both	   the	  assay	  development	  and	  an	  evaluation	  of	  mycobactin	  as	  an	  analytical	   target	   through	   in	  
vitro	   estimations	   of	   mycobactin	   production	   and	   testing	   clinical	   specimens	   for	   the	  presence	   of	   mycobactin.	   Ultimately,	   this	   dissertation	   aims	   to	   draw	   conclusions	  regarding	   diagnostic	   approaches	   to	   TB	   and	   to	   propose	   future	   strategies	   for	   assay	  development.	  	   In	   line	   with	   the	   goals	   stated	   above,	   the	   research	   reported	   in	   this	   dissertation	  investigates:	  	   1. The	  physiological	  level	  of	  mycobactin	  production	  in	  infected	  tissues	  to	  elucidate	  its	  role	  in	  Mtb	  infection	  based	  on	  in	  vitro	  data	  by:	  a. Studying	  the	  production	  of	  mycobactin	  by	  Mtb	  under	  different	  conditions.	  b. Developing	  a	  framework	  to	  understand	  how	  the	  conditions	  inside	  an	  actively	  infected	  lung	  will	  affect	  the	  expression	  of	  mycobactin	  and	  determine	  what	  levels	  of	  mycobactin	  might	  be	  expected	  within	  the	  local	  tissues.	  	   2. The	  electrochemical	  properties	  of	  mycobactin	  to	  determine	  whether	  an	  assay	  based	  on	  electrochemical	  interrogation	  of	  the	  iron	  coordination	  complex	  can	  be	  created	  that	  is	  adaptable	  for	  use	  in	  a	  plurality	  of	  sampling	  media	  and	  methods	  of	  mycobactin	  extraction.	  	   3. The	  utility	  of	  the	  assay	  for	  monitoring	  mycobactin	  levels	  within	  an	  example	  biological	  medium.	  	   4. The	  presence	  of	  mycobactin	  and	  carboxymycobactin	  within	  clinical	  specimens	  of	  different	  biological	  media	  from	  TB	  patients	  and	  Mtb	  infected	  animal	  models	  in	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order	  to	  draw	  conclusions	  regarding	  use	  of	  the	  assay	  as	  a	  measure	  of	  Mtb	  infection.	  	   As	   a	   result	   of	   these	   studies,	   strategies	   are	   outlined	   for	   future	   investigation	   of	  mycobactin	  as	  a	  measure	  of	  Mtb	  infection	  and	  preliminary	  scoping	  research	  reported	  to:	  	   1. Develop	  a	  method	  to	  improve	  the	  electrochemical	  assay	  through	  capture	  ligand	  modification	  of	  the	  electrode.	  	   2. Develop	  synthetic	  mycobactin	  and	  carboxymycobactin	  standards	  and	  validate	  their	  function	  in	  Fe	  uptake	  by	  Mtb.	  Based	  on	  these	  data,	  the	  synthetic	  siderophores	  can	  be	  assessed	  as	  potential	  PET	  imaging	  probes	  and	  as	  antigens	  to	  which	  anti-­‐mycobactin	  antibodies	  may	  be	  raised.	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2 Production	  of	  Mycobactin	  In	  Vitro	  
An	   initial	   goal	   of	   this	   dissertation	   was	   to	   obtain	   preliminary	   estimates	   of	   the	  physiological	  level	  of	  mycobactin	  production	  in	  infected	  tissues	  and	  elucidate	  its	  role	  in	  
Mtb	  infection	  based	  on	  in	  vitro	  data.	  In	  order	  to	  best	  inform	  the	  development	  of	  a	  simple	  mycobactin	  assay	  for	  TB	  diagnosis,	  it	  is	  important	  to	  understand	  the	  local	  environment	  of	   Mtb	   living	   within	   the	   lung	   and	   how	   this	   affects	   the	   production	   of	   mycobactin,	  particularly	   in	   regard	   to	   the	   availability	   of	   iron.	   A	   key	   component	   of	   this	   is	   the	  heterogeneous	  nature	  of	  the	  environments	  encountered	  by	  Mtb5,	  which	  make	  prediction	  difficult.	  However,	   as	  discussed	   in	  Section	  1.2.3,	   it	  has	  been	   shown	   that	  Mtb	   increases	  the	  transcription	  of	  mycobactin	  biosynthesis	  genes	  both	  when	  infecting	  macrophages	  in	  
vitro	   and	   within	   the	   human	   lung113.	   This,	   coupled	   with	   the	   established	   necessity	   of	  mycobactin	   production	   for	   the	   pathogenicity	   of	  Mtb	  makes	   it	   clear	   that	   some	   level	   of	  mycobactin	  production	  must	  take	  place	  within	  the	  infected	  lung,	  but	  how	  much?	  Detection	   of	   mycobactin	   produced	   by	   Mtb	   in	   vivo	   has	   thus	   far	   eluded	  researchers178,	   partly	   due	   to	   the	   lack	   of	   an	   effective	   and	   sensitive	   assay	   for	   the	  siderophore.	  However,	  this	  information	  is	  important	  in	  order	  to	  ascertain	  the	  sensitivity	  requirements	  for	  a	  perspective	  diagnostic	  sensor.	  Chapter	  1	  discussed	  the	  environment	  of	   the	   infected	  human	  lung.	  Clearly	  the	  multiple	   local	  microenvironments	   inhabited	  by	  any	   of	   the	   infecting	   bacteria	   present	   a	   complex	   array	   of	   conditions	   in	   which	   the	  organism	  must	  live5.	  In	  that	  context,	  focus	  shall	  be	  maintained	  upon	  investigating	  a	  few	  key	  points	  that	  are	  most	  likely	  to	  affect	  the	  production	  of	  mycobactin:	  	   1. The	  iron-­‐restricted	  environment	  of	  the	  bacteria	  	   2. Their	  inhabitation	  and	  ability	  to	  thrive	  in	  lipid-­‐rich	  environments,	  such	  as	  those	  induced	  within	  foamy	  macrophages	  	   3. The	  metabolic	  need	  for	  iron	  is	  highest	  when	  the	  organism	  is	  dividing	  rapidly	  in	  the	  exponential	  phase	  of	  growth,	  as	  is	  analogous	  to	  a	  rapidly-­‐dividing	  active	  infection	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2.1 Materials	  and	  Methods	  
2.1.1 Culture	  of	  Mycobacterium	  tuberculosis	  The	  laboratory	  strain	  M.	  tuberculosis	  H37Rv	  (ATCC	  27294)	  from	  the	  stocks	  of	  the	  Tuberculosis	   Research	   Section,	   NIAID	   was	   used	   for	   all	   experiments	   unless	   otherwise	  noted.	  An	  mbtB	  mycobactin	  deletion	  mutant	  (ΔmbtB)	  of	  the	  Mtb	  H37Rv	  was	  also	  used	  in	  this	  dissertation33.	  Mtb	  stocks	  were	  grown	  in	  liquid	  Middlebrook	  7H9	  medium	  in	  roller	  bottles	  (Nalgene)	  at	  37°C	  with	  constant	  rolling.	  All	  culturing	  of	  Mtb	  organisms	  took	  place	  in	  the	  BSL3	  biocontainment	  facility	  of	  NIAID.	  
2.1.1.1 Low-­Iron	  Media	  The	   production	   of	   mycobactin	   is	   regulated	   by	   the	   availability	   of	   iron	   to	   the	  organism	   via	   the	   iron-­‐responsive	   IdeR	   regulatory	   pathway88.	   Because	   iron	   is	   a	  micronutrient,	   even	   trace	   quantities	   of	   iron	   can	   dramatically	   affect	   mycobactin	  production.	  Mtb	   exists	   in	   an	   iron-­‐restricted	   state	   in	   vivo.	   For	   the	   in	   vitro	   model	   it	   is	  imperative	  to	  precisely	  control	  the	  iron	  levels	  not	  only	  in	  the	  culture	  medium,	  but	  also	  the	  internal	  iron	  stores	  within	  the	  bacteria.	  Because	   Mtb	   reside	   in	   a	   lipid-­‐rich	   environment	   within	   the	   host,	   it	   was	  hypothesised	   that	   it	  would	   be	  necessary	   to	   take	   steps	   to	  maintain	   the	  mobility	   of	   the	  lipophilic	   mycobactin.	   To	   maintain	   this	   mobility	   in	   the	   relatively	   aqueous	   culture	  medium,	   the	   detergent	   Tween	   80	   was	   included	   in	   the	  medium	   to	   facilitate	   lipophilic	  mycobactin	  mobility.	  This	  can	  have	  the	  effect	  of	  dissociating	  lipophilic	  mycobactin	  from	  the	  cell	  wall,	  as	  may	  also	  be	  the	  case	  inside	  of	  infected	  foamy	  macrophages179.	  Low-­‐iron	  glycerol	  alanine	  salts	  Tween	  (GAST)	  medium	  consisted	  of	  the	  following	  (per	   litre):	   0.3	  g	   of	   Bacto	   Casitone	   (pancreatic	   digest	   of	   casein,	   BD),	   4.0	  g	   of	   dibasic	  potassium	  phosphate,	  2.0	  g	  of	  citric	  acid,	  1.0	  g	  of	  L-­‐alanine,	  1.2	  g	  of	  magnesium	  chloride	  hexahydrate,	   0.6	  g	   of	   potassium	   sulfate,	   2.0	  g	   of	   ammonium	   chloride,	   1.80	  mL	  of	   10	  M	  sodium	  hydroxide,	   10.0	  mL	  of	   glycerol,	   and	  0.5	  mL	  of	  Tween	  8033.	  Note	   that	   50	  mg	  of	  ferric	  ammonium	  citrate	  was	  excluded	  from	  the	  original	  glycerol	  alanine	  salts	  medium	  recipe	  except	  where	  indicated	  as	  ‘iron	  replete’	  GAST.	  All	  ingredients	  were	  purchased	  as	  metals-­‐basis	   pure	   except	   for	   Casitone.	   Where	   indicated,	   hygromycin	   was	   added	   at	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50	  µg/mL.	   Growth	   was	   regularly	   measured	   by	   the	   650	  nm	   absorbance	   of	   the	   culture	  after	  subtracting	  a	  blank	  media	  baseline.	  It	  should	  be	  noted	  that	  citrate	  has	  demonstrated	  a	  low	  to	  moderate	  promotion	  of	  mycobacterial	   growth	   under	   low	   iron	   conditions,	   compared	   with	   a	   high	   growth	  promotion	  effect	  from	  mycobactin115.	  However,	  it	  was	  postulated	  that	  the	  citrate	  effect	  is	  merely	  due	  to	  citrate	  transferring	  iron	  to	  mycobactin.	  
2.1.1.1.1 Effects	  of	  Different	  Media	  Preparations	  In	  order	  to	  establish	  reproducible	  methods	  of	  strict	  iron	  limitation	  in	  the	  media,	  the	  effect	  of	  different	  methods	  of	  media	  preparation	  and	  the	  use	  of	  the	  polyvalent	  metal	  ion	  chelator	  resin	  Chelex	  100	  (Sigma)	  on	  the	  rate	  of	  Mtb	  growth	  were	  measured.	  Where	  indicated,	  the	  water	  or	  water-­‐Casitone	  solution	  used	  to	  make	  the	  GAST	  was	  treated	  by	  shaking	  with	  Chelex	  100	  and	  allowing	  to	  stand	  for	  15	  min	  before	  filtering.	  Except	  where	  indicated,	  GAST	  was	  made	  in	  plastic	  bottles,	  avoiding	  contact	  with	  glassware	  and	  metal	  spatulas.	  
2.1.1.2 Siderophore	  Production	  Two	   different	   batches	   of	   iron-­‐restricted	   Mtb	   cultures	   were	   grown	   for	  comparison.	  Batch	  A	  (4.4	  L)	  was	  growth	  from	  Mtb	  H37Rv	  that	  had	  been	  iron-­‐restricted	  for	   two	   subculture	   periods,	  while	   batch	   B	   (6	  L)	  was	   growth	   from	   cells	   that	   had	   been	  iron-­‐restricted	   for	   seven	   subculture	   periods,	   thereby	   having	   a	   greater	   level	   of	   iron	  starvation.	  The	  growth	  rates	  were	  monitored	  by	  their	  optical	  density	  at	  650	  nm	  (OD650).	  Batch	  A	  was	  harvested	  after	  19	  days	  of	  growth	  at	  which	  point	  the	  culture	  had	  reached	  stationary	   phase.	   Batch	   B	   was	   harvested	   after	   12	   days	   of	   growth	   while	   still	   in	   the	  exponential	  phase.	  
2.1.1.3 Correlation	  of	  Optical	  Density	  and	  Cell	  Mass	  Figure	  10	   illustrates	   the	   correlation	  between	  OD650	   and	   the	  wet	   cell	  mass.	  Wet	  cell	   mass	   measurements	   are	   subject	   to	   a	   high	   degree	   of	   variability	   due	   to	   both	  compositional	   variation180,	   181	   and	   experimental	   error	   due	   to	   loss	   of	   cell	   mass	   and	  reproducibility	  of	  dryness	  associated	  with	  centrifugation	  and	  decanting	  the	  supernatant.	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Figure	  10:	  Correlation	  of	  wet	  cell	  mass	  per	  volume	  with	  650	  nm	  absorbance	  values,	  n	  =	  3.	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2.1.2 HPLC	  Analysis	  
2.1.2.1 HPLC/DAD/MSD	  Instrumentation	  High	   performance	   liquid	   chromatography/mass	   spectrometry	   (HPLC/MS)	  analysis	   was	   performed	   using	   an	   Agilent	   1100	   HPLC/electrospray	   quadrupole	   mass	  detector	   (MSD)	   with	   a	   diode	   array	   detector	   (DAD)	   for	   measurement	   of	   UV-­‐visible	  absorbance.	  The	  column	  used	  was	  a	  2.1	  mm	  x	  50	  mm	  Phenomenex	  Luna(2)	  C18	  column	  with	   3	  µm	   particles	   and	   100	  Å	   pore	   size.	   A	   0.3	  mL/min	   flow	   rate	   was	   used	   and	   the	  column	  temperature	  was	  set	  at	  60°C.	  The	  MSD	  was	  used	  in	  scanning	  mode	  300-­‐750	  m/z	  at	   400	  V	   fragment	   voltage	   and	   751-­‐1500	   m/z	   at	   100V	   fragment	   voltage.	   Capillary	  voltage	  was	  set	  to	  3000	  V,	  the	  gain	  was	  set	  to	  0.10,	  the	  step	  to	  0.25,	  and	  the	  drying	  gas	  flow	  rate	  to	  12	  L/min.	  An	  injection	  volume	  of	  10	  µL	  was	  used.	  Several	  different	  elution	  protocols	  were	  used	  for	  mycobactin	  detection	  via	  HPLC/MS.	  
2.1.2.2 Techniques	  Used	  for	  Mtb	  Culture	  Extracts	  The	   buffers	   and	   gradients	   are	   given	   in	   the	   tables	   below.	   Ferric	   mycobactin	   J	  (FeMJ,	  Allied	  Monitor)	  was	  used	  as	  a	  quantitative	  standard.	  
Table	  3:	  Isocratic	  70%	  acetonitrile	  method	  (ISOYJ70F).	  
Buffer	  A:	   Aqueous	  with	  0.1%	  formic	  acid	  
Buffer	  B:	   Acetonitrile	  with	  0.1%	  formic	  acid	  
Time	  (min)	   0	   60	  
%	  B	   70	   70	  
Table	  4:	  MYCEX	  method.	  
Buffer	  A:	   Aqueous	  with	  0.1%	  formic	  acid	  
Buffer	  B:	   Acetonitrile	  with	  0.1%	  formic	  acid	  
Time	  (min)	   0	   20	   50	   120	   140	   170	   175	   180	  
%	  B	   30	   30	   70	   70	   98	   98	   30	   30	  
	  	   50	  
Table	  5:	  NM_MYCO3	  method.	  
Buffer	  A:	   Aqueous	  with	  0.05%	  trifluoroacetic	  acid	  
Buffer	  B:	   Acetonitrile	  with	  0.035%	  trifluoroacetic	  acid	  
Time	  (min)	   0	   75	   130	   135	   150	   152	   160	  
%	  B	   15	   70	   70	   98	   98	   15	   15	  
	  
Figure	  11:	  Graphical	  representation	  of	  the	  solvent	  gradients	  that	  were	  used	  for	  HPLC/MS	  analysis.	  
2.1.2.3 HPLC/DAD	  Quantification	  of	  Mycobactin	  For	   quantification	   of	   extracted	   ferric	   mycobactin	   T	   (FeMT)	   compounds	   by	  HPLC/DAD,	  a	  standard	  curve	  was	  created	  by	  measuring	   the	   integrated	  area	  under	   the	  450	  nm	   absorbance	   signals	   of	   both	   the	   unsaturated	   and	   saturated	   peaks	   of	   known	  concentrations	  of	  FeMJ.	  This	  curve	  is	  given	  in	  Figure	  12.	  
	  
Figure	  12:	  Standard	  curve	  of	  A450	  peak	  area	  vs.	  FeMJ	  concentration.	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2.2 Results	  	  
2.2.1 Comparison	  of	  Media	  Preparation	  Methods	  The	  results	  from	  the	  650	  nm	  absorbance	  (OD650)	  growth	  curves	  shown	  in	  Figure	  13A	   indicate	   that	   GAST	   that	   had	   been	   prepared	   in	   glass	   bottles	   produced	   a	  markedly	  higher	  growth	  rate	  compared	  with	  media	  prepared	  in	  plastic	  bottles.	  This	  difference	  had	  a	   dominant	   effect	   on	   the	   growth.	   The	   wet	   cell	   mass	   measurements	   yielded	   similar	  evidence,	  as	  shown	  in	  Figure	  13B.	  The	  glass	  bottles	  that	  were	  used	  are	  reusable	  bottles,	  used	  frequently	  for	  making	  iron-­‐replete	  medium,	  cleaned	  and	  autoclaved	  for	  reuse.	  This	  finding	   aroused	   concern	   that	   this	   cleaning	   process	   did	   not	   fully	   remove	   the	   media	  nutrients	   (iron	   specifically,	   however	   potentially	   other	   unknown	   compounds	   could	   be	  present	  as	  well),	  some	  of	  which	  may	  have	  remained	  adsorbed	  to	  the	  inside	  of	  the	  bottle	  and	  leached	  into	  new	  media	  preparations.	  This	  is	  in	  contrast	  to	  the	  plastic	  bottles,	  which	  were	  factory	  sterilised	  and	  not	  reused.	  The	  findings	  could	  also	  be	  explained	  by	  leaching	  of	   components	   from	   the	   plastic	   that	   cause	   growth	   inhibition182,	   however	   to	   ensure	  consistency	   between	   preparations,	   all	   cultures	   were	   grown	   in	   the	   same	   plastic	   roller	  bottles,	   since	   preparation	   of	   media	   in	   these	   bottles	   is	   unlikely	   to	   have	   an	   additional	  variable	   effect.	   Previously	   researchers	  have	   gone	   to	   great	   lengths	   to	   ensure	   that	   their	  glassware	   is	   free	   from	   trace	  metal	   contamination	   including	   overnight	   treatment	  with	  ethanolic	  potassium	  hydroxide	  and	  nitric	  acid183-­‐185.	  The	   OD650	   data	   (Figure	   13A)	   also	   indicate	   that	   Chelex	   100	   treatment	   of	   the	  Casitone	  may	   limit	   the	   nutrients	   in	   such	   a	   way	   as	   to	   slow	   growth.	   Given	   that	   this	   is	  intended	  to	  be	  an	  iron-­‐limiting	  medium	  and	  that	  the	  other	  essential	  metals	  were	  added	  after	   treatment	  with	  Chelex,	   iron	  depravation	   is	  assumed	   to	  be	   the	  cause	  of	   the	   lower	  growth	  rate.	  However,	   this	  contrasts	  with	  the	  wet	  cell	  mass	  data,	  which	   indicated	  that	  Chelex	  100	  treatment	  did	  not	  have	  a	  significant	  effect	  on	  the	  wet	  cell	  mass	  (Figure	  13B).	  	  Chelex	  100	  treatment	  of	  the	  already	  purified	  water	  made	  no	  difference	  in	  growth	  rate.	  The	  wet	   cell	  mass	  measurements	  were	   prone	   to	   greater	   experimental	   error	   than	   the	  absorbance	  measurements	   as	   described	   in	   Section	  2.1.1.3,	   therefore	   in	   order	   to	   avoid	  any	   possibility	   of	   iron	   contamination	   in	   further	   experiments	   relied	   on	   GAST	  made	   in	  plastic	  bottles	  with	  the	  Casitone	  fraction	  of	  the	  medium	  treated	  by	  Chelex	  100.	  This	  was	  intended	   to	   achieve	   the	   most	   reproducible	   results	   by	   avoiding	   any	   trace	   iron	  contamination	  or	   the	   contribution	  of	   any	  potential	  unknown	  nutrients	  due	   to	  unclean	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Figure	  13A:	  Growth	  curves	  of	  Mtb	  H37Rv	  in	  differently	  prepared	  GAST	  media;	  blue	  indicates	  that	  
both	  the	  water	  and	  the	  Casitone	  solution	  were	  Chelex	  100	  treated	  and	  media	  was	  mixed	  in	  plastic	  
bottles,	  red	  indicates	  that	  only	  the	  water	  was	  Chelex	  100	  treated	  and	  media	  was	  mixed	  in	  plastic	  
bottles,	  green	  indicates	  no	  Chelex	  100	  treatment	  with	  media	  mixed	  in	  plastic	  bottles,	  and	  yellow	  
indicates	  no	  Chelex	  100	  treatment	  with	  media	  mixed	  in	  glass	  bottles.	  B:	  Total	  wet	  cell	  masses	  from	  
each	  culture	  condition	  at	  day	  16.	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indicative	   of	   a	   ferric	   compound	   containing	   the	   54Fe	   isotope	   in	   the	   naturally	   occurring	  abundance	  of	  5.8	  percent.	  	  
	  





Figure	  15A:	  Absorbance	  spectrums	  of	  mycobactin	  J	  (FeMJ)	  containing	  either	  unsaturated	  or	  
saturated	  acyl	  moieties.	  B:	  comparable	  absorbance	  spectrums	  captured	  from	  HPLC	  elution	  of	  
mycobactin	  T	  extracted	  from	  Mtb	  culture	  (FeMT).	  Spectrums	  were	  normalised	  at	  450	  nm,	  then	  
plotted	  with	  a	  maximum	  absorbance	  of	  unity.	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Table	  6:	  Predicted	  mass	  spectrum	  of	  the	  protonated	  ion	  of	  FeMJ	  containing	  an	  unsaturated	  acyl	  
chain	  (ChemDraw).	  
m/z	   Relative	  
Abundance	  895.4	   100.0	  %	  896.4	   54.0	  %	  897.4	   16.7	  %	  893.4	   6.4	  %	  898.4	   3.5	  %	  894.4	   3.2	  %	  	  








	   	  
Observed	  Error	  3.9	  ppm	  
	   	  
	  
Figure	  16:	  Mass	  spectrum	  of	  FeMJ;	  note	  the	  M	  –	  2	  peak	  indicating	  the	  presence	  of	  54Fe	  at	  the	  
natural	  isotopic	  composition	  of	  5.8	  percent.	  
2.2.3 Siderophore	  Production	  Growth	  Curves	  The	   growth	   curves	   for	   two	   different	   batches	   of	   Mtb	   grown	   for	   siderophore	  extraction	  are	  shown	  in	  Figure	  17.	  Batch	  A	  was	  grown	  from	  Mtb	  that	  had	  a	  lower	  degree	  of	  iron	  depletion	  through	  division	  in	  low-­‐iron	  GAST,	  while	  batch	  B	  was	  grown	  from	  Mtb	  that	  had	  a	  higher	  degree	  of	  iron	  depletion.	  This	  resulted	  in	  the	  higher	  initial	  growth	  rate	  exhibited	  by	  batch	  A.	  Growth	  of	  batch	  A	  also	  plateaued	  into	  stationary	  phase	  growth	  at	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an	  earlier	  time	  point	  (7	  days)	  versus	  batch	  B,	  which	  had	  not	  reached	  stationary	  phase	  at	  the	  time	  of	  harvest	  (12	  days).	  	  
	  
Figure	  17:	  Batch	  A	  was	  inoculated	  with	  Mtb	  that	  had	  been	  subcultured	  twice	  in	  low-­iron	  GAST;	  
batch	  B	  was	  inoculated	  with	  Mtb	  that	  had	  been	  subcultured	  seven	  times	  in	  low-­iron	  GAST.	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Figure	  18:	  Mycobactin	  yield	  from	  culture	  extracts.	  
Table	  7:	  Total	  mycobactin	  yields	  from	  extractions	  A	  and	  B.	  
Extraction	   Yield/culture	  volume	   Yield/g	  wet	  cells	   Purity	  Batch	  A	  pellet	   3.4	  mg/L	   0.8	  mg/g	   4.9%	  Batch	  B	  pellet	   1.2	  mg/L	   0.3	  mg/g	   3.3%	  Batch	  B	  supernatant	   7.8	  mg/L	   2.1	  mg/g	   2.2%	  	  
Table	  8:	  Detailed	  mycobactin	  yield	  information	  for	  each	  chromatographic	  peak;	  yields	  are	  given	  as	  
percentage	  of	  total	  mycobactin	  detected.	  The	  general	  structure	  of	  mycobactin	  T	  is	  given	  for	  
reference	  with	  the	  substituents	  of	  structural	  variation	  highlighted	  in	  blue	  and	  iron	  coordination	  
ligands	  in	  red;	  a	  Δ20	  fatty	  acyl	  moiety	  is	  shown	  for	  example.	  
	  
Peak	   Experimental	  
m/z*	  
Carbons	  in	  Fatty	  
Acyl	  Moiety**	  





B	  1	   827.5	   Δ18	   H	   4.10%	   1.90%	   1.84%	  2	   829.6	   18	   H	   2.54%	   11.02%	   10.89%	  3	   841.4	   Δ18	   CH3	   8.23%	   1.49%	   1.71%	  4	   843.6	   18	   CH3	   3.10%	   2.76%	   2.21%	  5	   855.6	   Δ20	   H	   20.48%	   13.78%	   6.52%	  6	   857.5	   20	   H	   10.95%	   46.52%	   47.95%	  7	   869.5	   Δ20	   CH3	   38.43%	   5.32%	   11.89%	  8	   871.6	   20	   CH3	   12.17%	   15.17%	   14.81%	  
*Represents	  exact	  mass	  of	  major	  isotope	  signal,	  M	  +	  H+	  of	  the	  ferric	  compound.	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Comparison	  of	   the	   total	  mycobactin	   yield	   from	   the	   two	  batches	   shows	   that	   the	  batch	  A	  pellet	  (harvested	  at	  19	  days)	  had	  a	  higher	  yield	  per	  unit	  of	  wet	  cell	  mass	  than	  that	  of	  the	  batch	  B	  pellet	  (harvested	  at	  12	  days).	  Literature	  values	  indicate	  that	  yields	  up	  to	  98	  mg/g	   (dry	   cell	  mass)	   are	   achievable	   under	   conditions	   optimised	   for	  mycobactin	  production118.	   The	   difference	   between	   batch	   yields	   can	   be	   attributed	   to	   the	   fact	   that	  batch	  A	  had	  grown	   for	  a	   longer	  period	  of	   time	  and	  achieved	  stationary	  phase	  growth,	  while	  batch	  B	  was	  harvested	  earlier	  while	  still	  in	  logarithmic	  growth	  phase.	  This	  shows	  that	   mycobactins	   are	   able	   to	   accumulate	   over	   time	   and	   continue	   to	   build	   up	   as	   the	  organism	  remains	  in	  an	  iron-­‐restricted	  state	  over	  a	  long	  period	  of	  time.	  This	  is	  further	  supported	   by	   a	   subsequent	   experiment	   in	   which	   two	   different	   cultures	   were	   grown	  under	  iron-­‐depleted	  conditions.	  One	  was	  harvested	  and	  the	  mycobactins	  extracted	  after	  15	   days	   of	   growth,	   the	   other	   after	   32	   days	   of	   growth	   (both	   of	   which	   had	   reached	  stationary	   phase).	   Significant	   quantities	   of	   mycobactin	   were	   detected	   in	   the	   32-­‐day	  extract,	  but	  only	  traces	  were	  found	  in	  the	  15-­‐day	  extract	  (data	  not	  shown).	  These	  data	  also	  serve	  to	  indicate	  that	  Mtb	  continues	  to	  produce	  mycobactin	  even	  as	  it	  is	  exiting	  the	  logarithmic	  growth	  phase	  and	  beginning	  to	  enter	  stationary	  phase.	  This	  is	  perhaps	  due	  to	   consumption	   of	   all	   available	   internal	   iron	   stores	   coinciding	   with	   the	   inability	   to	  sustain	  further	  bacterial	  division	  within	  the	  culture.	  
2.2.5 Abundance	  of	  Different	  Mycobactin	  Species	  The	  chromatograms	  from	  cell	  pellet	  extracts	  of	  siderophore	  production	  batches	  A	  and	  B	   are	   compared	   in	   Figure	   19A.	   The	   sequentially	   eluting	   peaks	   exhibit	   alternating	  absorbance	   spectra	   characteristic	   of	   unsaturated	   followed	   by	   saturated	   structures	  eluting	  shortly	  thereafter,	  similar	  to	  the	  results	  from	  FeMJ	  (see	  Figure	  14	  and	  Figure	  15).	  The	   slight	   shift	   to	   later	   elution	   times	   for	   batch	   B	   can	   be	   explained	   by	   the	   aging	   of	   a	  heavily	   used	   column	   becoming	   slightly	   slower	   (the	   samples	   were	   analysed	   38	   days	  apart).	  The	  same	  pattern	  of	  eight	  compounds	  is	  apparent	  in	  both	  batches,	  however	  their	  abundance	   ratios	   vary	   considerably	   (Figure	   19B).	   The	   unsaturated	   mycobactins	   are	  dominant	   in	   batch	   A,	   whereas	   the	   saturated	  mycobactins	   were	   dominant	   in	   batch	   B.	  During	  mycobactin	  biosynthesis	  the	  acyl	  chain	  of	  mycobactin	  is	  dehydrogenated	  by	  the	  protein	   MbtN,	   which	   is	   part	   of	   the	   mbt-­2	   mycobactin	   biosynthetic	   gene	   locus	   first	  characterised	  by	  Krithika	  et	  al.74	   (see	  Figure	  5	   for	  a	  complete	  overview	  of	  mycobactin	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Figure	  19A:	  Chromatogram	  of	  mycobactins	  comparing	  the	  pellet	  extracts	  from	  batches	  A	  and	  B	  
using	  the	  ISOYJ70	  HPLC	  method.	  B:	  Relative	  abundance	  of	  each	  species	  of	  detected	  mycobactin.	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This	  would	  be	  difficult	  to	  test	  directly	  given	  that	  both	  compounds	  would	  possess	  extremely	   high	   affinities	   for	   ferric	   iron33.	   However,	   it	   is	   supported	   by	   recent	   findings	  from	  a	   large	   lipidomic	  study	  that	  showed	  unsaturated	  monodeoxymycobactin	  was	  still	  able	   to	   bind	   iron	   to	   some	   degree,	   while	   saturated	   monodeoxymycobactin	   was	   only	  detected	  in	  its	  desferri	  form84.	  Therefore	  the	  unsaturation	  would	  provide	  an	  advantage	  to	  the	  iron-­‐chelation	  ability	  of	  mycobactin,	  but	  not	  a	  critical	  one.	  As	   such,	   the	   process	   by	   which	   a	   particular	   mycobactin-­‐bound	   acyl	   chain	   is	  dehydrogenated	  may	  be	  stochastic	  and	  governed	  by	  the	  relative	  turnover	  rates	  of	  MbtN	  and	   the	   ‘competing’	   protein	   that	   performs	   the	   final	   acylation	   of	   mycobactin,	   MbtK.	  Kinetics	  have	  been	  reported	  for	  MbtK74,	  82	  but	  not	  MbtN.	  As	  a	  culture	  enters	  stationary	  phase,	  by	  definition	  the	  rate	  of	  division	  and	  many	  metabolic	  processes	  slow,	  which	  could	  lead	   to	   depleted	   levels	   of	   acylated	   MbtL	   within	   the	   cell.	   If	   it	   were	   assumed	   that	   the	  turnover	  rate	  of	  MbtK	  is	  higher	  than	  that	  of	  MbtN	  (to	  account	  for	  the	  general	  production	  of	  saturated	  mycobactins),	  such	  a	  scenario	  would	  result	  in	  a	  higher	  proportion	  of	  acyl-­‐MbtL	   being	   dehydrogenated	   before	   attachment	   to	   the	   mycobactin	   core	   structure	   by	  MbtK.	  This	  could	  account	  for	  the	  greater	  ratio	  of	  unsaturated	  to	  saturated	  mycobactins	  extracted	  from	  batch	  A.	  Another	   explanation	   could	   be	   that	   this	   ratio	   is	   influenced	   by	   the	   relative	  abundance	  of	  the	  fatty	  acids	  that	  are	  already	  available	  within	  the	  cell,	  which	  can	  include	  fatty	  acids	  that	  have	  already	  been	  dehydrogenated.	  Mechanistic	  studies	  of	  recombinant	  MbtK	  have	  revealed	  a	  clear	  preference	  for	   longer	  acyl	  chains,	  however	  only	  fatty	  acids	  up	   to	  16	   carbons	  were	   tested	  due	   to	   complications	  arising	   from	  micelle	   formation	   for	  longer	  chain	  lengths82.	  Unfortunately	  preference	  for	  α-­‐β	  unsaturated	  fatty	  acids	  was	  not	  tested.	   Enzymatic	   promiscuity	   of	   MtbL	   and	   MbtK	   is	   likely	   advantageous	   to	  Mtb.	   The	  composition	  of	  this	  acyl	  moiety	  shows	  greater	  variability	  than	  are	  able	  to	  be	  bound	  by	  Lcn2127	   or	   antigen	   display	   protein	   CD1a58,	   83,	   126,	   components	   of	   the	   human	   immune	  system	   that	   have	   evolved	   to	   recognise	   them.	   Binding	   of	   incomplete	  mycobactins	   and	  carboxymycobactins	  of	  relatively	  short	  acyl	  chain	  length	  has	  been	  observed	  with	  these	  proteins	   and	   variation	   in	   the	   acyl	   moiety	   would	   be	   an	   effective	   means	   to	   avoid	  recognition	   through	   these	   sterically	   constrained	   binding	   events.	   This	   points	   toward	   a	  strategy	   for	   avoiding	   immune	   recognition	   of	   one	   particular	   mycobactin	   structure	   in	  favour	  of	   presenting	   a	   variable	   and	   rotating	   series	   of	   compounds	   to	   the	  host	   immune	  system	  through	  enzymatic	  promiscuity.	  This	  is,	  of	  course,	  assuming	  that	  the	  bacterium	  is	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not	   gaining	   an	   advantage	   in	   being	   recognised10.	   A	   late-­‐stage	   culture	  may	   simply	   have	  more	  dehydrogenated	  fatty	  acids	  present	  due	  to	  degratory	  processes74,	  which	  are	  then	  opportunistically	  incorporated	  into	  mycobactin	  by	  MtbL	  and	  MbtK.	  An	  important	  note	  in	  regard	  to	  this	  is	  that	  the	  cultures	  grown	  in	  this	  study	  used	  only	  glycerol	  and	  alanine	  as	  their	  carbon	  source	  with	  no	  supplementation	  fatty	  acids	  such	  as	  oleic	  acid.	  Therefore	  all	  of	  the	  longer	  fatty	  acids	  that	  are	  present	  are	  the	  products	  of	  Mtb	  biosynthesis	  from	  these	  rudimentary	  building	  blocks.	  This	  underscores	  the	  idea	  that	  the	  observed	  change	  is	  due	  to	  differences	   in	   the	   growth	  phases	  of	   the	   culture.	   There	   is	   likely	   to	  be	  a	  much	  wider	  array	  of	  lipids	  available	  to	  the	  bacterium	  within	  the	  host	  environment,	  especially	  within	  foamy	  macrophages179.	  Similar	  ratios	  and	  patterns	  of	  mycobactins	  were	  found	  to	  be	  present	  in	  extracts	  from	  the	  cell	  pellet	  and	  the	  supernatant	  of	  batch	  B.	  The	  supernatant	  of	  batch	  A	  was	  not	  extracted	   because	   at	   the	   time	   of	   its	   growth	   it	   was	   not	   realized	   that	   the	   supernatant	  would	   yield	   such	   large	   quantities	   of	  mycobactin.	   These	   two	   extracts	   are	   compared	   in	  Figure	  20.	  No	   carboxymycobactins	  were	  detected	  using	   this	   extraction	   technique.	  The	  extraction	   method	   was	   adapted	   from	   that	   employed	   by	   Gobin	   et	   al.47,	   which	   was	  designed	   to	   extract	   carboxymycobactins	   as	   well	   as	   mycobactin	   and	   included	   an	  acidification	  step	  intended	  to	  protonate	  the	  free	  acids	  of	  carboxymycobactins	  and	  allow	  them	   to	   better	   partition	   into	   chloroform.	   Further	   experiments	   showed	   that	  carboxymycobactin	  partitioned	  into	  chloroform	  with	  greater	  efficiency	  than	  mycobactin	  even	  without	  this	  protonation	  step	  (see	  Figure	  43).	  The	   inability	   to	   detect	   carboxymycobactin	   is	   consistent	  with	   literature	   reports	  that	   lipophilic	   mycobactins	   are	   produced	   in	   much	   greater	   quantities	   than	  carboxymycobactins,	   which	   comprise	   only	   0.2-­‐3.1	   percent	   of	   total	   mycobactin	  production	  by	  mass119.	  This	  means	  that	  carboxymycobactin	  levels	  in	  the	  in	  vitro	  cultures	  would	  have	  been	  below	  the	  limit	  of	  detection	  of	  the	  instruments	  used.	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Figure	  20:	  Chromatogram	  of	  mycobactins	  comparing	  the	  pellet	  and	  supernatant	  of	  extract	  B	  using	  
the	  MYCEX	  HPLC	  method.	  
2.3 Conclusion	  
2.3.1 The	  Role	  of	  Mycobactin	  in	  Mtb	  Pathogenesis	  This	  study	  found	  substantial	  production	  and	  secretion	  of	   lipophilic	  mycobactins	  under	  the	  given	  experimental	  conditions.	  Carboxymycobactin	  was	  not	  detected	  in	  either	  the	   cell	   pellet	   extract	   or	   the	   culture	   filtrate.	   Such	   a	   high	   lipophilic	   mycobactin	   to	  carboxymycobactin	   production	   ratio	   challenges	   the	   model	   of	   carboxymycobactin-­‐mediated	   iron	   trafficking	   set	   forth	   in	   Section	   1.2.3.1	   and	   instead	   supports	   a	  model	   in	  which	  lipophilic	  mycobactin	  acts	  as	  the	  primary	  extracellular	  siderophore.	  Further	  supporting	  this	  new	  model,	  Luo	  et	  al.	  recently	  showed	  that	  the	  lipophilic	  mycobactins	   were	   able	   to	   diffuse	   freely	   in	   and	   around	   macrophages	   when	   added	  exogenously,	   and	   that	   gallium-­‐loaded	   mycobactins	   were	   found	   preferentially	   in	   lipid	  bodies	   in	   direct	   contact	   with	   phagosomes186.	   Interestingly,	   other	   studies	   have	   shown	  that	  the	  oxygenated	  mycolic	  acids	  produced	  by	  Mtb	  and	  M.	  avium	  induce	  the	  formation	  of	   ‘foamy’	   macrophages	   that	   are	   filled	   with	   many	   lipid	   bodies.	  Mtb	   living	   within	   the	  phagosomes	  of	  foamy	  macrophages	  colocalise	  with,	  and	  subsequently	  engulf	  these	  lipid	  bodies179.	  Not	  only	  does	  this	  provide	  the	  bacteria	  with	  a	  lipid-­‐rich	  environment	  in	  which	  to	   persist179,	   but	   it	   may	   represent	   a	   new	   route	   for	   trafficking	   iron	   that	   involves	  subverting	  host	  lipid	  bodies	  to	  serve	  as	  reservoirs	  of	  nutrients	  and	  ferrimycobactins,	  a	  veritable	  smörgåsbord	  on	  which	  to	  grow	  fat	  and	  lazy187.	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These	  findings	  also	  complement	  research	  discussed	  earlier	  in	  Section	  1.2.1	  on	  the	  formation	  of	  marinobactin	  micelles42,	  70	  and	  the	  finding	  that	  mycobacterial	  lipids	  in	  Mtb-­‐	  and	  M.	  avium-­‐infected	  macrophages	  are	  capable	  of	   trafficking	  out	  of	   the	  mycobacterial	  vacuole8.	  The	  new	  model	  for	  mycobacterial	  iron	  acquisition	  begins	  to	  emerge,	  in	  which	  lipophilic	  mycobactins	  act	  as	  extracellular	  siderophores,	  and	   iron	   is	   trafficked	  through	  intracellular	  lipid	  bodies	  back	  to	  phagosomes	  infected	  by	  Mtb188.	  It	  should	  be	  noted	  that	  in	  contrast	  to	  the	  findings	  reported	  here,	  in	  the	  absence	  of	  Tween	  lipophilic	  mycobactin	  is	   more	   likely	   to	   stay	   associated	   with	   the	   cell	   wall116.	   However,	   the	   lipid-­‐rich	  environment	   of	   the	   foamy	   macrophage	   likely	   lends	   greater	   mobility	   to	   the	   lipophilic	  mycobactins	  than	  does	  the	  aqueous	  environment	  of	  liquid	  culture	  media.	  Figure	   21	   depicts	   a	   model	   of	   mycobactin-­‐mediated	   iron	   acquisition	   within	  macrophages	   that	   takes	   advantage	   of	   lipid	   body	   trafficking186.	   This	   can	   be	   contrasted	  with	   the	   classical	   model	   for	   mycobacterial	   iron	   acquisition,	   depicted	   in	   Figure	   6.	  Mycobactins	  leave	  the	  bacterium	  either	  by	  trafficking	  out	  of	  the	  phagosome	  with	  other	  mycobacterial	  lipids8	  or	  by	  forming	  micelles70.	  It	  might	  be	  necessary	  for	  mycobactins	  to	  use	  a	  specific	  mechanism	  that	  has	  yet	   to	  be	  discovered	   in	  order	   to	  cross	   the	   thick	  cell	  wall.	   The	   micelles	   diffuse	   throughout	   the	   macrophage	   and	   bind	   iron	   from	   the	  macrophage	   iron	   pool,	   including	   iron	   plundered	   from	   ferritin	   and	   imported	  transferrin100.	   Ferric	   mycobactins	   then	   traffic	   preferentially	   to	   macrophage	   lipid	  bodies186	   that	   are	   engulfed	   by	   infected	   phagosomes179.	   The	   ferric	   mycobactins	  translocate	   through	   the	   cell	   wall	   once	   again	   and	   may	   exchange	   iron	   with	  carboxymycobactin	  on	  an	  equilibration	  basis100.	  This	  iron	  can	  then	  be	  imported	  through	  the	   IrtAB	   system.	  Alternatively,	   the	  mycobactins	  may	  diffuse	   across	   the	  membrane	  or	  handoff	   their	   iron	   payload	   to	   other	   mycobactins	   within	   the	   cell	   membrane.	   Because	  membrane	  affinity	   is	  modulated	  by	   the	   length	  and	  degree	  of	  unsaturation	  of	   the	  alkyl	  chain70,	   these	   recipient	   mycobactins	   in	   the	   membrane	   could	   form	   a	   gradient	   of	  mycobactins	  with	   differential	  membrane	   affinities.	   In	   this	  way	   they	   could	   assemble	   a	  ‘bucket	  brigade’	  to	  transport	  the	  iron	  into	  the	  bacterium189.	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2.3.2 Species	  of	  Mycobactins	  Produced	  Eight	   specific	   mycobactin	   structures	   were	   identified	   in	   Mtb	   culture	   extracts	  (Table	   8).	   These	   structures	   corroborate	   well	   with	   the	   structures	   detected	   in	   other	  studies84.	  There	  are	  three	  points	  of	  variation	  between	  the	  structures:	  	   1. Length	   of	   the	   fatty	   acid	   component:	   here	   the	   inclusion	   of	   stearic	   acid	   and	  arachidic	  acid	  have	  been	  detected,	  although	  other	  studies	  have	  also	  reported	  smaller	  quantities	  of	  palmitic	  acid	  incorporation84.	  	   2. The	   presence	   or	   absence	   of	   an	   unsaturation	   in	   the	   fatty	   acid	   component:	  saturated	   acyl	   chains	   were	   dominant	   in	   logarithmically	   growing	   culture,	  while	  unsaturated	  acyl	  chains	  were	  dominant	  in	  stationary	  phase	  culture.	  	   3. The	  inclusion	  of	  either	  serine	  or	  threonine	  (or	  potentially	  α-­‐methyl	  serine,	  as	  discussed	  in	  Section	  1.2.2,	  see	  Figure	  5	  for	  details	  of	  the	  biosynthesis)	  in	  the	  oxazoline	   ring:	   the	   results	   presented	   here	   indicate	   either	   component	   is	  incorporated	  indiscriminately.	  	   The	  length	  of	  the	  fatty	  acyl	  chain	  and	  the	  addition	  of	  a	  methyl	  group	  may	  affect	  the	   biodistribution	   of	   the	   different	   species	   of	   mycobactin	   as	   depicted	   in	   Figure	   21	  however	  it	  is	  unlikely	  to	  effect	  the	  metal	  coordination	  in	  any	  way.	  It	  is	  difficult	  to	  predict	  whether	   this	  differentiation	   in	  hydrophobicity	  would	  have	  a	  major	   influence	  on	  which	  mycobactin	   species	   being	   more	   likely	   to	   be	   found	   in	   the	   blood	   or	   preferentially	  distributed	   in	   other	   bodily	   fluids	   of	   a	   TB	   patient.	   If	   the	   unsaturation	   does	   affect	   the	  affinity	  of	  mycobactin	  for	  iron,	  then	  this	  could	  potentially	  affect	  the	  reduction	  potential	  of	  the	  complex,	  as	  will	  be	  discussed	  further	  in	  Chapter	  3.	  However,	  this	  will	  once	  again	  be	  difficult	  to	  test	  experimentally	  in	  that	  it	  is	  very	  difficult	  to	  obtain	  usable	  quantities	  of	  sufficiently	  purified	  FeMT,	  especially	  without	  contamination	  from	  other,	  closely	  eluting	  structures.	  
2.3.3 Physiological	  Range	  of	  Mycobactin	  Production	  These	   studies	   have	   shown	   that	   lipophilic	   mycobactins	   can	   be	   produced	   in	   the	  filtrate	  of	   liquid	  cultures	  at	  concentrations	  up	  to	  7.8	  mg/L	  or	  8.6	  µM.	  Any	  mycobactins	  available	  to	  a	  prospective	  biosensor	  would	  likely	  be	  equivalent	  to	  quantities	  recovered	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from	  the	  supernatant	  (Section	  2.2.4)	  rather	  than	  the	  cell	  pellet.	  Bearing	  this	  in	  mind,	  the	  supernatant	  extract	  B	  yield	  of	  2.1	  mg/g	  cells	  can	  be	  taken	  as	  a	  conservative	  value	  to	  use	  in	   the	   calculation	   of	   mycobactin	   production	   in	   the	   iron-­‐restricted,	   lipid-­‐rich	   host	  environment.	  Assuming	  a	  rod	  shape,	  the	  average	  volume	  of	  a	  bacterium	  is	  calculated	  to	  be	  3.46×10-­‐19	  m3	   (190),	  which	  gives	  a	  mass	  of	  3.71×10-­‐13	  g	  per	  cell	  assuming	  an	  average	  density	   of	   1.08	  g/cm3	   (191).	   Mycobactin	   production	   per	   bacterium	   is	   therefore	  7.80×10-­‐16	  g,	  or	  8.64×10-­‐19	  mol	  using	  the	  averaged	  molecular	  weight	  of	  the	  mycobactin	  compounds	   extracted	   from	   Mtb	   culture	   (902	  g/mol).	   Information	   on	   the	   number	   of	  bacteria	  that	  might	  be	  found	  in	  infected	  lung	  tissue	  is	  difficult	  to	  obtain,	  however	  a	  good	  estimation	   for	   bacteria	   within	   the	   granuloma	   of	   an	   early-­‐stage	   primate	   infection	   is	  106	  colony-­‐forming	   units	   (CFU)/g(192).	   This	   yields	   an	   estimated	   mycobactin	  concentration	  of	  864	  pM	  within	  the	  granuloma.	  If	  the	  highest	  reported	  production	  level	  of	   mycobactin	   (98	  mg/g	   dry	   cell	   mass118)	   is	   used,	   and	   adjusting	   for	   an	   estimated	  mycobacterial	  water	  content	  of	  83	  percent193,	   the	  estimated	  mycobactin	  concentration	  rises	  to	  circa	  250	  nM.	  It	   should	   be	   noted	   that	   these	   in	   vitro	   estimations	   are	   limited	   in	   their	   ability	   to	  simulate	   the	  complexity	  of	   the	  host	  environment	   that	  Mtb	   inhabits	   in	  vivo.	  Add	  to	   that	  the	  complexity	  of	  the	  many	  different	  microenvironments	  that	  define	  specific	  regions	  of	  the	   lung	   and	   granuloma	   and	   at	   different	   stages	  within	   the	   spectrum	  of	   infection5.	   For	  example	  Mtb	   organisms	   in	   close	   proximity	   to	   neutrophils,	   as	   they	   are	  within	   caseous	  granulomas5,	   may	   have	   more	   exposure	   to	   siderophore-­‐sequestering	   Lcn2,	   thus	  necessitating	   increased	  production	  of	   siderophores.	  Varying	   levels	  of	  hypoxia	   are	  also	  likely	  to	  effect	  siderophore	  production	  as	  it	  is	  intimately	  linked	  with	  the	  iron	  trafficking	  pathway88.	   The	   expression	   of	  mycobactin	   biosynthesis	   genes	   is	   downregulated	   under	  conditions	  of	  oxidative	  stress	  to	  the	  organism.	  This	  is	  due	  the	  risk	  that	  excess	  iron	  poses	  under	   oxidative	   conditions	   in	   which	   highly	   reactive	   hydroxyl	   radicals	   are	   produced	  through	  the	  Fenton	  reaction194:	  	  
€ 
Fe2+	  +	  H2O2	  →	  Fe3+	  +	  OH⋅	  +	  OH-­‐	  
The	  Fenton	  reaction	  thus	   more	   siderophores	   may	   be	   produced	   under	   hypoxic	   conditions,	   such	   as	   within	  some,	  if	  not	  all,	  granulomas5,	  195.	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2.3.4 Implications	  for	  Development	  of	  an	  Assay	  for	  Mycobactin	  These	   results	   affirm	   the	   production	   of	  mycobactin	   and	   thus	   form	   the	   basis	   for	  development	  of	  a	  simple	  mycobactin	  assay	  with	  the	  potential	   to	  serve	  as	  a	  measure	  of	  
Mtb	  infection	  within	  the	  lung.	  Such	  an	  assay	  should	  have	  sensitivity	  in	  the	  range	  of	  0.85-­‐250	  nM	  in	  order	  to	  enable	  detection	  mycobactin	  at	  the	  physiological	  levels	  of	  production	  projected	  from	  this	   in	  vitro	  study.	  This	  would	  of	  course	  have	  to	  be	  adjusted	  depending	  on	  the	  still-­‐unknown	  biodistribution	  profile	  of	  mycobactin	  and	  whether	  the	  compound	  may	  be	  widely	  distributed	  within	  the	  body	  or	  whether	  it	  might	  become	  concentrated	  in	  specific	   bodily	   fluids	   that	   would	   be	   conducive	   to	   sampling.	   Given	   the	   evidence	   that	  lipophilic	   mycobactin	   is	   more	   prevalent	   than	   carboxymycobactin,	   the	   assay	   and	   any	  optimisation	   or	   accompanying	   sample	   processing	   techniques	  must	   have	   the	   ability	   to	  handle	  this	  lipidic	  analyte.	  This	  could	  present	  challenges,	  but	  also	  opportunities	  for	  ways	  to	  tailor	  sample	  preparation	  through	  established	  organic	  extraction	  techniques	  and	  the	  specificity	   of	   the	   assay	   by	   taking	   advantage	   of	   the	   unique	   molecular	   properties	   of	  mycobactin.	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3 A	  Simple	  Electrochemical	  Assay	  for	  Mycobactin	  
One	   example	   of	   a	   very	   successful	   assay	   for	   medical	   purposes	   is	   the	  electrochemical	   glucose	   oxidase-­‐based	   blood	   glucose	   meter196.	   This	   type	   of	   sensor	   is	  currently	  in	  use	  for	  monitoring	  and	  control	  of	  diabetes	  symptoms	  worldwide,	  including	  deployment	  in	  impoverished	  and	  developing	  markets	  similar	  to	  those	  most	  afflicted	  by	  TB.	   This	   technology	   offers	   a	   suitable	   low-­‐cost	   sensing	   platform	   for	   point-­‐of-­‐care	   TB	  diagnostic	  applications.	  Thus,	   the	  goal	  of	   this	  chapter	   is	   to	  explore	  the	  electrochemical	  properties	   of	   mycobactin	   and	   determine	   whether	   an	   assay	   based	   on	   electrochemical	  interrogation	  of	  the	  iron	  coordination	  complex	  can	  be	  created	  that	  is	  adaptable	  for	  use	  in	   a	   plurality	   of	   sampling	   media.	   In	   particular,	   electrochemical	   sensing	   appears	   well	  suited	  for	  measurement	  of	  mycobactin	  because	  of	  the	  following	  factors:	  	   1. Ferric	  mycobactin	  contains	  one	  ferric	  iron	  atom,	  which	  may	  be	  interrogated	  via	  electrochemical	  redox	  processes	  to	  yield	  information	  about	  the	  complex.	  	   2. The	  unique	  chelation	  chemistry	  of	  different	  siderophores	  shifts	  the	  ferric/ferrous	  redox	  couple	  to	  a	  potential	  that	  is	  specific	  to	  that	  particular	  siderophore	  complex197,	  thus	  allowing	  assay	  specificity.	  	   3. Reduction	  of	  ferric	  to	  ferrous	  mycobactin	  greatly	  decreases	  the	  affinity	  of	  the	  siderophore	  for	  the	  iron,	  which	  may	  also	  be	  exploited	  to	  gain	  information	  about	  the	  complex.	  There	  is	  speculation	  that	  this	  is	  how	  the	  bacterium	  frees	  the	  iron	  from	  mycobactin	  for	  its	  own	  use	  by	  means	  of	  a	  putative	  reductase120.	  	   Ferric	   mycobactin	   J	   (FeMJ)	   was	   chosen	   as	   the	   model	   mycobactin	   for	   these	  experiments	   due	   to	   its	   ready	   availability	   in	   a	   relatively	   pure	   form	   and	   similarity	   to	  mycobactin	  T	  in	  its	  core	  structure	  and	  iron-­‐coordination	  ligands	  (see	  Table	  2).	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3.1 Methods	  
3.1.1 Instrumentation	  Cyclic	   voltammetry	   and	   potentiostatic	   measurements	   were	   performed	   on	   a	  Princeton	  Applied	  Research	  263A	  potentiostat	  and	  a	  PC	  running	  CorrWare	  software.	  For	  high-­‐speed	   cyclic	   voltammetry	   a	   Solartron	   1286	   potentiostat	   was	   used	   in	   analogue	  mode	   to	   drive	   the	   potential,	  while	   a	   PicoScope	   4224	  was	   used	   for	   data	   acquisition.	   A	  custom	  Matlab	  program	  was	  written	  to	  process	  the	  high-­‐speed	  cyclic	  voltammetry	  data,	  which	  can	  be	  found	  in	  Appendix	  1.	  A	   3	  mm	   diameter	   glassy	   carbon	   electrode	   (GCE)	   was	   purchased	   from	  Bioanalytical	   Systems,	   Inc.	   (BASi)	   The	   electrode	   surface	   was	   prepared	   by	   polishing	  successively	  with	  1.0	  µm	  and	  0.05	  µm	  alumina	  powder	  using	  MicroCloth	  polishing	  cloths	  (Buehler)	  affixed	  to	  a	  glass	  base.	  A	  1.6	  mm	  diameter	  gold	  electrode	  (AuE)	  was	  also	  used	  for	   one	   experiment.	   An	   Ag/AgCl	   matrix	   pellet	   electrode	   was	   used	   as	   a	   reference	  electrode	  in	  aqueous	  media,	  while	  a	  silver	  wire	  Ag/Ag+	  pseudo	  reference	  electrode	  was	  created	  for	  non-­‐aqueous	  electrochemistry.	  A	  coiled	  platinum	  wire	  was	  used	  as	  a	  counter	  electrode.	  
3.1.2 Electrode	  Pretreatment	  For	  all	  electrochemical	  experiments	  alumina	  residue	  was	  removed	  by	  oxidative	  cleaning	   at	   0.8	  V	   vs.	   Ag/AgCl	   in	   aqueous	   1	  M	   sodium	   hydroxide	   and	   1	  M	   potassium	  chloride	  using	  the	  method	  of	  Kiema	  et	  al.198	  This	  is	  a	  procedure	  seeks	  to	  firstly	  remove	  the	  layer	  of	  aluminium	  oxide	  residue	  left	  over	  from	  the	  electrode	  polishing	  process	  and	  secondly	  creating	  a	   chemically	   reproducible	   surface	  by	  oxidising	  off	   a	   layer	  of	   carbon.	  This	  is	  done	  with	  a	  minimal	  increase	  in	  glassy	  carbon	  surface	  oxidation,	  increasing	  the	  X-­‐ray	  photoelectron	  spectroscopy	  (XPS)	  band	  area	  attributable	  to	  oxygen	  species	  on	  the	  surface	  from	  approximately	  9	  percent	  to	  13	  percent198.	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3.1.3 Electrochemical	  Techniques	  
3.1.3.1 Cyclic	  Voltammetry	  Aqueous	   electrochemistry	   was	   carried	   out	   in	   a	   1:1	   water:ethanol	   solution	  containing	   0.1	  M	   potassium	   chloride.	   FeMJ	   was	   dissolved	   in	   this	   solution	   at	   a	   stock	  concentration	   and	   diluted	   with	   the	   same	   solvent	   when	   necessary.	   Nonaqueous	  electrochemistry	  was	  performed	  in	  dimethyl	  sulfoxide	  (DMSO)	  containing	  0.1	  M	  lithium	  chloride	   supporting	   electrolyte	   except	   for	   square-­‐wave	   voltammetry,	  which	  was	   done	  using	   0.5	  M	   lithium	   chloride.	   Oxygen	   was	   removed	   from	   the	   electrochemical	   cell	   by	  bubbling	   nitrogen	   gas	   for	   at	   least	   10	  min	   and	   maintaining	   a	   unidirectional	   gas-­‐flow	  environment;	   longer	   times	   were	   required	   to	   adequately	   deoxygenate	   desferri	  mycobactin	  solutions.	  Care	  had	  to	  be	  taken	  to	  deoxygenate	  the	  solution	  thoroughly	  in	  order	  to	  avoid	  the	  oxygen	  reduction	  wave	   in	   the	  potential	  window	  of	   interest.	  This	  was	  accomplished	  by	  bubbling	  nitrogen	  gas	  through	  the	  electrochemical	  cell	  for	  at	  least	  10	  min.	  
3.1.3.2 Amperometric	  Titration	  A	   GC	   working	   electrode	   was	   maintained	   at	   -­‐0.6	  V	   versus	   Ag/Ag+.	   A	   magnetic	  stirrer	  was	  placed	  in	  the	  bottom	  of	  the	  electrochemical	  cell	  and	  FeMJ	  was	  titrated	  into	  the	  cell	  with	  stirring.	  After	  each	  addition	  of	  FeMJ,	  stirring	  was	  stopped	  and	  the	  solution	  was	  allowed	  to	  settle.	  
3.1.4 Deferration	  and	  Referration	  of	  Mycobactin	  Because	  of	   its	  extremely	  high	  affinity	   for	   iron	   (ka	  ≈	  4×1026	  M-­‐1)43,	  mycobactin	   is	  almost	  always	  encountered	  in	  its	  ferric	  form.	  This	  is	  attributable	  to	  the	  fact	  that	  during	  isolation,	   synthesis,	   or	   purification	   it	   is	   difficult	   to	   maintain	   an	   environment	   so	  completely	  free	  from	  trace	  iron	  that	  mycobactin	  will	  not	  acquire	  any.	  The	  commercially	  available	  mycobactin	  J	  is	  obtained	  in	  its	  ferric	  form.	  Thus,	  to	  investigate	  the	  properties	  of	  desferri	   mycobactin	   the	   iron	   had	   to	   be	   removed.	   The	   iron	   removal	   was	   done	   as	   a	  simplified	   technique	   first	   pioneered	   by	   Snow91.	   Under	   low-­‐pH	   conditions	   the	  hydroxamic	   acid	   and	   phenolic	   ligands	   of	   mycobactin	   are	   protonated,	   allowing	   the	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chelated	   ferric	   ion	   to	   escape.	   Figure	   22	   shows	   presumptive	   pKa	   values	   for	   the	   iron-­‐chelating	  ligands	  of	  mycobactin.	  	  
	  
Figure	  22:	  Mycobactin	  J	  shown	  with	  pKa	  values	  for	  its	  iron-­chelating	  ligands	  based	  upon	  





















Figure	  23A:	  Spectrophotometric	  titration	  for	  ferric	  chloride	  into	  deferrated	  MJ	  (DFMJ)	  in	  
methanol.	  B:	  Plot	  of	  450	  nm	  absorbance	  versus	  ferric	  chloride	  concentration	  for	  both	  addition	  of	  
ferric	  chloride	  to	  DFMJ	  and	  ferric	  chloride	  alone.	  
3.2 Results	  and	  Discussion	  
3.2.1 Cyclic	  Voltammetry	  of	  Mycobactin	  
3.2.1.1 Aqueous	  Cyclic	  Voltammetry	  Cyclic	  voltammograms	   (CVs)	  of	  FeMJ	   showed	  a	  distinctive	   redox	  couple	   for	   the	  ferric	  complex	  centred	  at	  -­‐0.600	  V	  versus	  Ag/AgCl	  as	  shown	  in	  Figure	  24.	  Since	  CVs	  of	  desferri	   mycobactin	   J	   (DFMJ)	   show	   no	   peaks,	   it	   can	   be	   deduced	   that	   this	   couple	  corresponds	   to	   the	   redox	   activity	   associated	   with	   the	   chelated	   iron	   bound	   by	   FeMJ	  rather	   than	   structural	   components	   of	   the	   siderophore	   itself.	   The	   clearly	   discernible	  oxidation	   peak	   is	   in	   contrast	   to	   recent	   reports	   of	   FeMJ	   exhibiting	   irreversible	  electrochemistry	   in	   95	   percent	   ethanol	   with	   a	   cathodic	   peak	   at	   -­‐0.856	   V	   versus	   the	  standard	  hydrogen	  electrode	  (equivalent	  to	  -­‐1.144	  V	  versus	  Ag/AgCl)200.	  The	  CVs	  shown	  by	  Miller	   et	   al.	   in	   this	   report	  were	   done	   at	  much	  more	   negative	   potentials	   and	   could	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correspond	  to	  a	  further	  reduction	  of	  the	  mycobactin	  complex	  that	  does	  not	  correspond	  to	  the	  Fe3+/Fe2+	  couple	  observed	  here.	  However,	  as	  shown	  in	  Figure	  24,	  CVs	  down	  to	  -­‐1.25	  V	   versus	   Ag/AgCl	   failed	   to	   produce	   an	   additional	   cathodic	   peak.	   However,	   since	  Miller’s	   experiments	   were	   performed	   in	   95%	   ethanol	   with	   NaClO4,	   the	   protonation	  equilibria	  will	  be	  different.	  This	  can	  have	  a	  significant	  effect	  on	  the	  reduction	  potential,	  as	  discussed	  below.	  In	   order	   to	   discover	   whether	   the	   redox	   couple	   could	   be	   restored	   to	   DFMJ	   by	  referration	  to	  form	  the	  ferric	  complex,	   ferric	  iron	  was	  titrated	  into	  the	  electrochemical	  solution.	  The	  addition	  of	   ferric	  chloride	   to	  DFMJ	  under	  unbuffered	  aqueous	  conditions	  led	  to	  a	  significant	  drop	  in	  pH	  and	  subsequent	  loss	  of	  reversibility	  as	  indicated	  both	  by	  an	   increase	   in	   redox	   peak	   separation	   and	   a	   decrease	   in	   the	   ratio	   of	   the	   anodic	   peak	  current	  to	  the	  cathodic	  peak	  current	  (ipa/ipc)	  (data	  not	  shown).	  When	  the	  solution	  was	  buffered	   using	   phosphate	   buffered	   saline	   (PBS)	   at	   pH	   7.4,	   DFMJ	   was	   successfully	  referrated	  to	  recover	  the	  characteristic	  redox	  couple	  as	  shown	  in	  Figure	  25.	  Note	  that	  in	  this	  instance	  the	  DFMJ	  CV	  shows	  a	  residual	  peak	  due	  to	  incomplete	  deferration,	  however	  the	  amplitude	  of	  this	  peak	  is	  increased	  significantly	  upon	  addition	  of	  ferric	  chloride.	  	  
	   	  
Figure	  24:	  Cyclic	  voltammograms	  of	  FeMJ	  and	  DFMJ	  in	  50	  percent	  ethanol,	  0.1	  M	  potassium	  
chloride,	  0.2	  V/s	  scan	  rate.	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Figure	  25:	  Cyclic	  voltammograms	  of	  DFMJ	  and	  referrated	  DFMJ	  in	  PBS	  buffered	  50	  percent	  ethanol,	  
0.1	  M	  potassium	  chloride,	  0.2	  V/s	  scan	  rate.	  A	   rearrangement	   of	   the	   Nernst	   equation,	   as	   shown	   by	   Harrington	   et	   al.199,	  provides	   the	   relationship	  between	   the	  reduction	  potential	  of	   the	  siderophore	  complex	  and	  of	  ratio	  of	  formation	  constants	  between	  the	  two	  oxidation	  states	  of	  iron:	  	  
	   Equation	  1	  	  where	   	   is	   the	   standard	   potential	   for	   reduction	   of	   the	   complex,	  Eaq	   is	   standard	  potential	  for	  reduction	  of	  Fe3+	  in	  solution,	  and	  βIII	  and	  βII	  are	  the	  formation	  constants	  for	  the	  complex	  with	  Fe3+	  and	  Fe2+	  respectively.	  Using	  the	  redox	  midpoint	  from	  the	  aqueous	  experiment	  (Figure	  24),	  this	  yields	  a	  βIII/βII	  ratio	  of	  1.9×1018.	  This	  signifies	  a	  difference	  in	  the	  affinity	  of	  mycobactin	  for	  the	  different	  oxidation	  states	  of	  iron,	  preferring	  Fe3+	  to	  Fe2+	  by	  18	  orders	  of	  magnitude.	  This	  finding	  is	  in	  agreement	  with	  previously	  published	  estimations	  for	  a	  water-­‐soluble	  analogue	  of	  mycobactin199.	  The	  underlying	  mechanism	  behind	  this	  difference	  in	  affinity	  is	  due	  not	  only	  to	  the	  resulting	   coordination	   mismatch	   within	   the	   structurally-­‐constrained	   hexadentate	  siderophore	   but	   also	   because	   the	   ‘hard’	   Lewis	   acid	   Fe3+	   has	   a	   preference	   for	   hard	  electron	  donor	  groups	  (e.g.	  the	  oxygen-­‐containing	  anionic	  ligands	  found	  in	  hydroxamic	  acids).	  It	  is	  typical	  for	  this	  to	  result	  in	  Fe3+	  equilibrium	  constants	  that	  differ	  from	  those	  of	   the	   ‘soft’	   Lewis	   acid	   Fe2+	   by	   13	   orders	   of	   magnitude,	   as	   measured	   for	   other	  hydroxamate	  siderophores201,	  202.	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Cyclic	   voltammetry	   of	   FeMJ	  was	   also	   tested	   using	   a	   gold	   electrode	   (AuE)	  with	  similar	   results.	   A	   comparison	   of	   CVs	   of	   FeMJ	   using	   Au	   and	   GC	   working	   electrodes	   is	  given	  in	  Figure	  26.	  The	  residual	  oxygen	  reduction	  peak	  was	  more	  pronounced	  on	  gold,	  merging	   with	   the	   reduction	   peak	   of	   the	   FeMJ	   complex.	   Notwithstanding	   this	  confounding	  factor,	  ipa/ipc	  was	  increased	  slightly	  using	  AuE	  in	  contrast	  to	  GCE.	  	  
	  
Figure	  26:	  	  Cyclic	  voltammograms	  of	  FeMJ	  on	  either	  AuE	  or	  GCE	  in	  50	  percent	  ethanol,	  0.1	  M	  
potassium	  chloride,	  0.2	  V/s	  scan	  rate.	  
3.2.1.2 Nonaqueous	  Cyclic	  Voltammetry	  The	   solubility	   of	   the	   mycobactins	   is	   a	   limitation	   in	   the	   study	   of	   their	  electrochemistry.	   The	   relatively	   hydrophobic	   nature	   of	   mycobactin	   lends	   itself	   to	  solvation	  in	  organic	  solvents.	  Furthermore,	  it	  may	  be	  desirable	  to	  utilise	  this	  property	  of	  mycobactin	   for	   pre-­‐analysis	   sample	   processing,	   which	   may	   include	   elution	   of	  mycobactin	   into	   the	   test	   cell	   by	   an	   organic	   solvent,	   as	   discussed	   in	   Chapter	   2.	   In	   this	  context,	   DMSO	  was	   chosen	   for	   its	   useful	   electrochemical	   window,	   universal	   solvation	  properties,	   and	   low	   volatility,	   which	   allowed	   facile	   deoxygenation	   of	   the	   solvent	   by	  bubbling	   nitrogen	   gas	   through	   the	   cell.	   Under	   this	   nonaqueous	   solvent	   system,	  more	  detailed	  and	  quantitative	   information	  was	  gained	  about	  the	  redox	  couple	  attributed	  to	  the	  FeMJ	  complex.	  	  Under	  this	  nonaqueous	  solvent	  system	  typical	  CVs	  of	  FeMJ	  (Figure	  27A)	  show	  a	  redox	  couple	  assigned	  to	  Fe3+/Fe2+	  with	  midpoint	  -­‐0.409	  V	  versus	  Ag/Ag+	  (at	  25	  mV/s,	  0.64	  mM).	   The	   effective	   elimination	   of	   interfering	   oxygen	   reduction	   allowed	   for	   a	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Figure	  27A:	  Cyclic	  voltammogram	  of	  FeMJ	  (640	  µM);	  0.2	  V/s	  in	  DMSO	  with	  0.1	  M	  LiCl.	  B:	  
Background-­corrected	  CVs	  of	  FeMJ	  at	  varying	  scan	  rates	  showing	  oxidation	  and	  reduction	  peaks.	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3.2.1.2.1 Coupled	  Chemical	  Reaction	  After	  Reduction	  to	  Ferrous	  Mycobactin	  For	  a	  simple	  electron	  transfer	  that	  is	   limited	  by	  diffusion,	   ip/ν1/2	  is	  independent	  of	  scan	  rate	  (ν),	  as	  given	  by	  a	  rearrangement	  of	  the	  Randles-­‐Sevcik	  equation203,	  204:	  	  
	   Equation	  2	  	  where	   n	   is	   the	   number	   of	   electrons	   transferred,	   F	   is	   the	   Faraday	   constant,	   D	   is	   the	  diffusion	  coefficient,	  R	   is	  the	  universal	  gas	  constant,	  and	  T	   is	  the	  absolute	  temperature.	  However,	   diagnostic	   plots	   of	   ip/ν1/2	   versus	   ν1/2	   decreased	   with	   scan	   rate	   (Figure	   28)	  with	  a	  slope	  that	  increased	  with	  FeMJ	  concentration.	  This	  points	  toward	  a	  more	  complex	  process	  characterised	  by	  a	  coupled	  electrochemical-­‐chemical	  pathway.	  	  
	  
Figure	  28:	  Plot	  of	  ip/ν1/2	  versus	  ν1/2	  shown	  for	  both	  the	  reduction	  and	  oxidation	  peaks	  of	  FeMJ.	  The	   anodic	   (oxidation)	   peak	   is	   typically	   small	   compared	   with	   the	   cathodic	  (reduction)	  peak,	  with	  ipa/ipc	  less	  than	  1	  for	  all	  scan	  rates	  and	  concentrations,	  as	  shown	  in	   Table	   9	   and	   Figure	   29.	   This	   is	   also	   consistent	   with	   the	   presence	   of	   a	   competing	  chemical	   reaction	   following	   reduction.	   For	   FeMJ	   this	   could	   be	   due	   to	   the	   partial	   or	  complete	  dissociation	  of	  reduced	  Fe2+	  from	  the	  MJ	  complex	  (k2	  in	  Scheme	  1).	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Table	  9:	  FeMJ	  ia/ic	  ratios	  on	  GCE	  in	  DMSO	  with	  0.1	  M	  LiCl.	  	   Scan	  Rate	  (V/s)	  
FeMJ	  Concentration	   0.025	   0.05	   0.1	   0.2	   0.4	   0.8	   1.6	   3.2	  
10	  µM	   0.25	   0.23	   0.17	   0.33	   0.30	   0.46	   0.94	   0.73	  
20	  	  µM	   0.42	   0.14	   0.10	   0.15	   0.14	   0.50	   0.57	   0.70	  
40	  	  µM	   0.53	   0.38	   0.31	   0.14	   0.11	   0.49	   0.42	   0.59	  
80	  	  µM	   0.48	   0.40	   0.27	   0.26	   0.32	   0.23	   0.27	   0.66	  
160	  	  µM	   0.76	   0.60	   0.42	   0.41	   0.42	   0.54	   0.48	   0.50	  
320	  	  µM	   0.99	   0.83	   0.78	   0.77	   0.79	   0.82	   0.70	   0.61	  
640	  	  µM	   0.92	   0.88	   0.88	   0.85	   0.85	   0.88	   0.87	   0.68	  	  
	  
Figure	  29:	  FeMJ	  ia/ic	  ratios	  on	  GCE	  in	  DMSO	  with	  0.1	  M	  LiCl.	  	  
	  



























	  	   78	  
However,	  at	  high	  concentrations	  of	  FeMJ	  (greater	  than	  150	  µM)	  ipa/ipc	  appeared	  to	  decrease	  (from	  ~0.9	  to	  ~0.8),	  or	  remain	  constant	  with	  increasing	  scan	  rate	  (see	  CVs	  in	  Figure	  27B).	  This	  also	   supports	  a	   scheme	  whereby	  Fe2+	  dissociation	  competes	  with	  the	  electrochemical	  oxidation	  of	  FeMJ-­‐.	  Upon	  addition	  of	  exogenous	  Fe3+	   in	  the	  form	  of	  Fe(acac)3,	   ipa/ipc	  continues	  to	  increase	  to	  near	  unity	  for	   low	  scan	  rates,	  possibly	  due	  to	  high	   Fe2+	   concentrations	   near	   the	   electrode	   (from	   exogenous	   Fe3+	   being	   reduced	   at	   a	  potential	  cathodic	  of	  the	  Fe(acac)3	  redox	  potential)	  driving	  the	  k2/k-­‐2	  equilibrium	  away	  from	  dissociation.	  
3.2.1.2.2 Referration	  of	  DFMJ	  in	  Nonaqueous	  Solvent	  CVs	  of	  DFMJ	   in	  nonaqueous	  solvent	   lacked	   the	  peaks	  characteristic	  of	  FeMJ	  but	  these	  peaks	  returned	  upon	  titration	  with	  Fe(acac)3,	  as	  shown	  in	  Figure	  30.	  The	  1:1	  iron-­‐binding	  ratio	  of	  DFMJ	  to	  Fe3+	  is	  evident	  and	  in	  the	  presence	  of	  excess	  Fe(acac)3,	  with	  the	  reduction	  peak	  of	  this	  compound	  appearing	  at	  ‑0.28	  V	  versus	  Ag/Ag+.	  This	  also	  creates	  a	  background	   current	   due	   to	   Fe(acac)3	   reduction,	   resulting	   in	   	   excess	   Fe2+	   near	   the	  electrode	   surface	   and	   pushing	   the	   k2/k-­‐2	   equilibrium	   toward	   stability	   of	   the	   Fe2+	  complex,	  as	  discussed	  above.	   In	  accordance	  with	  this,	   reversibility	  appears	   to	   increase	  with	   increasing	   Fe3+:DFMJ	   ratio	   as	   well	   as	   with	   increasing	   overall	   siderophore	  concentration,	   suggesting	   that	  higher	   concentrations	  of	   the	   ferric	   complex	   inhibit	  Fe2+	  dissociation.	  
	  
Figure	  30:	  Referration	  of	  DFMJ	  by	  titration	  with	  Fe(acac)3	  at	  0.2	  V/s	  in	  DMSO,	  0.1	  M	  LiCl.	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The	   chelated	   ferric	   iron	   in	   Fe(acac)3	   and	   FeMJ,	   exhibit	   distinctly	   different	  reduction	   potentials.	   This	   is	   due	   to	   the	   greater	   stabilisation	   effect	   of	   the	   high-­‐affinity	  iron-­‐chelating	  ligand	  of	  mycobactin,	  which	  shifts	  the	  reduction	  potential	  in	  the	  negative	  direction197,	   requiring	   more	   energy	   to	   achieve	   reduction	   than	   the	   relatively	   unstable	  Fe(acac)3	  iron	  ion.	  CVs	  of	  Fe(acac)3	  alone	  are	  shown	  in	  Figure	  31	  for	  reference.	  These	  data	  allow	  us	  to	  expand	  upon	  Scheme	  1	  to	   include	  the	   initial	   ferration	  of	  DFMJ	   as	   given	   in	   Scheme	   2	   below.	   The	   depiction	   of	   Fe(acac)3	   in	   Scheme	   2	   is	   an	  oversimplification,	  as	  the	  relatively	  labile	  complex205	  most	  likely	  dissociates	  to	  different	  degrees	  in	  the	  DMSO	  solvent.	  This	  is	  readily	  observed	  in	  the	  CVs	  of	  Fe(acac)3	  in	  Figure	  31	   where	   the	   complex	   gives	   rise	   to	   several	   different	   redox	   couples,	   which	   likely	  correspond	   to	   different	   species	   of	   metal-­‐ligand	   coordination	   and	   solvation	   by	   DMSO	  (such	   as	   [Fe(acac)2(DMSO)2]+).	   However,	   in	   the	   interest	   of	   maintaining	   focus	   on	   the	  electrochemistry	  of	  mycobactin,	  it	  has	  been	  simplified	  as	  Fe(acac)3	  in	  Scheme	  2.	  	  
	  
Figure	  31:	  Cyclic	  voltammetry	  of	  Fe(acac)3	  at	  0.2	  V/s	  in	  DMSO,	  0.1	  M	  LiCl.	  
	  
Scheme	  2	  
-0.8 -0.6 -0.4 -0.2 0 0.2 0.4 0.6


































DFMJ + Fe(acac)3 [DFMJ]
3- + Fe2+
	  	   80	  
3.2.1.2.3 Thermodynamic	  Stability	  of	  the	  Complex	  Analysis	  of	  plots	  of	  the	  peak	  potential	  (Ep)	  versus	  ln	  ν	  (Figure	  32A)	  reveals	  that	  the	   peak	   potential	   tends	   toward	   more	   negative	   potentials	   with	   increase	   in	   FeMJ	  concentration,	   specifically	  at	   low	  scan	  rates.	  The	  same	  phenomenon	   is	  observed	  when	  the	  concentration	  of	  DFMJ	   is	  held	  constant	  and	  Fe(acac)3	   is	   titrated	   into	   the	  cell,	   as	   in	  Figure	   30	   and	   Figure	   32B,	   but	   not	  when	   Fe(acac)3	   is	   titrated	   into	   solution	   containing	  already	  ferrated	  FeMJ	  as	  shown	  in	  Figure	  32C.	  This	  indicates	  that	  the	  shift	  is	  specific	  to	  concentration	  of	  the	  complex	  and	  not	  to	  excess	  DFMJ	  or	  Fe(acac)3	  that	  might	  be	  present.	  This	  is	  comparable	  to	  the	  increase	  in	  reversibility	  that	  is	  also	  observed	  with	  increasing	  complex	  concentration.	  A	  negative	  shift	   in	   the	  position	  of	   the	  redox	  couple	   indicates	  a	  further	  stabilisation	  of	  the	  ferric	  siderophore	  complex	  taking	  place197.	  Pursuant	   to	   Equation	   1,	   any	   increase	   in	   the	   ratio	   of	   the	   affinity	   constants	   for	  Fe3+/Fe2+	   will	   result	   in	   a	   negative	   potential	   shift	   for	   the	   complex	   redox	   couple.	   This	  could	  be	  either	  due	  to	   increased	  stability	  of	  the	  Fe3+	  complex,	  or	  decreased	  stability	  of	  the	  Fe2+	  complex.	  The	  reversibility	  data	  indicate	  that	  stability	  of	  the	  Fe2+	  complex	  mostly	  increases	  with	  siderophore	  concentration,	  which	  would	  indicate	  that	  stability	  of	  the	  Fe3+	  complex	   must	   be	   increasing	   in	   order	   to	   exhibit	   this	   negative	   peak	   potential	   shift.	   A	  possible	   explanation	   for	   this	   is	   that	   at	   relatively	   high	   concentrations	   of	   mycobactin,	  some	   self-­‐assembly	   into	  micelles	   takes	   place,	   leading	   to	   a	   higher	   degree	   of	   structural	  stability,	   and	   thus	   stability	   of	   the	   complex.	   Measurements	   of	   related	   siderophores	   in	  aqueous	  media	  have	  yielded	  critical	  micelle	  concentrations	  in	  the	  range	  of	  25-­‐150	  µM42,	  however	  this	  would	  likely	  be	  much	  higher	  in	  organic	  solvents	  such	  as	  DMSO.	  Additionally,	   the	   transition	   from	   quasi-­‐reversible	   character	   to	   irreversible	  character,	   as	   indicated	   by	   spreading	   peak	   separation,	   shifts	   from	   relatively	   high	   scan	  rates	   at	   low	   FeMJ	   concentrations	   to	   lower	   scan	   rates	   at	   high	   concentrations.	   This	   is	  especially	   evident	   in	   the	   oxidation	   peak.	   Peak	   separation	   at	   low	   scan	   rates	   also	  decreases	  with	   increase	   in	  concentration,	   lending	   further	  support	   to	   the	   idea	  that	  Fe2+	  dissociation	  is	  reversed	  in	  the	  presence	  of	  higher	  concentrations	  of	  FeMJ.	  	  







Figure	  32A:	  Ep	  versus	  ln	  ν;	  dashed	  lines	  indicate	  bounds	  of	  the	  lower	  concentration	  data,	  while	  
solid	  lines	  indicate	  bounds	  of	  the	  higher	  concentration	  data	  for	  either	  the	  reduction	  or	  oxidation	  
peak;	  light	  dotted	  lines	  are	  linear	  trend	  lines	  for	  the	  low	  and	  high	  scan	  rate	  oxidation	  data,	  the	  
intersection	  of	  which	  indicates	  the	  critical	  scan	  rate	  (νc).	  B:	  The	  same	  plot,	  but	  for	  a	  constant	  
concentration	  of	  DFMJ	  referrated	  by	  a	  titration	  of	  Fe(acac)3.	  C:	  The	  same	  plot,	  but	  for	  a	  constant	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3.2.1.2.4 Calculation	  of	  the	  Heterogeneous	  Electron	  Transfer	  Rate	  Constant	  Plots	  of	   the	  cathodic	  peak	  potential	   (Epc)	   for	  FeMJ,	  versus	   log10	  ν	  yielded	  slopes	  greater	  than	  30	  mV	  per	  decade	  for	  scan	  rates	  greater	  than	  0.2	  V/s	  at	  all	  concentrations	  (Figure	  32A	  shows	  Epc	  versus	  ln	  ν).	  The	  same	  is	  true	  for	  the	  anodic	  peak	  potential	  (Epa)	  at	  high	  FeMJ	  concentrations.	  This	   indicates	  an	  adequate	  degree	  of	   irreversibility	  of	  the	  reaction206	  at	  scan	  speeds	  greater	  than	  0.2	  V/s	  to	  allow	  use	  of	  a	  theory	  first	  developed	  by	  Nicholson	  and	  Shain207,	  followed	  by	  Klingler	  and	  Kochi206.	  This	  theory	  is	  applicable	  to	  organometallic	   complexes	   such	   as	  mycobactin	   and	   allows	   calculation	   of	   the	   apparent	  transfer	  coefficients	  βv	  and	  βw	  from	  kinetic	  data	  at	  Ep.	  Ultimately	  this	  allows	  calculation	  of	   the	  heterogeneous	  electron	   transfer	   rate	   constant	   (ks).	  According	   to	   this	  method	  βv	  and	  βw	  are	  given	  by:	  	  
	   Equation	  3	  	   	  	   Equation	  4	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with	  βw	   obtained	   from	  Equation	   4	   (shown	   in	   Figure	   33),	  which	   tends	   toward	  ~0.4	   at	  high	   scan	   rates	   and	   concentrations.	   According	   to	   Klingler	   and	   Kochi,	   good	   agreement	  between	   βw	   and	   βv	   	   (correlated	   with	   a	   reversibility	   factor	   less	   than	   0.5)	   allows	   the	  electron	  transfer	  rate	  constant	  at	  the	  CV	  peak	  potential	  k(Ep)	  to	  be	  obtained	  and	  thence	  ks	  according	  to:	  	  
	   Equation	  5	  	   Assuming	   a	   diffusion	   coefficient	   (D)	   of	   1.7×10-­‐5	   cm2/s	   yields	   ks	   ≈	   5×10-­‐3	   cm/s.	  These	  data	   further	  support	   the	  proposed	  quasi-­‐reversible	   chemically	   coupled	   reaction	  scheme	  as	  summarised	  in	  Scheme	  2	  above.	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Figure	  34:	  Amperometric	  titration	  of	  FeMJ	  at	  -­0.6	  V	  versus	  Ag/Ag+.	  The	  areas	  with	  spikes	  of	  noise	  
correspond	  to	  periods	  of	  stirring	  with	  a	  magnetic	  stir	  bar	  following	  addition	  of	  FeMJ.	  No	  FeMJ	  was	  
added	  to	  the	  cell	  during	  the	  first	  two	  stirring	  events	  to	  serve	  as	  controls.	  
	  
Figure	  35:	  Ratio	  of	  the	  measured	  current	  (i)	  over	  background	  current	  (i0)	  at	  -­0.8	  V	  from	  CV	  data	  to	  
approximate	  steady-­state	  values.	  In	   most	   electrochemical	   test	   strips	   an	   immobilisation	   system	   is	   employed	   to	  either	   capture	   the	   analyte	   or	   catalyse	   an	   electrochemical	   reaction	   to	   enhance	   the	  measured	  charge	  transfer	  at	  the	  electrode	  surface.	  In	  the	  former	  case	  this	  enhancement	  occurs	   because	   analyte	   is	   concentrated	   near	   the	   electrode	   surface	   for	   immediate	  reduction.	  Such	  a	  capture	  and	  concentration	  scheme	  is	  especially	  useful	  when	  trying	  to	  detect	   low	  analyte	  concentrations.	   In	  contrast	   to	   the	   test	  strips,	   the	  measurand	  of	   this	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assay	   is	   not	   being	   generated	   or	   captured	   at	   the	   electrode	   surface	   and	   this	   low,	   bulk	  solution	   response	   is	   typical	   for	   some	   redox	   systems	  with	   slow	  kinetics.	   If	   this	   type	  of	  technique	  were	  to	  be	  used	  it	  would	  require	  a	  mycobactin	  binding	  ligand	  on	  the	  electrode	  to	   capture	   and	   concentrate	  mycobactin	   from	   the	   sample.	   This	   possibility	   is	   discussed	  further	  in	  Chapter	  6.	  Another	   way	   of	   potentially	   improving	   upon	   this	   response	   is	   by	   improving	   the	  specific	   surface	  binding	  properties	  between	   the	   electrode	   and	  FeMJ	   itself.	   This	   can	  be	  done	  through	  surface	  engineering	  of	  the	  electrode,	  which	  will	  also	  be	  discussed	  further	  in	  Chapter	  7.	   Since	   the	   target	  mycobactin	   concentration	  proposed	   in	  Chapter	  1	   is	   less	  than	  250	  nM,	  potentiostatic	  methods	  were	  not	  pursued	  any	  further	  at	  this	  stage.	  
3.2.3 Electrochemical	  Limit	  of	  Detection	  Using	   cyclic	   voltammetry,	   peak	   height/non-­‐faradaic	   current	   ratios	   can	   be	  manipulated	  through	  scan	  speed.	  High	  scan	  speeds	  yield	  a	  greater	  current	  peak	  at	  high	  FeMJ	   concentrations,	   as	   would	   be	   expected.	   However,	   this	   advantage	   is	   lost	   at	   lower	  concentration	   due	   to	   peak	   broadening	   at	   high	   scan	   rates	   inhibiting	   accurate	  quantification.	  The	  result	  is	  that	  low	  scan	  rates	  (25	  mV/s)	  produced	  the	  best	  sensitivity	  and	  a	  linear	  relationship	  between	  ip	  and	  concentration	  at	  FeMJ	  concentrations	  in	  the	  10-­‐160	  µM	  range	  (Figure	  36).	  As	  predicted	  from	  the	  mechanistic	  analysis	  in	  section,	  3.2.1.2,	  the	   electron	   transfer	   exhibits	   a	  more	   irreversible	   character	   at	   low	  concentrations	   and	  the	  oxidation	   signal	   does	  not	  begin	   to	   appear	  until	   FeMJ	   concentrations	  have	   reached	  20	  µM.	   At	   1	  mM,	   FeMJ	   redox	   peaks	   were	   observed	   up	   to	   20	  V/s	   scan	   rate;	   however,	  quantitative	  analysis	  was	  only	  possible	  up	  to	  5	  V/s	  due	  to	  excessive	  broadening	  of	   the	  peaks.	   A	   standard	   curve	   was	   created	   based	   on	   these	   measurements	   to	   enable	  electrochemical	  quantification	  of	  mycobactin.	  	  





Figure	  36A:	  Titration	  of	  FeMJ	  by	  cyclic	  voltammogram	  at	  0.2	  V/s	  in	  DMSO,	  0.1	  M	  LiCl.	  B:	  CV	  peak	  
current	  versus	  FeMJ	  concentration.	  In	   section,	  3.2.1.2,	   it	  was	   shown	   that	  addition	  of	  Fe(acac)3	   to	   the	  FeMJ	   solution	  increased	  the	  reversibility.	  The	  relationship	  between	  the	  electrochemistry	  of	  FeMJ	  and	  Fe(acac)3	   may	   also	   offer	   another	   way	   of	   increasing	   the	   sensitivity	   of	   mycobactin	  detection.	   When	   DFMJ	   was	   titrated	   into	   a	   solution	   of	   Fe(acac)3	   the	   decrease	   in	   the	  concentration	  of	  Fe(acac)3	  upon	  the	  iron	  being	  competitively	  chelated	  by	  DFMJ	  to	  form	  FeMJ	  was	  observable	  with	  higher	  sensitivity	  than	  the	  signal	  due	  to	  the	  increase	  of	  [FeMJ]	  alone.	   This	   suggested	   a	   potential	   use	   in	   which	   the	   concentration	   of	   DFMJ	   may	   be	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indirectly	  measured	  through	  ratiometric	  measurement	  of	  Fe(acac)3	  redox	  peaks.	  This	  is	  demonstrated	  in	  Figure	  37.	  The	  best	  sensitivity	  could	  be	  achieved	  by	  taking	  the	  ratio	  of	  the	  current	  at	  0.38	  V	   to	   the	  current	  at	   -­‐0.02	  V,	   taking	  advantage	  of	   the	  changes	   in	   the	  electrochemical	  signal	  from	  Fe(acac)3	  with	  addition	  of	  DFMJ.	  However,	  in	  order	  for	  this	  method	  to	  be	  used,	  we	  encounter	   the	   limitation	  of	  having	   to	  deferrate	   the	  mycobactin	  prior	  to	  conducting	  the	  detection	  assay,	  which	  is	  an	  unrealistic	  requirement.	  However,	  changes	  are	  observable	  for	  DFMJ	  concentrations	  at	  least	  as	  low	  as	  10	  µM.	  	  
	  
Figure	  37:	  Titration	  of	  DFMJ	  into	  a	  300	  µM	  solution	  of	  Fe(acac)3	  at	  0.2	  V/s	  in	  DMSO,	  0.1	  M	  LiCl.	  
3.3 Conclusions	  The	   redox	   electrochemistry	   for	   FeMJ	   shows	   slow	  quasi-­‐reversible	   kinetics.	   The	  chemically	  coupled	  electron	  transfer	  mechanism	  for	  FeMJ	  is	  influenced	  by	  the	  presence	  of	  Fe2+	   and	  Fe3+	   in	   solution,	  despite	   the	  affinity	   for	  Fe3+	  being	  18	  orders	  of	  magnitude	  greater	   than	   for	   Fe2+.	   At	   the	   redox	   potential	   for	   FeMJ,	   Fe3+	   (typically	   complexed	  with	  acetylacetone	  under	   the	   conditions	  used	  here)	   is	   reduced	   to	  Fe2+	   at	   the	  electrode	  and	  thus	   [Fe2+]	   is	  always	  elevated,	  pushing	   the	  FeMJ-­‐	  dissociation	  equilibrium	   towards	   the	  complex	  (Scheme	  2).	  	  In	  a	  simple	  voltammetric	  experiment	  the	  limit	  of	  detection	  for	  mycobactin	  by	  CV	  was	   found	   to	   be	   in	   the	   order	   of	   10	  µM	   and	   allowed	   quantitative	   analysis	   of	   the	  mycobactin	   content	   of	   an	   electrochemical	   test	   solution.	   This	   compares	   with	   a	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preliminary	  target	  of	   less	  than	  250	  nM	  as	  suggested	  in	  Chapter	  2.	  Unfortunately	  it	  was	  not	   possible	   to	   improve	   upon	   this	   limit	   of	   detection	   through	   the	   use	   of	   other	  electrochemical	   techniques	   including	   chronoamperometry,	   square-­‐wave	   voltammetry	  (data	   not	   shown),	   and	   dual-­‐circuit	   four-­‐electrode	   gap	   electrochemistry	   utilising	  feedback	  diffusion	  (data	  not	  shown).	  Addition	  of	   excess	  Fe2+	   into	   the	   sample	   can	   improve	   the	   chemical	   reversibility,	  but	   did	   not	   improve	   sensitivity	   of	   the	   assay.	   Sensitivity	   of	   the	   sensor	   is	   core	   to	   its	  usefulness	  as	   the	  quantity	  of	  mycobactin	   to	  be	   found	  circulating	  within	  TB	  patients	   is	  likely	  to	  be	  minute.	  The	  level	  of	  mycobactin	  production	  in	  an	  infection	  and	  the	  level	  at	  which	   it	   may	   be	   present	   is	   crucial	   to	   whether	   an	   effective	   TB	   diagnostic	   can	   be	  developed.	  Clearly,	  based	  on	  the	  Chapter	  2	  estimate	  of	  physiological	  mycobactin	  production	  further	  work	  on	  either	  the	  electrochemical	  method	  or	  sample	  preparation	  is	  required	  to	  further	  reduce	  the	  detection	   limit.	  As	  seen	  here,	  solubility	  of	   the	  mycobactin	   in	  typical	  biological	  aqueous	  based	  media	  is	  poor	  (hence	  its	  association	  with	  lipids)	  so	  that	  DMSO	  has	  been	  employed	  as	  the	  assay	  solvent.	  	  This	  preparation	  step	  also	  offers	  the	  possibility	  of	   linking	   sample	   concentration	   into	   the	   protocol	   thereby	   improving	   on	   the	   detection	  limit.	   Therefore	   this	   electrochemical	   assay	   is,	   in	   principle,	   applicable	   for	   use	   with	  material	   from	  a	  variety	  of	  biological	  sampling	  media	  depending	  on	  sample	  processing.	  This	   is	   further	   explored	   in	   Chapter	   4	   with	   a	   proof	   of	   concept	   detection	   and	  quantification	  of	  mycobactin	  from	  urine	  as	  an	  example	  sampling	  medium.	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4 Proof-­of-­Concept	  Application	  of	  the	  Assay	  
The	   research	   reported	   in	   this	   chapter	   demonstrates	   the	   utility	   of	   the	   simple	  electroanalytical	  mycobactin	  assay,	  described	   in	  Chapter	  3,	   for	  monitoring	  mycobactin	  levels	   within	   an	   example	   biological	   medium.	   This	   included	   a	   determination	   as	   to	  whether	   there	   is	   any	   significant	   background	   interference	   when	   using	   the	   example	  medium.	  The	  primary	  motivation	   for	   this	   investigation	  was	   the	  need	   for	   a	   biosensor	   for	  use	   as	   a	   TB	   diagnostic.	   However,	   since	  mycobactin	   trafficking	  within	   the	   body	   of	   the	  host	   is	  still	  under	   investigation,	  concentration	  of	  mycobactins	   in	  different	  bodily	   fluids	  or	   tissues	   is	  not	  yet	  well	   enough	  defined	   to	  allow	  an	  assay	   to	  be	  directed	   toward	  one	  specific	   sampling	   medium	   to	   the	   exclusion	   of	   others.	   Thus,	   an	   example	   biological	  sampling	  medium	  had	  to	  be	  selected	  for	  proof-­‐of-­‐concept	  testing	  of	  the	  assay.	  Collection	   and	   handling	   of	   the	   sample	   material,	   particularly	   when	   it	   is	   of	  biological	   origin	   is	   integral	   to	   the	   ultimate	   safety,	   utility,	   and	   sensitivity	   of	   the	   assay.	  Relatively	  simple	  analyte	  concentration	  methods	  can	  be	  applied	  to	  the	  sample	  prior	  to	  analysis,	   thus	   greatly	   increasing	   the	   sensitivity,	   and	   also	   removing	   a	   great	   deal	   of	  background	   interference.	  Thus,	   a	   further	  goal	   in	   this	   chapter	   is	   to	  define	  and	  evaluate	  the	   processing	   steps	   to	   collect	   the	   mycobactin	   that	   might	   be	   present	   in	   a	   complex	  biological	   matrix	   while	   simultaneously	   removing	   bulk	   contaminants	   that	   could	  physically	  impede	  the	  analysis.	  It	  is	  also	  necessary	  to	  ascertain	  whether	  any	  conflicting	  signals	  might	  be	  observed	  from	  compounds	  commonly	  found	  in	  the	  sampling	  medium.	  An	   example	   of	   this	   would	   be	   a	   hypothetical	   compound	   that	   exhibits	   a	   similar	   redox	  potential	  to	  ferric	  mycobactin,	  thereby	  interfering	  with	  the	  electrochemical	  assay.	  The	   biological	   sampling	   media	   of	   potential	   interest	   for	   consideration	   in	  mycobactin	  detection	  include	  blood,	  urine,	  hair,	  and	  stool	  as	  well	  as	  homogenised	  lung	  tissue,	   sputum,	   and	   saliva.	   The	   collection	   and	   handling	   of	   blood	   samples	   poses	   a	  significant	  risk	  of	  infection	  to	  the	  clinician	  obtaining	  the	  sample,	  as	  well	  as	  anyone	  who	  must	  process	  it	  thereafter.	  This	  is	  especially	  risky	  in	  areas	  with	  high	  rates	  of	  HIV/AIDS	  co-­‐infection	  with	  TB,	  which	  is	  a	  growing	  problem	  in	  many	  populations.	  This,	  as	  well	  as	  the	  invasiveness	  of	  sample	  collection	  makes	  blood	  a	  less	  desirable	  diagnostic	  sampling	  medium.	   Urine	   would	   be	   the	   ideal	   sampling	   medium	   due	   to	   its	   relatively	   low	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infectiousness	   and	   ease	   of	   collection.	   For	   comparison,	   of	   the	   clinically	   useful	  siderophores,	   deferoxamine	   and	   deferiprone	   are	   excreted	   primarily	   in	   the	   urine,	  whereas	   deferasirox	   is	   excreted	   faecally.	   However,	   the	   biodistribution	   and	  pharmacokinetics	  of	  mycobactin	  and	  carboxymycobactin	  are	  still	  unknown.	   It	   remains	  to	  be	  seen	  as	  to	  whether	  these	  compounds	  would	  be	  found	  in	  the	  urine	  due	  to	  filtration	  in	   the	   kidneys	   and	   partitioning	   of	   the	   significantly	   hydrophobic	  mycobactins	   into	   cell	  membranes.	  Saliva	  would	  be	  a	  secondary	  choice,	  as	  a	  relatively	  non-­‐invasive	  sampling	  medium.	  It	  is	  considered	  more	  infectious	  and	  may	  harbour	  live	  mycobacteria.	  In	  contrast,	  homogenised	   lung	   tissue,	  while	  being	   the	  most	  probable	   to	  contain	  high	  concentrations	  of	  mycobactin	  produced	  by	  the	  infecting	  organism,	  is	  both	  difficult	  to	  obtain	  and	  unsuitable	  for	  ongoing	  monitoring	  of	  patients.	  Routine	  harvesting	  of	  lung	  tissue	  is	  only	  an	  option	  in	  the	  case	  of	  animal	  models	  during	  necropsy.	  Sputum	  samples	  are	   also	   difficult	   to	   obtain	   and	   to	   ship	   due	   to	   their	   potential	   to	   be	   highly	   infectious,	  thereby	   requiring	   measures	   to	   avoid	   infection	   at	   all	   times	   during	   sample	   handling.	  Additionally,	  sputum	  samples	  have	  a	  high	  degree	  of	  variability	  and	  inconsistency.	  Taking	  all	  of	  these	  considerations	  into	  account	  urine	  was	  chosen	  as	  the	  example	  biological	  medium	  on	  which	  to	  test	  the	  assay.	  
4.1 Materials	  and	  Methods	  
4.1.1 Bovine	  Urine	  Samples	  Bovine	  urine	  donated	  anonymously	  by	   cattle	   from	   the	  University	  of	  Cambridge	  dairy	   herd	   was	   made	   available	   through	   collaboration	   with	   Duncan	   Maskell	   of	   the	  Department	   of	   Veterinary	   Medicine.	   The	   herd	   is	   tested	   every	   four	   years	   for	   bovine	  tuberculosis	  via	  intradermal	  skin	  test	  with	  the	  last	  test	  having	  taken	  place	  in	  August	  of	  2009.	   Routine	   testing	   for	   Jöhne’s	   disease	   is	   not	   done,	   however	   there	   had	   been	   no	  suspected	   clinical	   cases	  within	   the	  past	   six	   years	   at	   the	   time	  of	  writing.	  Urine	   sample	  collection	  was	   carried	   out	   by	  Nicholas	  McBride	   on	   the	   27th	   of	   September	   and	   22nd	   of	  October,	  2010.	  Urination	  was	  induced	  in	  female	  cattle	  by	  rubbing	  the	  perineum.	  In	  the	  capacity	  that	  this	  sampling	  medium	  may	  also	  serve	  for	  future	  TB	  diagnostic	  testing	  there	  is	   relevance	   in	   the	   prevalence	   of	   the	   spread	   of	   bovine	   tuberculosis	   in	   the	   United	  Kingdom.	   The	   urine	   was	   spiked	   with	   FeMJ	   to	   test	   both	   the	   effectiveness	   of	   the	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electrochemical	   detection	   method	   and	   to	   develop	   a	   chromatographic	   mycobactin	  concentration	  step	  that	  is	  effective	  for	  an	  actual	  biological	  matrix.	  
4.1.2 Preparatory	  Chromatographic	  Concentration	  of	  Mycobactin	  Due	   to	   the	   relatively	   hydrophobic	   nature	   of	   mycobactin,	   and	   even	  carboxymycobactin,	   chromatographic	   concentration	   was	   performed	   using	   reverse-­‐phase	  Waters	   Sep-­‐Pak	   tC18	   cartridges	   containing	   50	  mg	   of	   sorbent	   and	   having	   a	   bead	  size	  of	  37-­‐55	  µm,	  pore	  size	  of	  125	  Å,	  and	  bed	  volume	  of	  0.13	  mL.	  The	  sample	  was	  eluted	  in	   3×0.5	  mL	   of	   diethyl	   ether	   and	   the	   eluate	   solvent	  was	   subsequently	   removed	   under	  vacuum.	  Spectrophotometric	  analysis	  was	  done	  after	  dissolving	  the	  residue	  in	  0.75	  mL	  methanol.	   Alternatively,	   electrochemical	   analysis	   was	   performed	   after	   dissolving	   the	  residue	  in	  0.1	  mL	  DMSO	  containing	  0.1	  M	  lithium	  chloride.	  In	  the	  case	  that	  both	  analyses	  were	   performed,	   the	   dry	   eluates	   were	   first	   analysed	   spectrophotometrically,	   the	  methanol	  was	  removed,	  then	  the	  samples	  were	  analysed	  electrochemically.	  
4.1.3 Spiking	  of	  Samples	  Initial	   testing	  of	   the	  chromatographic	  method	  was	  done	  using	  water	   in	  place	  of	  urine.	  25	  mL	  of	  purified,	  deionised	  water	  was	  spiked	  with	  a	  stock	  solution	  of	  5	  mM	  FeMJ	  in	  either	  DMSO	  or	  methanol	  to	  give	  final	  concentrations	  of	  5	  µM	  FeMJ	  and	  0.1	  percent	  of	  the	  respective	  solvent.	  For	  the	  triplicate	  bovine	  urine	  experiment,	  urine	  was	  collected	  from	  three	  female	  cows	  and	  divided	  into	  25	  mL	  aliquots.	  These	  samples	  were	  then	  either	  spiked	  with	  2	  µM	  FeMJ	   and	  0.1%	  DMSO	   (final	   concentration),	   or	   left	   unspiked	   and	   frozen	   at	   -­‐80°C	  until	  chromatography	  was	  performed.	  They	  were	  not	  filtered	  prior	  to	  analysis.	  
4.1.4 Effects	  of	  Sample	  Processing	  The	  urine	  processing	  was	   tested	  using	  urine	   collected	   from	  one	  healthy	   female	  cow	  and	   split	   into	  25	  mL	  aliquots.	   Each	   aliquot	   (designated	  NEG1,	  NEG2,	  POS1,	  POS2,	  and	   POS3)	   was	   then	   treated	   as	   defined	   in	   Table	   10.	   When	   indicated,	   spiking	   of	   the	  samples	  by	  FeMJ	  was	  done	  as	  above	  using	  a	  DMSO	  stock	  of	  FeMJ.	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Table	  10:	  Bovine	  urine	  processing	  method	  validation;	  addition	  of	  FeMJ	  gave	  a	  final	  concentration	  
of	  5	  µM	  FeMJ.	  The	  steps	  highlighted	  in	  red	  were	  performed	  at	  the	  University	  of	  Cambridge	  
Department	  of	  Veterinary	  Medicine	  due	  to	  biosafety	  category	  2	  requirements,	  whereas	  steps	  
highlighted	  in	  green	  were	  performed	  and	  the	  Department	  of	  Chemical	  Engineering	  and	  
Biotechnology.	  
	   Treatment	   NEG1	   NEG2	   POS1	   POS2	   POS3	  Add	  FeMJ	  before	  filtration	   -­‐	   -­‐	   +	   +	   -­‐	  0.22	  µm	  filtration	   -­‐	   +	   -­‐	   +	   +	  Add	  FeMJ	  after	  filtration	   -­‐	   -­‐	   -­‐	   -­‐	   +	  Frozen	  at	  -­‐80°C	   +	   +	   +	   +	   +	  Sep-­‐Pak	  tC18	  chromatography	  	   +	   +	   +	   +	   +	  
Process	  Steps	  →
 Analysis	  (spectrophotometric	  and	  electrochemical)	   +	   +	   +	   +	   +	  
4.2 Results	  and	  Discussion	  
4.2.1 Chromatographic	  Collection	  and	  Elution	  of	  Mycobactin	  Spectrophotometric	   analysis	   of	   the	   eluates	   and	   flow-­‐throughs	   from	   initial	   C18	  chromatography	  of	  spiked	  water	  reveal	  that	  when	  FeMJ	  is	  initially	  solubilised	  in	  DMSO,	  it	  is	  retained	  on	  the	  C18	  column,	  whereas	  when	  it	  is	  initially	  solubilised	  in	  methanol,	  the	  vast	  majority	  of	  FeMJ	  passes	  through	  the	  column	  with	  only	  a	  small	  quantity	  retained	  on	  the	  stationary	  phase.	  This	  is	  demonstrated	  by	  the	  difference	  in	  absorption	  at	  450	  nm,	  as	  shown	   in	   Figure	   38.	   A	   potential	   explanation	   for	   this	   phenomenon	   is	   that	   the	   DMSO	  remains	  associated	  with	  the	  mycobactin	  even	  upon	  dilution	  in	  water.	  This	  is	  consistent	  with	   studies	   of	   DMSO	   solvation	   of	   lipid	   membranes	   that	   show	   strong	   associations	  between	   DMSO	   and	   the	   lipids,	   thus	   creating	   a	   disordered	   solvation	   environment	  between	   the	   hydrophobic	   tails	   and	   increasing	   permeability	   of	   the	   membrane	   to	  water208.	   In	   contrast,	   methanol	   has	   been	   shown	   to	   induce	   aggregate	   transition	   of	  chlorophyll	  at	   relatively	   low	  water	  content	   (32%)209.	  This	   is	  due	   to	   the	  relatively	  high	  charge	   density	   of	   the	   small,	   polar	   methanol	   molecule	   acting	   to	   dissociate	   it	   form	  mycobactin	  and	  in	  preference	  to	  contributing	  the	  structure	  and	  stability	  of	  water-­‐water	  interactions209,	   210.	   Hydrophobic	   aggregation	   of	   the	   lipid	   tails	   of	   mycobactin	   would	  sequester	   them	   from	   interacting	   with	   the	   stationary	   phase	   of	   the	   column.	   Further	  supporting	  this	  is	  the	  observation	  that	  methanol-­‐solvated	  mycobactin	  tended	  to	  form	  a	  precipitate	   at	   the	   bottom	   its	   vial	   of	   after	   several	   days	   on	   the	   bench,	   whereas	   DMSO-­‐solvated	   mycobactin	   did	   not	   form	   a	   precipitate.	   Based	   on	   these	   data,	   DMSO	  solubilisation	  of	  FeMJ	  was	  used	  for	  all	  further	  experiments.	  





Figure	  38:	  Effectiveness	  of	  Sep-­Pak	  tC18	  separation	  of	  FeMJ	  from	  water	  when	  FeMJ	  is	  initially	  
solubilised	  in	  either	  DMSO	  or	  methanol	  (MeOH).	  A:	  spectrophotometric	  absorbance	  after	  elution	  
in	  diethyl	  ether,	  drying,	  and	  dissolution	  in	  methanol;	  solutions	  were	  diluted	  to	  give	  the	  stated	  
concentrations	  given	  100	  percent	  theoretical	  retention.	  B:	  absorbance	  of	  the	  undiluted	  flow-­
through	  of	  the	  initial	  25	  mL	  sample.	  
4.2.2 Effects	  of	  Sample	  Processing	  This	  simple	  procedure	  formed	  a	  basis	  for	  developing	  an	  assay	  protocol.	  However,	  other	   practicalities	   in	   the	   procedure	   also	   needed	   to	   be	   accommodated.	   In	   order	   to	  mitigate	  risk	  of	   infection	   from	  the	  sample,	  passage	   through	  a	  0.22	  µm	  filter	   to	  remove	  any	   infectious	   bacteria	   is	   desirable.	   For	   experimental	   purposes,	   this	  would	   also	   allow	  easier	   handling	   of	   samples	   under	   less	   stringent	   biosafety	   precautions.	   However,	   the	  possibility	  that	  mycobactin	  may	  be	  retained	  on	  the	  filter	  would	  negate	  the	  utility	  of	  the	  assay	  for	  filtered	  samples.	  The	  samples	  used	  to	  test	  the	  impact	  of	  filtration	  were	  aliquots	  from	  a	  single	  pool	  of	   urine	   from	  one	   female	   cow	  and	  designated	  NEG1,	  NEG2,	  POS1,	   POS2,	   and	  POS3,	   as	  defined	   in	   Table	   10.	   Their	   absorbance	   spectra	   are	   shown	   in	   Figure	   39A.	   Unfiltered	  samples	  (NEG1	  and	  POS1)	  exhibited	  high	  background	  absorbance	  in	  the	  450	  nm	  region,	  making	  spectrophotometric	  detection	  of	  mycobactin	  impossible.	  In	  the	  filtered	  samples,	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the	  presence	  of	  a	  significant	  450	  nm	  peak	  attributed	  to	  FeMJ	  is	  observable	  when	  FeMJ	  is	  added	  after	  filtration	  of	  the	  sample	  (POS3),	  but	  not	  when	  added	  before	  filtration	  (POS2).	  This	  suggests	  that	  mycobactin	  may	  aggregate	  or	  otherwise	  adsorb	  to	  particulates	  in	  the	  urine	   that	   are	   unable	   to	   pass	   through	   the	  0.22	  µm	   filter,	   or	   that	   it	   is	   adsorbed	  on	   the	  filter	  itself.	  This	  also	  has	  implications	  for	  the	  chromatographic	  separation,	  as	  the	  pores	  in	  the	  reverse-­‐phase	  cartridges	  are	  smaller	  than	  0.22	  µm,	  FeMJ	  may	  remain	  on	  top	  of	  the	  sorbent	   column,	   then	   elute	   off	   and	   simultaneously	   through	   the	   column,	   rather	   than	  eluting	   off	   the	   column	   itself.	   It	   should	   be	   noted	   that	   in	   contrast	   to	   the	   urine	   samples,	  which	   showed	   visible	   concentration	   on	   top	   of	   the	   reverse-­‐phase	   cartridge,	   when	  mycobactin	   was	   dissolved	   in	   water	   alone	   (Section	   4.2.1)	   the	   FeMJ	   colouration	   was	  observed	   to	   adsorb	   throughout	   the	   length	   of	   the	   reverse-­‐phase	   cartridge.	   This	  supported	  the	  idea	  that	  it	  is	  a	  specific	  property	  of	  the	  urine	  that	  causes	  the	  aggregation	  or	  adsorption	  to	  particulates	  of	  mycobactin.	  The	   electrochemical	   analyses	   of	   these	   samples,	   shown	   in	   Figure	   39B,	   are	   also	  broadly	   consistent	   with	   the	   above	   interpretation.	   However,	   in	   contrast	   to	   the	  spectrophotometric	  assay,	  the	  CVs	  demonstrate	  an	  eloquent	  and	  clean	  signal,	  free	  from	  interference	   except	   for	   a	   small	   peak	   in	   the	   unfiltered	  NEG1	   sample.	   This	   sample	  was	  repeated	  using	   the	   same	   source	  urine	  with	   similar	   results,	   but	   the	   same	  peak	  did	  not	  reappear	  in	  any	  subsequent	  samples	  from	  other	  cows	  (see	  Figure	  41).	  This	  is	  interesting	  because	   of	   the	   possibility	   that	   the	   cow	   in	   question	   may	   have	   contracted	   an	   as-­‐yet	  undetected	   infection	   by	   a	   mycobacterium	   or	   other	   siderophore-­‐producing	   bacterium.	  The	  peak	   is	  more	  negative	   than	   the	  results	   for	   the	  reduction	  potential	  of	  FeMJ,	  but	   its	  reproducibility	  indicates	  a	  redox	  active	  species	  that	  is	  appearing	  in	  the	  potential	  range	  for	  Fe-­‐complexed	  siderophores	  (and	  other	  compounds).	   It	  may	  serve	  as	  an	   interesting	  target	   for	   future	   analysis,	   if	   it	   can	   be	   correlated	   with	   other	   routine	   diagnostic	  measurements	  amongst	  the	  herd.	  Unfortunately	  we	  were	  unable	  to	  revalidate	  the	  health	  status	  of	  the	  specific	  cow	  in	  question	  because	  the	  samples	  were	  donated	  anonymously.	  It	  is	  clear	  from	  these	  data	  that	  identification	  of	  mycobactin	  is	  limited	  as	  much	  by	  the	  extraction	  method	  as	  by	  the	  electrochemical	  detection.	  The	  signal	  is	  completely	  lost	  by	   filtration,	   indicating	   a	   loss	   of	   greater	   than	   99%	   of	   the	   material.	   Therefore	   it	   was	  determined	   that	   filtration	   was	   not	   suitable	   for	   processing	   of	   the	   urine	   samples	   and	  testing	  proceeded	  on	  the	  basis	  of	  using	  unfiltered	  urine.	  The	  variability	  between	  POS1	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Figure	  39:	  Analysis	  of	  Sep-­Pak	  tC18	  eluates	  from	  the	  bovine	  urine	  samples	  from	  a	  single	  urine	  pool	  
and	  treated	  as	  defined	  in	  Table	  10;	  spectrophotometric	  absorbance	  in	  0.75	  mL	  methanol	  (A)	  and	  
CV	  analysis	  in	  0.1	  mL	  DMSO,	  0.1	  M	  LiCl	  at	  0.2	  V/s	  scan	  rate	  (B)	  are	  shown.	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4.2.3 Application	  of	  the	  Assay	  for	  Monitoring	  Mycobactin	  in	  Urine	  Following	  initial	  testing	  of	  the	  urine	  sample	  processing	  and	  analysis	  protocol,	  the	  investigation	  was	  expanded	  to	  gather	  data	  from	  a	  larger	  set	  of	  cattle.	  Samples	  from	  three	  cows	   were	   each	   subjected	   to	   chromatographic	   concentration	   and	   electrochemical	  analysis.	   The	   samples	  were	  unfiltered,	  making	   the	  processing	  of	   the	  negative	   controls	  equivalent	  to	  NEG1,	  and	  the	  positives	  equivalent	  to	  POS1.	  Although	  it	  was	  possible	  to	  discern	  the	  addition	  of	  FeMJ	  spectrophotometrically	  by	   comparison	  with	   the	   unspiked	   control	   samples,	   variability	   between	   the	   spectra	   of	  different	  samples	  precluded	  the	  usefulness	  of	  this	  technique	  to	  detect	  mycobactin	  from	  a	  complex	  biological	  matrix	  in	  the	  absence	  of	  a	  negative	  control,	  as	  shown	  in	  Figure	  40.	  CV	  analysis	  of	  the	  samples	  (Figure	  41)	  revealed	  a	  recovery	  yield	  of	  mycobactin	  in	  spiked	  bovine	  urine	  samples	  of	  40	  ±	  10%	  (standard	  deviation)	  based	  upon	  the	  standard	  curve	   for	   the	   peak	   current	   developed	   in	   Chapter	   3.	   This	   was	   done	   using	   a	   starting	  concentration	  of	  2	  µM	  FeMJ.	  Based	  on	  these	  results	  it	  can	  be	  seen	  that	  the	  opportunity	  to	  detect	   mycobactin	   is	   limited	   by	   poor	   extraction	   and	   that	   recovery	   yields	   are	   clearly	  influenced	  by	  the	  sample	  matrix	  as	  discussed	  above.	  
	  
Figure	  40:	  Spectrophotometric	  absorbance	  of	  bovine	  urine	  Sep-­Pak	  tC18	  eluates	  in	  0.75	  mL	  
methanol;	  C1-­C3	  refer	  to	  samples	  take	  from	  three	  individual	  cows	  with	  and	  without	  the	  addition	  of	  
2	  µM	  FeMJ.	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Figure	  41:	  Mean	  cyclic	  voltammogram	  of	  standardised	  bovine	  urine	  eluates;	  the	  grey	  area	  
indicates	  the	  range	  of	  standard	  deviation.	  
4.3 Conclusions	  These	  proof-­‐of-­‐concept	  testing	  results	  in	  bovine	  urine	  demonstrated	  the	  ability	  of	  this	  simple	  assay	  system	  to	  detect	  and	  quantify	  mycobactin	  present	  within	  one	  example	  of	   a	   complex	   biological	   medium.	   Using	   the	   simple	   electrochemical	   method,	   a	   clean	  background	   signal	   could	   be	   obtained	   even	   using	   raw	   sample	   urine.	   It	   is	   highly	  encouraging	  that	  this	  approach	  yielded	  such	  low	  levels	  of	  background	  interference,	  even	  within	  the	  complex	  biological	  matrix	  of	  a	  urine	  sample.	  This	  is	  an	  important	  finding	  and	  suggests	  that	  the	  assay	  could	  easily	  be	  adapted	  to	  use	  other	  sampling	  media.	  The	   quantitative	   limit	   of	   detection	   by	   CV	   of	   10	  µM,	   as	   discussed	   in	   Chapter	   3,	  could	   be	   reduced	   to	   300	  pM	   for	   an	   original	   sample	   size	   of	   25	  mL	   through	   sample	  concentration	  using	  C18	  separatory	  columns,	   thereby	  placing	   the	  assay	  within	  reach	  of	  the	  preliminary	   target	  of	  0.85-­‐250	  nM	  (Chapter	  2).	  This	  could	  be	  achieved	  assuming	  a	  0.3	  µL	   assay	   volume,	   which	   is	   common	   for	   handheld	   electrochemical	   diagnostic	  products,	   and	   extrapolating	   the	   recovery	   yield	   of	   40	   percent.	   Thus,	   in	   the	   design	   of	   a	  stand-­‐alone	  single	  use	  test-­‐strip,	  the	  inclusion	  of	  a	  lateral	  flow	  chromatography	  support	  for	  sample	  concentration	  must	  be	  envisaged.	  From	  spiked	  samples,	  it	  could	  be	  seen	  that	  filtration	   to	   remove	   incidental	   bacteria	   also	   removed	   greater	   than	   99	   percent	   of	   the	  mycobactin,	  which	  would	  have	  the	  effect	  of	  rendering	  false	  negatives	  were	  filtration	  to	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be	   applied	   in	   the	   use	   of	   this	   assay.	   Therefore	   it	   can	   be	   concluded	   that	   such	   filtration	  should	  be	  avoided	  during	  sample	  processing,	  or	  that	  filtration	  could	  potentially	  be	  used	  as	  a	  simple	  method	  for	  sample	  concentration,	  eliminating	  the	  need	  for	  a	  reverse-­‐phase	  column.	  The	   simple	   electroanalytical	   assay	   developed	   in	   Chapter	   3,	   was	   robust	   in	   its	  applicability	  to	  the	  example	  sampling	  medium	  of	  urine.	  This	  gives	  considerable	  scope	  to	  improve	  the	  detection	  limit	  through	  further	  sample	  capture	  or	  concentration	  methods.	  The	  ability	  to	  use	  this	  simple	  assay	  to	  detect	  and	  quantify	  mycobactins	  could	  provide	  a	  low-­‐cost	  sensor	  to	  effectively	  diagnose	  active	  TB	  in	  resource-­‐poor	  settings	  if	  the	  actual	  concentrations	  of	  mycobactin	  within	  samples	  from	  infected	  patients	  can	  be	  determined	  and	  found	  to	  be	  within	  the	  range	  of	  sensitivity	  determined	  here.	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5 Evaluation	  of	  Siderophore	  Contents	  of	  Different	  Biological	  
Media	  
Leading	   on	   from	   the	   improved	   detection	   levels	   for	   mycobactin	   estimated	   in	  Chapter	  4	  following	  sample	  concentration,	  the	  goal	  of	  the	  work	  reported	  in	  this	  chapter,	  was	   to	   explore	   the	   presence	   of	   mycobactin	   and	   carboxymycobactin	   within	   clinical	  specimens	   of	   different	   biological	   media,	   from	   TB	   patients	   and	   Mtb	   infected	   animal	  models	  and	  to	  draw	  conclusions	  regarding	  use	  of	  the	  electrochemical	  assay	  as	  a	  measure	  of	  Mtb	   infection.	  Although	  the	   in	  vitro	  modelling	   in	  Chapter	  2	   is	  useful	   to	  give	  a	  rough	  idea	  of	  mycobactin	  production	   levels	   by	  Mtb	   in	   an	   infection	   scenario,	   the	  only	  way	   to	  determine	   the	   true	  mycobactin	   levels	  within	  TB	  patients	   is	   to	  analyse	  clinical	   samples	  directly.	   Availability	   and	   access	   to	   such	   samples	   is	   costly	   in	   terms	   of	   both	   time	   and	  resources.	  For	  the	  purposes	  of	  this	  research,	  clinical	  specimens	  of	  both	  urine	  and	  blood	  plasma	  were	  obtained	  from	  Korean	  TB	  patients	  as	  part	  of	  an	  ongoing	  clinical	  protocol.	  Sputum	  samples	  were	  unobtainable	  due	  to	  the	  regulatory	  complexity	  of	  securing	  their	  international	   shipment	   and	   containment.	   Specimens	   of	   urine,	   stool,	   and	   hair	   from	  infected	   animal	  models	  were	   obtained	   for	   this	   study.	   The	   rationale	   behind	   the	   use	   of	  these	  sampling	  media	  has	  already	  been	  explored	   in	  the	   introduction	  to	  Chapter	  4.	  The	  rationale	  for	  also	  examining	  hair	  and	  stool	  was	  that	  the	  relatively	  lipophilic	  mycobactin	  might	  be	  excreted	   through	   these	  pathways.	  Hair	  would	  only	  be	  useful	  as	  a	  marker	   for	  long-­‐term	  infection	  unless	  recent-­‐growth	  root	  samples	  are	  used.	  As	   a	   gold	   standard	   of	   mycobactin	   detection	   to	   be	   compared	   with	   the	  electrochemical	   assay,	   high	   performance	   liquid	   chromatography/high	   resolution	  mass	  spectrometry	   (HPLC/HRMS)	   was	   adopted	   as	   the	   most	   sensitive	   laboratory-­‐based	  detection	  of	  mycobactin	   to	   reveal	   information	   about	   the	  distribution	  of	  mycobacterial	  siderophores	  within	  the	  different	  tissues	  of	  infected	  individuals.	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5.1 Materials	  and	  Methods	  
5.1.1 Samples	  All	   work	   involving	   potentially	   infectious	   Mtb	   including	   handling	   of	   infected	  animals	   and	   clinical	   samples	   was	   performed	   in	   the	   BSL3	   biocontainment	   facility	   of	  NIAID.	  
5.1.1.1 Infected	  Animal	  Samples	  Infected	   animal	   samples	  were	   obtained	   from	   the	   NIAID	   Tuberculosis	   Research	  Section	   facility	   in	   Bethesda,	   Maryland,	   United	   States.	   The	   protocol	   governing	   animal	  handling,	   infection,	  sample	  collection,	  and	  euthanasia	  procedures	  was	  approved	  by	  the	  NIAID	   Animal	   Care	   and	  Use	   Committee	   (ACUC)	   prior	   to	   commencement	   of	   the	   study.	  The	  ACUC	   is	   responsible	   for	   applying	  U.S.	   Government	   Principle	   IV.	   Animal	   infections	  and	  sample	  collections	  were	  carried	  out	  by	   facility	  staff	   including	   Jacqueline	  Gonzales,	  Laura	  Via,	  Danielle	  Weiner,	  and	  Emmanuel	  Dayao.	  Animals	   were	   placed	   into	   tubular	   polycarbonate	   exposure	   chambers	   for	   nose	  only	   exposure	  using	   the	  CH	  Technologies	   inhalation	  exposure	   system.	  Aerosol	   inocula	  were	  delivered	   via	   a	   dynamic	   aerosol	   chamber	  modified	   to	   allow	  nose-­‐only	   exposure.	  Animals	  were	  acclimated	   to	   the	  aerosol	   chamber	  by	  allowing	   them	   to	  breathe	   filtered	  air,	  provided	  to	  the	  chamber	  at	  25	  L/min,	  prior	  to	  the	  initiation	  of	  Mtb	  aerosol	  delivery.	  The	   aerosol	   was	   generated	   using	   a	   BioAerosol	   Nebulising	   Generator	   (BANG)	   using	  20	  lb/in2	  (psi)	  of	  filtered	  air	  at	  a	  flow	  rate	  of	  6.5	  L/min.	  Mice	  and	  rabbits	  do	  not	  require	  sedation	  as	  they	  readily	  enter	  the	  holding	  tubes.	  Mouse211	   and	   rabbit195	   infections	   were	   carried	   out	   as	   described	   previously.	  Virulent	   Mtb	   reference	   strains	   and	   M.	   bovis	   were	   used	   in	   this	   study.	   Animals	   were	  monitored	   visually	   during	   the	   exposure	   period.	   An	   all-­‐glass	   impinger	   was	   used	   to	  sample	  bacilli	  in	  the	  aerosol	  generated	  by	  the	  nebuliser	  at	  each	  concentration	  of	  bacteria	  used.	   Before	  infection,	  Mtb	  cultures	  were	  adjusted	  to	  OD650	  of	  0.5	  and	  stored	  at	  -­‐70  °C	  as	   20%	   glycerol	   stocks.	   Inocula	   were	   prepared	   by	   diluting	   these	   stocks	   to	  4×106	  CFU/mL	  in	  PBS/Tween	  80	  (0.05%).	  Six-­‐week-­‐old	  B6D2	  F1	  (C57BL/6×DBA/2;	  F1	  progeny)	   mice	   (Taconic)	   were	   loaded	   into	   nose-­‐only	   aerosol-­‐exposure	   tubes	   without	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sedation,	   exposed	   to	   the	   BANG	   generated	   aerosol	   for	   10	  minutes	   and	   clean	   air	   for	   5	  minutes,	  and	  then	  removed	  from	  the	  tubes	  and	  replaced	  in	  their	  cages.	  In	  this	  manner,	  approximately	   50–100	  CFU	   per	   lung	   were	   implanted	   as	   confirmed	   by	   homogenising	  sample	  lungs	  in	  M7H9/ADC	  at	  3 h	  after	  infection	  and	  plating	  for	  CFU	  determination.	  For	   rabbit	   infection	   the	   aerosol	   inocula	   were	   prepared	   by	   diluting	   the	   frozen	  stocks	   to	   1-­‐1.5×105	  CFU/mL	   in	   phosphate-­‐buffered	   saline	   PBS/Tween	   80	   (0.05%).	  Rabbits	  were	  placed	  (without	  sedation)	  in	  cat-­‐restraint	  bags	  with	  hoods	  and	  then	  loaded	  into	   the	   rabbit	   nose-­‐only	   aerosol	   exposure	   tubes.	   They	  were	   exposed	   to	   the	   bacteria-­‐laden	  aerosol	   for	  10	  minutes	  and	  clean	  air	   for	  5	  minutes,	   and	   then	   removed	   from	   the	  tubes	  and	  the	  bags	  (cat	  restrainers)	  and	  replaced	  in	  their	  cages.	  The	  solution	  delivered	  approximately	  200	  CFU/L	  of	  infectious	  aerosol	  and	  generated	  50	  to	  100	  granulomas	  per	  rabbit	   lung.	   Animals	   used	   to	   determine	   bacterial	   deposition	   were	   harvested	   2	  h	  postinfection.	  Animals	  used	  in	  this	  study	  had	  been	  infected	  for	  a	  period	  of	  90-­‐120	  days	  before	  sample	  collection.	  
5.1.1.2 Clinical	  Samples	  Control	   human	   urine	   and	   plasma	   was	   obtained	   from	   healthy	   volunteers	   and	  human	   clinical	   samples	   were	   obtained	   from	   the	   International	   Tuberculosis	   Research	  Center	   facility	   in	   the	  Republic	  of	  Korea	  under	  ongoing	   clinical	  protocol	  NCT00341601	  (clinicaltrials.gov).	   The	   study	   population	   consisted	   of	   subjects	   with	   pulmonary	  tuberculosis	   receiving	   treatment	   at	   the	   National	   Masan	   Tuberculosis	   Hospital,	   the	  largest	   tertiary	   referral	   centre	   for	   patients	  with	   previously	   treated	   and	  drug-­‐resistant	  tuberculosis	  in	  the	  Republic	  of	  Korea.	  The	  hospital	  also	  serves	  as	  a	  site	  where	  the	  local	  population	   (~1,000,000)	   is	   treated	   as	   inpatients	   for	   new	   cases	   of	   tuberculosis.	   In	   all	  cases	  informed	  written	  consent	  was	  obtained	  prior	  to	  sample	  collection.	  Regulatory	   compliance	   for	   this	   study	   was	   monitored	   by	   the	   Regulatory	  Compliance	  and	  Human	  Subjects	  Protection	  Branch	  of	  the	  NIAID.	  Sample	  collection	  was	  conducted	  in	  compliance	  with	  International	  Conference	  on	  Harmonisation	  Good	  Clinical	  Practices	   and	   all	   applicable	   regulatory	   requirements.	   The	   sample	   collection	   protocol	  was	  approved	  by	  all	  local	  Institutional	  Review	  Boards	  before	  commencement	  of	  sample	  collection.	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5.1.2 HPLC/HRMS	  Instrumentation	  The	   HPLC/HRMS	   instrument	   used	  was	   a	   Thermo	   Electron	   Corporation	   system	  consisting	  of	   a	  Finnigan	  LTQ	   ion	   trap	   coupled	   to	   an	  LTQ	  FT	  Ultra	   time-­‐of-­‐flight	   (TOF)	  mass	  spectrometer.	  The	  analytical	  column	  was	  a	  monolithic	  0.1×150	  mm	  Phenomenex	  high-­‐density	  C18	  column,	  while	   the	   trap	  was	  as	  monolithic	  0.2×24.25	  mm	  Phenomenex	  high-­‐density	  C18	  column.	  Solvent	   flow	  was	  controlled	  by	  a	  Waters	  nanoACQUITY	  HPLC	  system.	   HRMS	   data	   were	   acquired	   using	   Xcaliber	   software.	   Column	   temperature	   was	  maintained	  at	  60°C	  unless	  otherwise	  noted.	  The	  HPLC/HRMS	  injection	  setup	  is	  shown	  in	  Figure	   42.	   The	   trap	   was	   taken	   out	   of	   line	   for	   sample	   loading	   and	   the	   samples	   were	  injected	  backward	  onto	  the	  trap.	  The	  trap	  was	  then	  reconnected	  to	  the	  solvent	  pumps	  and	  allowed	  to	  equilibrate	  for	  5	  min	  before	  connecting	  it	  to	  the	  analytical	  column.	  HPLC	   elution	   protocols	   were	   developed	   on	   an	   in-­‐house	   Agilent	   liquid	  chromatography	   (LC)	   system	   with	   a	   diode	   array	   detector	   (DAD)	   for	   UV-­‐visible	  absorbance	  detection,	  electrospray	  ionisation	  and	  an	  Agilent	  G1946D	  quadrupole	  mass	  selective	  detector	  (MSD).	  Column	  temperature	  was	  maintained	  at	  60°C.	  An	   5	  mM	   equimolar	   mixture	   of	   ferric	   synthetic	   carboxymycobactin	   (FeSCM),	  ferric	  synthetic	  mycobactin	  T	  (FeSMT),	  and	  FeMJ	  in	  DMSO	  was	  used	  as	  a	  positive	  control	  for	   all	   HPLC/MS	   experiments	   and	   was	   added	   to	   the	   sample	   to	   achieve	   the	   desired	  concentration.	  Synthesis	  of	  FeSCM	  and	  FeSMT	  is	  described	  in	  Section	  6.1.3.2.	  The	   HPLC	   methods	   that	   were	   optimised	   in	   the	   in-­‐house	   LC	   system	   were	  translated	   for	   use	   on	   the	   HPLC/HRMS	   instrument	   located	   at	   the	   National	   Institute	   of	  Diabetes	  and	  Digestive	  and	  Kidney	  Diseases	  facility	  in	  Bethesda,	  Maryland,	  United	  States	  by	  Nicholas	  McBride	  with	  the	  support	  of	  John	  Lloyd.	  Of	  the	  experimental	  setup	  depicted	  in	  Figure	  42,	  the	  instrument	  with	  nanospray	  needle,	  housing,	  pressure	  tubing,	  valve,	  and	  pumps	  was	  already	   in	  place	  while	   the	  choice	  of	  analytical	   column	  and	   trap	  system,	  as	  well	  as	  the	  solvent	  control	  protocol	  were	  developed	  and	  used	  by	  Nicholas	  McBride.	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Figure	  42:	  HPLC/HRMS	  injection	  configuration.	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base	   of	   the	   vial.	   The	   residue	  was	   then	   taken	   up	   in	  methanol	   (5	  µL)	   and	   injected	   into	  water	   (45	  µL).	   The	   vial	  was	   then	   centrifuged	   at	   4750	   rpm	   for	   10	  min	   at	   4°C	   to	   avoid	  injection	  of	  any	  precipitate	  into	  the	  instrument.	  The	  sample	  (25	  µL)	  was	  taken	  up	  into	  a	  syringe	  and	   injected	  onto	  the	  trap	   for	  HPLC/HRMS	  analysis	  as	  described	  above.	  Single	  ion	   chromatograms	   were	   obtained	   using	   a	   mass	   range	   of	   10.0	  ppm.	   A	   list	   of	   the	  mycobactin	   and	   carboxymycobactin	   ion	   masses	   that	   were	   screened	   is	   given	   in	  Appendix	  2.	  Mycobactins	   and	   carboxymycobactins	   were	   extracted	   from	   plasma	   by	   initially	  diluting	   the	   plasma	   sample	   1:10	   in	   water	   before	   shaking	   with	   a	   1:1	   volume	   of	  chloroform.	  Centrifugation	  was	  used	   to	  separate	   the	  organic	  phase,	  and	   it	  was	   filtered	  through	  Whatman	  #3	  filter	  paper	  and	  processed	  as	  above.	  Rabbit	  hair	  and	  stool	  samples	  underwent	  Soxhlet	  extraction.	  The	  samples	  were	  placed	   in	   a	   fiberglass	   thimble	   inside	   a	   Soxhlet	   extractor	   apparatus.	   Chloroform	   was	  refluxed	   through	   the	   apparatus	   for	   48	   hours,	   after	   which	   the	   solvent	   was	   removed	  under	  rotary	  evaporation	  and	  processed	  as	  above.	  
5.1.4 HPLC	  Method	  Development	  
5.1.4.1 Optimisation	  of	  HPLC	  Conditions	  HPLC	   analysis	   of	   mycobactin	   was	   optimised	   on	   an	   in-­‐house	   LC	   system.	   High-­‐sensitivity	   HPLC/HRMS	   detection	   of	   mycobactins	   required	   the	   development	   of	   an	  extraction	   technique	   that	   would	   produce	   samples	   suitable	   for	   HPLC	   injection	   from	  biological	   specimens	   that	   range	   from	   quite	   small	   (600	  µL)	   to	   large	   (80	  mL).	   The	  variability	  in	  specimen	  size	  stems	  from	  the	  desire	  to	  use	  as	  large	  a	  sample	  as	  possible	  to	  maximise	  the	  chances	  of	  mycobactin	  detection	  combined	  with	  the	  practical	  availability	  of	   difficult-­‐to-­‐obtain	   clinical	   materials.	   As	   such,	   conventional	   organic	   extraction	  techniques	  were	  used.	  In	  comparative	  extractions	  using	  chloroform	  and	  ethyl	  acetate	  it	  was	  found	  that	  FeSCM	  was	  extracted	  into	  chloroform	  with	  34	  fold	  better	  efficiency	  than	  into	  ethyl	  acetate.	  FeMJ	  and	  FeSMT	  were	  extracted	  into	  ethyl	  acetate	  with	  6.4	  fold	  better	  efficiency	  than	  into	  chloroform	  for	  a	  single	  extraction.	  This	  is	  demonstrated	  in	  Figure	  43.	  Ethyl	   acetate	   extraction	   also	   led	   to	   co-­‐extraction	   of	   significantly	   more	   unwanted	  material,	   which	   would	   limit	   the	   quantity	   of	   sample	   that	   could	   be	   injected	   into	   the	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HPLC/HRMS	   system.	   Bearing	   both	   of	   these	   factors	   in	   mind,	   the	   triple	   chloroform	  extraction	  described	  above	  was	  selected.	  	  
	  
Figure	  43:	  Comparison	  of	  chloroform	  versus	  ethyl	  acetate	  extraction	  of	  mycobactins	  from	  human	  
urine	  via	  in-­house	  LC/DAD;	  the	  three	  prominent	  absorbance	  peaks	  indicate	  the	  elution	  of	  FeSCM,	  
FeMJ,	  and	  FeSMT	  respectively.	  In	   order	   to	   select	   an	   appropriate	   column	   formulation	   for	   use	  with	  mycobactin	  and	  carboxymycobactin,	  several	  different	  stationary	  phases	  were	  tested	  to	  ascertain	  the	  degree	  of	  chromatographic	  separation	  that	   they	  would	  yield	  between	  different	  species	  of	   mycobactin.	   Figure	   44	   shows	   the	   difference	   in	   elution	   time	   (Δt)	   of	   different	  mycobactin	   compounds	   within	   the	   same	   chromatographic	   run.	   C18	   and	   C18-­‐pentafluorophenyl	   (PFP)	   phases	   gave	   the	   highest	   resolution	   between	   different	  mycobactin	  compounds.	  The	   results	   of	   a	   systematic	   optimisation	   of	   the	  MSD	   ionisation	   parameters	   are	  summarised	  in	  Figure	  45.	  The	  best	  ionisation	  efficiency	  for	  a	  bolus	  injection	  of	  FeMJ	  was	  achieved	  using	   a	   fragmentation	  voltage	  of	  160	  V,	  drying	  gas	   flow	   rate	  of	  9	  L/min,	   and	  capillary	   voltage	   of	   4	  kV.	   Capillary	   voltages	   higher	   than	   4	  kV	   run	   the	   risk	   of	   arcing	  through	   the	   spray,	   which	   not	   only	   destroys	   the	   ionisation	   efficiency,	   but	   can	   also	   be	  damaging	  to	  the	  instrument.	  	  























	  	   106	  
	  
Figure	  44:	  Comparison	  of	  different	  stationary	  phases	  for	  LC	  elution	  resolution.	  The	  y-­axis	  
measures	  the	  time	  between	  the	  elution	  of	  the	  mycobactin	  compounds	  indicated	  in	  the	  legend	  as	  a	  







Figure	  45:	  Optimisation	  of	  three	  mass	  spectrometry	  parameters;	  A:	  fragmentation	  voltage,	  B:	  
drying	  gas	  flow	  rate,	  and	  C:	  capillary	  voltage.	  Signal	  was	  optimised	  to	  give	  the	  greatest	  total	  ion	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1. The	  initial	  equilibration	  concentration	  of	  mobile	  phase	  must	  be	  kept	  very	  low	  (2%),	  followed	  by	  stepping	  up	  to	  near	  the	  elution	  concentration	  for	  carboxymycobactin.	  This	  allowed	  the	  sample	  to	  adsorb	  to	  the	  column	  in	  a	  unified	  bolus	  before	  elution.	  This	  element	  is	  incorporated	  in	  the	  solvent	  profiles	  displayed	  as	  solid	  lines	  in	  Figure	  46.	  	   2. Because	  of	  the	  relatively	  disparate	  hydrophobic	  character	  of	  the	  carboxymycobactins	  and	  the	  lipophilic	  mycobactins,	  a	  step-­‐up	  in	  mobile	  phase	  concentration	  was	  done	  between	  the	  elution	  of	  the	  carboxymycobactins	  and	  that	  of	  the	  lipophilic	  mycobactins.	  This	  helped	  to	  narrow	  the	  elution	  peaks	  of	  the	  lipophilic	  mycobactins	  while	  maintaining	  sensitivity	  for	  carboxymycobactins	  in	  the	  same	  chromatographic	  run	  and	  simultaneously	  shortening	  the	  run	  time.	  	   3. The	  steepness	  of	  the	  gradient	  was	  adjusted	  to	  optimise	  peak	  sensitivity	  while	  minimising	  co-­‐elution	  of	  interfering	  compounds.	  	  	  The	  final	  method	  (NMC18PF9,	  see	  Figure	  46)	  gathered	  all	  of	  these	  elements	  for	  optimal	  HPLC	  performance	  in	  detecting	  both	  carboxymycobactins	  and	  mycobactins.	  	  
	  
Figure	  46:	  Solvent	  gradient	  profiles	  that	  were	  tested	  to	  optimise	  sensitivity	  for	  
carboxymycobactins	  and	  mycobactins.	  Buffer	  A	  consisted	  of	  aqueous	  0.1	  percent	  formic	  acid,	  while	  
buffer	  B	  consisted	  of	  acetonitrile	  with	  0.1	  percent	  formic	  acid.	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Figure	  47:	  Results	  from	  elution	  of	  the	  test	  compounds	  using	  the	  solvent	  gradients	  displayed	  above.	  
All	  elutions	  were	  done	  on	  a	  C18-­PFP	  column	  except	  for	  the	  NMHFLO1	  method,	  which	  was	  tested	  on	  
C6-­phenyl	  and	  C18	  core-­shell	  columns	  as	  indicated.	  Note	  that	  the	  saturated	  form	  of	  FeMJ	  is	  only	  
present	  in	  trace	  quantities	  in	  the	  control	  samples,	  whereas	  FeSCM,	  FeMJ,	  and	  FeSMT	  are	  present	  in	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Figure	  48:	  The	  limit	  of	  detection	  for	  the	  test	  compound	  is	  shown	  to	  be	  in	  the	  range	  of	  50-­500	  fmol	  
using	  the	  NMC18PF9	  solvent	  profile;	  the	  50	  pmol	  standard	  (not	  to	  scale)	  is	  shown	  in	  gray	  to	  
indicate	  the	  expected	  elution	  times	  of	  the	  standard	  compounds	  FeSCM,	  FeMJ,	  and	  FeSMT.	  
	  
Figure	  49:	  Elution	  of	  mycobactins	  extracted	  from	  Mtb	  culture	  using	  the	  optimised	  NMC18PF9	  
LC/MSD	  method.	  
5.1.4.2 Adaptation	  to	  High-­Sensitivity	  HPLC/HRMS	  System	  It	  was	   expected	   that	   the	   HPLC/HRMS	   system	  would	   greatly	   improve	   upon	   the	  limit	  of	  detection	  that	  was	  established	  using	  the	  LC/MSD	  due	  to	  both	  the	  ion	  trap	  TOF	  mass	  detection	  setup	  versus	   the	  MSD	  and	  the	   increased	  mass	  resolution,	  which	  would	  result	  in	  an	  improved	  S/N.	  As	   the	   HPLC/HRMS	   instrument	   uses	   very	   low	   flow	   rates	   to	   achieve	   superior	  nanospray	  efficiency,	  there	  were	  a	  few	  parameters	  that	  had	  to	  be	  adjusted.	  The	  capillary	  column	   that	  was	   required	   for	   using	   the	   C18-­‐PFP	   stationary	   phase	  was	   found	   to	   cause	  precipitation	   of	   the	   sample	   at	   the	   end	   caps	   and	   was	   thus	   abandoned	   in	   favour	   of	   a	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monolithic	   C18	   capillary	   column.	   Elution	   at	   60°C	   improved	   the	   amplitude	   of	   the	   ion	  signal	   over	   elution	   at	   20°C	   by	   a	   factor	   of	   2.9	   for	   FeSCM,	   11.9	   for	   FeMJ,	   and	   19.8	   for	  FeSMT,	  as	  can	  be	  seen	  in	  Figure	  50.	  	  
	  
Figure	  50:	  Combined	  ion	  chromatograms	  of	  FeSCM,	  FeMJ,	  and	  FeSMT	  (2.5	  pmol)	  eluting	  at	  20°C	  and	  
60°C.	  
5.2 Results	  and	  Discussion	  
5.2.1 Limit	  of	  Detection	  in	  Urine	  and	  Plasma	  In	  order	  to	  test	  the	  limit	  of	  detection	  for	  mycobactins	  in	  urine	  through	  the	  entire	  sample	   extraction	   and	   analysis	   process,	   healthy	   human	   urine	   was	   spiked	   with	   the	  mycobactin	  positive	  control	  compound	  mixture.	  This	  was	  intended	  to	  be	  representative	  of	   mycobactin	   compounds	   in	   the	   urine	   of	   infected	   TB	   patients.	   Using	   the	   chloroform	  extraction	   process	   described	   in	   the	   methods	   section	   and	   analysis	   by	   HPLC/HRMS,	   a	  urine	  sample	  that	  was	  spiked	  with	  50	  fmol	  of	  the	  standards	  yielded	  a	  satisfactory	  S/N	  of	  6.0	   for	  FeMJ	  and	  2.8	   for	  FeSMT,	  as	   shown	   in	  Figure	  51A.	  The	  amplitude	  of	   the	  FeSCM	  signal	  was	  much	  lower,	  perhaps	  due	  to	  poorer	  ionisation	  than	  the	  lipophilic	  compounds,	  however	  the	  noise	  level	  in	  the	  FeSCM	  ion	  range	  was	  also	  lower	  (Figure	  51B),	  allowing	  a	  S/N	  of	  1.2	   to	  be	   achieved	  at	  50	  fmol	  of	   spiked	   compound.	  From	   this	   it	  was	   calculated	  that	   150	  fmol	   of	   FeSCM	   in	   the	   original	   urine	   sample	   would	   be	   required	   in	   order	   to	  achieve	  a	  satisfactory	  S/N	  for	  detection.	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Figure	  51A:	  HPLC/HRMS	  chromatogram	  of	  extract	  from	  human	  urine	  spiked	  with	  50	  fmol	  of	  
FeSCM,	  FeMJ,	  and	  FeSMT.	  B:	  An	  enlarged	  plot	  of	  the	  FeSCM	  ion	  signal	  alone	  to	  give	  detail.	  Extraction	  of	  mycobactins	  from	  plasma	  was	  more	  difficult	  than	  urine	  because	  of	  the	   high	   content	   of	   proteins	   and	   other	   organic-­‐soluble	   compounds.	   The	   extraction	  method	  had	  to	  be	  adjusted	  to	   include	   the	  dilution	  step	  described	   in	   the	  methods.	  This	  improved	  the	  yield	  of	  the	  extraction,	  but	  the	  achievable	  limit	  of	  detection	  was	  still	  higher	  than	  for	  urine.	  This	  result	  is	  probably	  due	  to	  poorer	  extraction	  of	  these	  compounds	  from	  the	  more	  complex	  biological	  matrix	  and	  highlights	  the	  potential	  problems	  in	  identifying	  the	  presence	  of	  mycobactins	  in	  any	  sample	  of	  biological	  origin.	  Interestingly,	  in	  plasma	  FeSCM	  was	  easier	   to	  detect	   than	   the	   lipophilic	  mycobactins.	  The	   limit	  of	  detection	   for	  FeSCM	  was	   350	  fmol	   versus	   at	   least	   1	  pmol	   for	   the	   lipophilic	  mycobactins.	   Figure	   52	  shows	   HPLC/HRMS	   analysis	   of	   2	  pmol	   of	   standard	   compounds	   spiked	   into	   6	  mL	   of	  plasma,	   which	   yielded	   a	   S/N	   of	   16.1,	   8.6,	   and	   3.6	   for	   FeSCM,	   FeMJ,	   and	   FeSMT	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respectively.	  The	  HPLC/HRMS	  limit	  of	  detection	  from	  spiked	  samples	  is	  summarised	  in	  Table	  11.	  	  
	  
Figure	  52:	  HPLC/HRMS	  chromatogram	  of	  extract	  from	  human	  plasma	  spiked	  with	  2	  pmol	  of	  FeSCM,	  
FeMJ,	  and	  FeSMT.	  	  
Table	  11:	  HPLC/HRMS	  limit	  of	  detection	  for	  siderophores	  spiked	  into	  either	  urine	  of	  plasma.	  	   Limit	  of	  Detection	  	   Carboxymycobactin	   Mycobactin	  
In	  spiked	  urine	   150	  fmol	   50	  fmol	  
In	  spiked	  plasma	   350	  fmol	   1000	  fmol	  	   The	  raised	  limit	  of	  detection	  for	  lipophilic	  mycobactins	  is	  consistent	  with	  the	  idea	  that	   they	   associate	   strongly	   with	   plasma	   components,	   making	   their	   extraction	   with	  organic	  solvents	  more	  difficult.	  The	  lipophilic	  compounds	  may	  be	  binding	  irreversibly	  to	  lipoprotein,	  cholesterol,	  and	  triglyceride	  components	  of	  plasma,	  or	  to	  albumin	  and	  other	  proteinaceous	   components.	   The	   same	   phenomenon	   would	   contribute	   to	   the	   poorer	  detection	  of	  FeSCM	   in	  plasma	  as	   compared	  with	  urine,	  but	  would	  not	  affect	  FeSCM	  as	  strongly	  as	  with	  the	  lipophilic	  mycobactins.	  The	  prospect	  that	  this	  occurs	  so	  readily	  calls	  into	  question	  the	  likelihood	  of	  these	  compounds	  traversing	  the	  body	  from	  their	  source	  in	  the	  lungs	  to	  be	  detectable	  in	  significant	  quantities	  in	  the	  urine	  or	  any	  other	  sample.	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5.2.2 Analysis	  of	  Clinical	  Tuberculosis	  Samples	  Using	   these	  methods,	   Table	   12	   summarises	   the	   various	   samples	   from	   infected	  animal	  models	  and	  TB	  patients	   that	  were	  extracted	  and	  analysed	  via	  HPLC/HRMS.	  No	  mycobactins	  were	  detected	  in	  any	  of	  the	  samples	  tested.	  The	  final	  two	  columns	  list	  the	  limit	  of	  detection	  back	  calculated	  to	  account	  for	  the	  sample	  size	  and	  injection	  volume	  for	  each	   sample	   to	   estimate	   the	   effective	   limit	   of	   detection	   for	   ferric	   carboxymycobactin	  (FeCM)	   and	   ferric	   mycobactin	   T	   (FeMT)	   within	   each	   original	   sample.	   The	   limits	   of	  detection	  reflect	  both	  the	  efficiency	  of	  the	  extractions	  from	  either	  urine	  or	  plasma	  and	  the	   limitations	   of	   the	   instrument,	   thereby	   taking	   into	   account	   any	   irreversible	  adsorption	   and	   retention	   on	   the	   sample	   matrix.	   These	   results	   are	   disappointing,	  particularly	  in	  view	  of	  the	  identification	  of	  other	  lipid	  antigens	  such	  as	  LAM	  in	  urine	  of	  infected	   patients.	   However,	   they	   highlight	   the	   ambiguity	   associated	   with	   correlating	  mycobactin	  excretion	  with	  TB	  infection.	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Table	  12:	  List	  of	  animal	  and	  human	  clinical	  samples	  analysed	  by	  HPLC/HRMS.	  
Subject	   Species	  
Study	  
Enrolment	  
Week	   Sample	  
Sample	  












Detection	  R1	   Rabbit	   	   Urine	   12	  mL	   3X	  CHCl3,	  1X	  EtAc	   2.97	  mg	  (CHCl3)	   0	   41.7	  pM	   13.9	  	  pM	  R2	   Rabbit	   	   Urine	   2	  mL	   1X	  CHCl3	   	   0	   107.1	  	  pM	   35.7	  	  pM	  R3	   Rabbit	   	   Urine	   0.5	  mL	   1X	  CHCl3	   	   0	   428.6	  	  pM	   142.9	  	  pM	  R4	   Rabbit	   	   Urine	   5	  mL	   3X	  CHCl3,	  1X	  EtAc	   	   0	   60.0	  	  pM	   20.0	  	  pM	  R5	   Rabbit	   	   Hair	   	   CHCl3	  48	  hrs	  Soxhlet	   0.75	  mg	   0	   	   	  	   	   	   Stool	   	   CHCl3	  48	  hrs	  Soxhlet	   60.81	  mg	   0	   	   	  R6	   Rabbit	   	   Hair	   300	  mg	   CHCl3	  48	  hrs	  Soxhlet	   5.73	  mg	   0	   	   	  	   	   	   Stool	   2.1	  g	   CHCl3	  48	  hrs	  Soxhlet	   79.25	  mg	   0	   	   	  R3	   Rabbit	   	   Hair	   339	  mg	   CHCl3	  48	  hrs	  Soxhlet	   	   0	   	   	  	   	   	   Stool	   1.98	  g	   CHCl3	  48	  hrs	  Soxhlet	   	   0	   	   	  R1	   Rabbit	   	   Urine	   12	  mL	   3X	  CHCl3	   ~0.2	  g	   0	   41.7	  	  pM	   13.9	  	  pM	  R7	   Rabbit	   	   Urine	   70	  mL	   3X	  CHCl3	   6.22	  mg	   0	   4.3	  	  pM	   1.4	  	  pM	  R8	   Rabbit	   	   Urine	   80	  mL	   3X	  CHCl3	   5.52	  mg	   0	   3.8	  	  pM	   1.3	  	  pM	  H1	   Human	   0	   Urine	   6	  mL	   3X	  CHCl3	   1.03	  mg	   0	   50.0	  	  pM	   16.7	  	  pM	  H2	   Human	   0	   Urine	   6	  mL	   3X	  CHCl3	   0.92	  mg	   0	   50.0	  	  pM	   16.7	  	  pM	  H3	   Human	   0	   Urine	   6	  mL	   3X	  CHCl3	   9.00	  mg	   0	   50.0	  	  pM	   16.7	  	  pM	  H4	   Human	   0	   Urine	   10	  mL	   3X	  CHCl3	   2.62	  mg	   0	   30.0	  	  pM	   10.0	  	  pM	  H5	   Human	   0	   Urine	   10	  mL	   3X	  CHCl3	   1.28	  mg	   0	   62.5	  	  pM	   20.8	  	  pM	  H6	   Human	   6	   Urine	   40	  mL	   3X	  CHCl3	   19.51	  mg	   0	   7.5	  	  pM	   2.5	  	  pM	  H7	   Human	   8	   Urine	   40	  mL	   3X	  CHCl3	   8.79	  mg	   0	   7.5	  	  pM	   2.5	  	  pM	  H6	   Human	   4	   Urine	   40	  mL	   3X	  CHCl3	   14.33	  mg	   0	   7.5	  	  pM	   2.5	  	  pM	  H5	   Human	   0	   Plasma	   0.6	  mL	   H2O	  dilution,	  CHCl3	   0.37	  mg	   0	   729.2	  	  pM	   2083.3	  	  pM	  H6	   Human	   0	   Plasma	   0.6	  mL	   H2O	  dilution,	  CHCl3	   0.67	  mg	   0	   1166.7	  	  pM	   3333.3	  	  pM	  H7	   Human	   0	   Plasma	   0.6	  mL	   H2O	  dilution,	  CHCl3	   0.44	  mg	   0	   729.2	  	  pM	   2083.3	  	  pM	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5.3 Conclusions	  HPLC/HRMS	  analysis	  was	  able	  to	  achieve	  an	  effective	  lower	  limit	  of	  detection	  for	  mycobactin	   that	   is	   below	   or	  within	   the	   physiological	   levels	   of	  mycobactin	   production	  that	  were	  calculated	  in	  Chapter	  2.	  Notwithstanding	  this,	  neither	  carboxymycobactin	  nor	  mycobactin	   were	   detected	   in	   any	   of	   the	   infected	   animal	   models	   or	   clinical	   patient	  samples.	  A	   higher	   degree	   of	   sensitivity	  was	   not	   possible	   due	   to	   the	   limited	   efficiency	   of	  extracting	   the	   siderophores	   from	   the	   samples,	  which	  had	   to	   contend	  with	   irreversible	  adsorption	   of	   the	   siderophores	   to	   the	   sample	  matrix	   proteins	   and	   other	   components,	  particularly	   in	   the	  case	  of	  plasma	  samples.	   If	   these	  compounds	  are	  present	  within	   the	  plasma	   or	   urine	   of	   infected	   individuals,	   they	   either	   fail	   to	   be	   extracted	   with	   a	   high-­‐enough	  degree	  of	  efficiency	   in	   the	  protocol	  developed	  here,	  or	  are	  only	   to	  be	   found	  at	  very	  low	  concentrations	  below	  the	  current	  detection	  threshold.	  On	  the	  other	  hand,	  it	  is	  certain	  that	  Mtb	  produces	  mycobactin	  in	  vivo,	  but	  many	  questions	  remain	  regarding	  the	  trafficking	   of	   this	   siderophore.	   The	   use	   of	   direct	   sputum	   and	   saliva	   samples	   was	   not	  investigated	   in	   this	   study,	   and	   sputum,	   while	   not	   ideal,	   may	   still	   provide	   a	   superior	  sample	  matrix	  for	  diagnosing	  TB	  through	  siderophore	  detection.	  As	  first	  discussed	  in	  Section	  1.1.3.2,	  Mtb	  glycolipid	  lipoarabinomannan	  (LAM)	  has	  been	   detected	   in	   the	   urine	   as	   a	   potential	   diagnostic	   biomarker212	   despite	   the	   strong	  lipophilic	   character	   of	   its	   structure,	   complemented	   by	   hydrophilic	   head	   groups,	  much	  like	   mycobactin24.	   This	   provided	   part	   of	   the	   rationale	   that	   mycobactin	   may	   also	   be	  detectable	  in	  urine.	  However,	  it	  now	  seems	  evident	  that	  mycobactin	  is	  not	  present	  in	  the	  urine	  at	  levels	  that	  would	  warrant	  its	  usefulness	  as	  a	  diagnostic	  biomarker.	  This	  may	  be	  due	  to	  the	  fact	  that	  relatively	  little	  mycobactin	  is	  produced	  in	  comparison	  to	  LAM,	  which	  composes	  a	  significant	  portion	  of	  the	  mycobacterial	  cell	  wall	  where	  they	  are	  anchored	  to	  the	  cell	  surface	  by	  their	   lipid	  components12.	  LAM	  is	  also	  shed	  and	  trafficked	  outside	  of	  the	   bacterium8,	   possibly	   as	   a	   means	   of	   causing	   inflammation	   advantageous	   to	  Mtb10.	  While	   there	   is	  a	   strong	  case	   for	   the	  extracellular	   trafficking	  of	  mycobactin186,	   it	   is	   still	  unclear	  whether	  mycobactin	   behaves	   in	   a	   similar	   fashion	   or	   in	   comparable	   quantities	  within	  the	  immediate	  environment	  of	  the	  bacterium.	  There	  is	  still	  considerable	  scope	  to	  improve	  the	  detection	  limit	  through	  the	  use	  of	  sample	   capture	   and	   concentration	   methods,	   alternative	   detection	   methods,	   or	   by	  
	  	   116	  
utilising	  other	  sampling	  media,	  such	  as	  saliva	  or	  sputum,	  which	  may	  prove	  more	  fruitful	  in	  the	  search	  for	  mycobactin	  and	  carboxymycobactin	  in	  vivo.	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6 Further	  Development	  of	  Mycobactin	  Assays	  
As	  an	  outcome	  of	  this	  thesis,	  the	  electrochemical	  properties	  of	  mycobactin	  have	  been	   elucidated	   and	   a	   protocol	   has	   been	   outlined	   for	   a	   mycobactin	   assay.	   However,	  while	   culture	   studies	   place	   the	   likely	   mycobactin	   levels	   in	   the	   range	   of	   0.85-­‐250	  nM	  (Chapter	   2),	   which	   is	   achievable	   for	   the	   electrochemical	   assay	   including	   a	  preconcentration	  step	  (Chapter	  4),	  no	  mycobactin	  could	  be	  detected	  in	  clinical	  samples	  of	  urine	  and	  plasma	   from	   infected	  patients	   (Chapter	  5).	  Yet	   it	   remains	   tantalising	   that	  the	   culture	   studies	   suggest	  mycobactin	   could	   become	   a	   useful	   analytical	   target.	   Thus,	  preliminary	  work	  was	  undertaken	  to:	  	   1. Develop	  a	  method	  to	  improve	  the	  electrochemical	  assay	  through	  capture	  ligand	  modification	  of	  the	  electrode.	  	   2. Develop	  synthetic	  mycobactin	  and	  carboxymycobactin	  standards	  and	  validate	  their	  function	  in	  Fe	  uptake	  by	  Mtb.	  Based	  on	  these	  data,	  the	  synthetic	  siderophores	  can	  be	  assessed	  as	  potential	  PET	  imaging	  probes	  and	  as	  antigens	  to	  which	  anti-­‐mycobactin	  antibodies	  may	  be	  raised.	  	   The	  ability	  to	  specifically	  bind	  mycobactin	  and	  thereby	  concentrate	  it	  close	  to	  the	  electrode	  surface	  has	  the	  potential	  to	  greatly	  increase	  the	  sensitivity	  of	  the	  assay	  as	  well	  as	  provide	  greater	  signal	  stability.	  The	  carboxymycobactin-­‐binding	  capabilities	  of	  Lcn2	  were	   reviewed	   in	   Section	   1.2.3.2.	   This	   human	   protein	   may	   hold	   the	   key	   to	   enabling	  specific	  binding	  of	  mycobactins	  close	  to	  the	  surface	  of	  the	  electrode	  for	  electrochemical	  interrogation.	   Design	   elements	   for	   a	   prospective	   biosensor	   device	   and	   receptor	  immobilisation	  strategy	  are	  shown	  in	  Figure	  53.	  In	  Figure	  53B	  a	  protein	  receptor,	  such	  as	  Lcn2,	   that	   specifically	  binds	   ferric	  mycobactin	   is	   immobilised	   to	   the	  electrode	  via	  a	  hexahistidine	   tag.	   In	   the	   presence	   of	   ferric	   siderophore,	   cyclic	   voltammetry	   or	   other	  electroanalytical	  methods	  can	  be	  used	  to	  interrogate	  the	  iron	  centre,	  producing	  a	  signal	  with	  superior	  sensitivity	  than	  for	  the	  siderophore	  in	  bulk	  solution.	  In	   making	   the	   first	   steps	   toward	   creating	   a	   Lcn2-­‐based	   biosensor	   the	   initial	  cloning	   of	   Lcn2	   is	   reported	   in	   this	   chapter	   together	   with	   preliminary	   synthesis	   and	  electrodeposition	  of	  an	  immobilisation	  ligand	  onto	  the	  surface	  of	  a	  GCE.	  






Figure	  53A:	  Lateral	  flow	  device	  design	  that	  could	  be	  used	  for	  concentrating	  mycobactin	  from	  a	  
sample	  into	  a	  small	  volume	  for	  electrochemical	  analysis.	  B:	  Example	  of	  a	  specific	  receptor	  (Lcn2)	  
for	  mycobactin	  bound	  to	  the	  electrode	  surface.	  An	  alternative	  strategy	  in	  capture	  ligand	  development	  would	  be	  to	  use	  antibodies	  against	   mycobactin.	   The	   development	   of	   the	   synthetic	   mycobactin	   compounds	   would	  allow	   the	   first	   antibodies	   against	   mycobactin	   and	   carboxymycobactin	   to	   be	   raised.	  Synthetic	   mycobactins	   and	   carboxymycobactin	   would	   also	   provide	   structurally	  authentic	  and	  pure	  materials	  to	  be	  used	  as	  standards	  for	  assay	  development.	  As	  seen	  in	  Chapter	  5,	  mycobactin	  and	  carboxymycobactin	  differ	  significantly	  in	  their	  extraction	  and	  detection	  properties.	  FeMJ	  is	  limited	  in	  its	  capacity	  as	  an	  analytical	  standard	  because,	  as	  an	   extract	   of	   biological	   origin,	   it	   is	   composed	   of	  multiple	   siderophore	   structures	   (see	  Section	  2.2.3)	  and	  contains	  other	   impurities	  as	  well.	  Furthermore,	   the	  development	  of	  synthetic	  mycobactin	   is	  useful	   for	  research	  on	  the	  use	  of	  siderophores	  as	  PET	  imaging	  agents,	  as	  discussed	  in	  Section	  1.4.	  As	  such,	  suitable,	  purified	  synthetic	  materials	  were	  created	  for	  both	  mycobactin	  and	  carboxymycobactin.	  The	  target	  synthetic	  compounds	  are	  shown	  in	  Figure	  54.	  This	  was	  desirable	  since	  it	  is	  still	  unconfirmed	  which	  siderophore	  would	  be	  more	  prevalent	  within	  the	  tissues	  of	  infected	  individuals.	  This	  synthetic	  standard	  also	  allowed	  studies	  to	  be	  carried	  out	  that	  elucidate	  the	  mechanism	  of	  Mtb	  iron	  acquisition	  and	  the	  question	  of	  whether	  lipophilic	  mycobactin	  or	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Figure	  54:	  Structure	  of	  synthetic	  mycobactins.	  A:	  Synthetic	  mycobactin	  T	  (SMT).	  B:	  Synthetic	  
carboxymycobactin	  (SCM).	  
6.1 Materials	  and	  Methods	  
6.1.1 Cloning	  of	  Lcn2	  Lcn2	  was	  cloned	  from	  the	  human	  cDNA	  (accession	  NM_005564,	  purchased	  from	  OriGene)	  and	  ligated	  into	  the	  pET28b	  expression	  vector	  for	  expression	  with	  an	  amino-­‐terminal	  hexahistidine	  tag	  in	  BL21	  E.	  coli.	  After	  induction	  of	  expression	  using	  isopropyl-­‐β-­‐D-­‐thio-­‐galactoside	   (IPTG),	   Lcn2	   was	   purified	   by	   nickel-­‐affinity	   chromatography.	  Sodium	   dodecyl	   sulfate	   polyacrylamide	   gel	   electrophoresis	   (SDS-­‐PAGE)213	   was	  performed	  using	  a	  4-­‐12%	  polyacrymalide	  gradient	  gel	  (Novex).	  
6.1.2 NTA	  Immobilisation	  Ligand	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Figure	  55:	  Synthesis	  of	  4-­aminophenyl-­NTA.	  
6.1.2.2 Deposition	  of	  NTA	  onto	  the	  Electrode	  Surface	  Deposition	  of	  4-­‐aminophenyl-­‐NTA	  onto	  the	  electrode	  surface	  was	  performed	  as	  described	   previously214	   and	   follow-­‐up	   electrochemistry	   was	   carried	   out	   in	   aqueous	  1	  mM	   ferricyanide	   (Fe(CN)6),	   0.1	  M	   potassium	   chloride,	   and	   in	   the	   presence	   of	   either	  phosphate	  buffer	  (pH	  7.5)	  or	  HCl	  (pH	  1.0).	  
6.1.3 Synthesis	  of	  Mycobactins	  Synthesis	  of	  mycobactins	  was	  carried	  out	  by	  Tobin	  J.	  Dickerson	  and	  Petr	  Čapek	  at	  Scripps	  Research	  Institute	  and	  the	  products	  of	  this	  effort	  are	  evaluated	  in	  this	  chapter.	  This	  synthesis	  and	  accompanying	  evaluation	  form	  the	  basis	  of	  one	  manuscript	  that	  has	  been	  submitted	  for	  publication215.	  
6.1.3.1 Synthesis	  of	  Mycobactin	  T	  Using	  the	  Reported	  “Minimal	  Protecting	  Group	  














































	  	   121	  
Burgess’s	   reagent.	   Finally,	   both	   benzyl	   protecting	   groups	   were	   cleaved	   by	   catalytic	  hydrogenolysis	  leading	  to	  oxazoline	  fragment	  4.	  	  
	  
Figure	  56:	  Retrosynthetic	  analysis	  of	  mycobactin	  T	  1a	  and	  mycobactin	  S	  1b.	  In	  mycobactin	  T,	  the	  
stereocentre	  is	  of	  the	  R	  configuration	  and	  in	  mycobactin	  S,	  this	  stereocentre	  is	  of	  the	  S	  
configuration.	  
	  
Figure	  57:	  Synthesis	  of	  oxazoline	  fragment	  4.	  Reagents	  and	  conditions:	  (a)	  (i)	  BnBr,	  K2CO3,	  
MeOH/DCM	  1:1,	  reflux,	  overnight,	  88%;	  (ii)	  NaOH,	  dioxane/water,	  reflux,	  2	  h,	  93%;	  (iii)	  L-­serine-­
OBn,	  EDC,	  DCM,	  RT,	  overnight,	  89%;	  (b)	  (i)	  Burgess’s	  reagent,	  THF,	  reflux,	  30	  min,	  66%;	  (ii)	  H2,	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7,	  which	  was	  used	  as	  a	  common	  intermediate	  leading	  to	  both	  hydroxamic	  acid	  building	  blocks.	  In	  one	  route,	  hydroxylamine	  7	  was	  treated	  with	  thionyl	  chloride	  in	  methanol	  and	  the	   resulting	   methyl	   ester	   9	   was	   acylated	   with	   an	   excess	   (4	   equivalents)	   of	  nonadecanoyl	   chloride	   to	   give	   a	   bis-­‐acylated	   hydroxyl-­‐amine.	   The	   undesired	   O-­‐nonadecanoyl	   group	   was	   then	   removed	   by	   treatment	   with	   6%	   N,N-­‐Diisopropylethylamine	   (DIPEA)	   in	  methanol	   to	   form	  10	   in	   36%	   overall	   yield	   from	   α-­‐Cbz-­‐L-­‐lysine.	   Quantitative	   deprotection	   by	   hydrogenolysis	   of	   the	   Cbz	   group	   then	  afforded	  the	  desired	  building	  block	  11.	   In	  order	  to	  make	  fragment	  8,	  hydroxylamine	  7	  was	   cyclised	   using	   ethyl(dimethylaminopropyl)	   carbodiimide	   (EDC)/1-­‐hydroxy-­‐7-­‐azabenzotriazole	  (HOAt)	  to	  generate	  the	  desired	  caprolactam	  hydroxamic	  acid216.	  	  
	  
Figure	  58:	  Synthesis	  of	  unprotected	  hydroxamic	  acid	  fragments.	  Reagents	  and	  conditions:	  (a)	  (i)	  
PhCHO,	  KOH,	  MS,	  MeOH,	  overnight,	  RT;	  (ii)	  m-­CPBA,	  MeOH,	  0	  °C	  to	  RT,	  5	  h;	  (iii)	  TFA/DCM,	  1:1,	  RT,	  
1	  h;	  (iv)	  PhCHO,	  EtOAc,	  0	  °C	  to	  RT,	  2	  days,	  66%	  over	  4	  steps;	  (b)	  NH2OH⋅HCl,	  MeOH,	  65	  °C,	  20	  min,	  
87%;	  (c)	  (i)	  EDC/HOAt,	  NaHCO3,	  CH3CN,	  DMF,	  RT,	  48	  h,	  50%;	  (ii)	  H2,	  Pd/C,	  MeOH,	  2	  h,	  97%;	  (d)	  
SOCl2,	  MeOH,	  0	  °C	  to	  RT,	  12	  h,	  83%;	  (e)	  (i)	  nonadecanoyl	  chloride,	  NaHCO3,	  DCM,	  RT,	  overnight;	  (ii)	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flask,	   as	   previously	   described.	   The	   final	   coupling	   of	   the	   sequence	   was	   initiated	   by	  addition	  of	  13b	  and	  an	  equivalent	  of	  EDC⋅HCl	  directly	  to	  the	  cobactin	  reaction	  mixture	  after	  consumption	  of	  all	  hydroxamic	  acid	  8	  (less	  then	  4	  h).	  The	  reaction	  was	  then	  stirred	  at	  room	  temperature	  overnight	  to	  produce	  coupling	  product	  15,	  which	  could	  be	  isolated	  by	   chromatography.	  The	   final	   product	  was	   characterised	  using	   standard	  methods	   and	  was	  consistent	  with	  previous	  literature	  data.	  	  
	  
Figure	  59:	  Assembly	  of	  fragments	  using	  the	  reported	  “minimal	  protecting	  group”	  strategy.	  
Reagents	  and	  conditions:	  (a)	  EDC/HOAt,	  DCM,	  RT,	  6	  h,	  49%;	  (b)	  Ba(OH)2,	  THF/water,	  RT,	  1	  h,	  95%;	  
(c)	  EDC⋅HCl/HOAt	  and	  catalytic	  DMAP,	  DMF,	  RT,	  4	  h;	  (d)	  EDC/HOAt,	  DMAP	  (cat.),	  DMF,	  RT,	  16	  h,	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Cyclised	  product	  17	  was	  highly	  unstable	   in	  solution.	  Attempts	   to	  generate	   the	  desired	  product,	   including	   increased	   reaction	   temperature	   (up	   to	   60°C),	   reaction	   time	   and/or	  additional	  DMAP	  catalyst,	  did	  not	  result	   in	  the	  desired	  coupling,	  suggesting	  that	  the	  β-­‐hydroxyacid	   fragment	   is	   not	   reactive	   enough	  under	   these	   conditions	   to	   form	   an	   ester	  with	  mycobactic	  acid.	  	  
	  
Figure	  60:	  Assembly	  of	  benzyl	  protected	  fragments.	  	  Reagents	  and	  conditions:	  (a)	  EDC/HOAt,	  
catalytic	  DMAP,	  DMF,	  RT,	  16	  h.	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Figure	  61:	  Synthesis	  of	  cyclic	  and	  linear	  benzyl	  hydroxamate	  fragments.	  Reagents	  and	  conditions:	  
(a)	  Na2[Fe(CN)5NO],	  water,	  pH	  9.5,	  60	  °C,	  6	  h,	  86%	  (crude);	  (b)	  (i)	  NH2OBn⋅HCl,	  EDC,	  THF/water,	  
pH	  4,	  2	  h,	  45%;	  (ii)	  I2,	  PPh3,	  imidazole,	  THF,	  RT,	  1	  h,	  80%;	  (c)	  Cs2CO3,	  DMF,	  70	  °C,	  2	  h,	  74%;	  (d)	  33%	  
HBr	  in	  AcOH,	  DCM,	  rt,	  30	  min,	  86%;	  (e)	  (i)	  CH2N2	  in	  Et2O,	  MeOH,	  rt,	  30	  min;	  (ii)	  I2,	  PPh3,	  imidazole,	  
THF,	  RT,	  1	  h,	  50%	  over	  2	  steps;	  (f)	  2	  or	  3,	  K2CO3,	  acetone,	  70	  °C,	  2	  h,	  79%;	  (g)	  33%	  HBr	  in	  AcOH,	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Figure	  62:	  Assembly	  of	  benzyl	  protected	  fragments.	  Reagents	  and	  conditions:	  (a)	  EDC/HOAt,	  DCM,	  
RT,	  5	  h,	  71%;	  (b)	  Ba(OH)2,	  THF/water,	  RT,	  1	  h,	  90%;	  (c)	  EDC/HOAt,	  DMF,	  RT,	  4	  h,	  63%;	  (d)	  PPh3,	  
DIAD,	  THF,	  RT,	  16	  h,	  45%;	  (e)	  H2,	  Pd/C,	  MeOH	  or	  EtOH/EtOAc,	  40	  psi,	  16	  h;	  for	  26a	  and	  mycobactin	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6.1.4 Evaluation	  of	  Synthetic	  Mycobactins	  Absorbance	   spectra	   were	   acquired	   using	   either	   a	   PerkinElmer	   Lambda	   16	  spectrophotometer	   in	  methanol,	   or	   by	   an	  HPLC/DAD	   in	  70	  percent	   acetonitrile.	  HPLC	  was	  performed	  using	  the	  NM_MYCO3	  protocol	  described	  in	  Section	  2.1.2.2.	  SCM,	  SMT,	  and	  SMS	  were	  also	  tested	  for	  biological	  activity.	  Valentina	  Dona	  of	  the	  NIAID	   Tuberculosis	   Research	   Section	   generously	   carried	   out	   these	   experiments	   for	  analysis	  in	  this	  work.	  
6.1.4.1 Radiolabelling	  of	  Mycobactins	  Radiolabelling	   of	   mycobactins	   was	   performed	   by	   Valentina	   Dona.	   FeSMT	   and	  FeSMS	   were	   diluted	   in	   chloroform	   and	   the	   bound	   iron	   was	   removed	   as	   described	  previously	   and	   the	   desferri-­‐mycobactins	  were	   diluted	   to	   the	   desired	   concentration	   in	  methanol.	  55FeCl3	  (American	  Radiolabeled	  Chemicals)	  was	  then	  mixed	  with	  the	  desferri-­‐mycobactins	  in	  1:1	  molar	  ratio.	  After	  an	  incubation	  of	  5	  minutes	  at	  room	  temperature,	  two	   volumes	   of	   chloroform	  were	   added.	   The	   samples	  were	   vortexed	   briefly	   and	   then	  centrifuged	  at	  15,000	  g	   for	  10	  minutes.	  After	   centrifugation,	   the	   chloroform	   layer	  was	  removed	  and	  washed	  once	  with	  ¼	  volumes	  of	  water	  in	  order	  to	  remove	  unbound	  iron.	  The	   samples	   were	   then	   left	   to	   evaporate	   at	   80°C	   in	   a	   heat-­‐block	   and	   were	   finally	  resuspended	  in	  methanol.	  Quantification	  of	  the	  radiolabelled	  mycobactins	  was	  achieved	  through	   liquid	   scintillation	   counting	   on	   a	   liquid	   scintillation	   counter	   (LSC,	   Beckman	  Coulter)	  and	  autoradiography.	  
6.1.4.2 Uptake	  by	  Mtb	  in	  Liquid	  Culture	  	  Mycobacterial	   cells	   were	   grown	   in	   iron-­‐replete	   GAST	   to	   an	   OD650	   0.5-­‐0.6.	   The	  cultures	  were	  washed	  once	  with	  low	  iron	  GAST	  and	  diluted	  in	  low	  iron	  GAST	  to	  an	  OD650	  0.1.	  After	  48	  hours	  the	  cultures	  were	  washed	  once	  with	  RPMI	  1640	  (Life	  Technologies)	  and	  diluted	  in	  RPMI	  1640	  containing	  0.05%	  Tween	  80	  to	  a	  final	  concentration	  of	  2×106	  CFU/mL.	   After	   the	   addition	   of	   80	   nM	   of	   radiolabelled	   FeSMT,	   FeSMS,	   or	   FeSCM	   the	  cultures	   were	   plated	   in	   24-­‐well	   plates	   (1	  mL/well)	   and	   the	   plates	   were	   incubated	   at	  37°C	  for	  24	  hours.	  The	  cells	  were	  then	  transferred	  to	  1.5	  mL	  tubes	  and	  centrifuged	  for	  3	  minutes	  at	  15,000	  g.	  The	  pellet	  was	  then	  washed	  three	  times	  with	  PBS	  +	  0.05%	  Tween	  80.	  Finally,	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the	   pellet	   was	   resuspended	   in	   200	  µL	   of	   PBS	  +	  0.05%	   Tween	   80	   and	   the	   amount	   of	  radioactivity	   quantified	  with	   a	   LSC.	   Three	  wells	  were	   used	   for	   each	   time	   point.	  Wells	  containing	  medium	  alone	  were	  used	  as	  negative	  controls.	  
6.1.4.3 Growth	  Rescue	  Assay	  
Mtb	   H37Rv	   or	   the	   ΔmbtB	   mutant	   strain	   were	   grown	   in	   iron-­‐replete	   GAST	  medium	   to	  mid-­‐exponential	  phase	   (OD650	  0.4-­‐0.6),	  washed	  once	  with	  1	  volume	  of	   low	  iron	  GAST	  and	  diluted	  in	  low	  iron	  GAST	  to	  OD650	  0.05.	  The	  strains	  were	  then	  plated	  in	  24	  well	   plates	   (1	  mL/well)	   in	   absence	   or	   in	   presence	   of	   0.1	  µM,	   0.01	  µM,	   or	   0.001	  µM	   of	  FeSMT,	   FeSMS,	   or	   FeSCM.	   The	   plates	   were	   incubated	   at	   37°C,	   and	   3	   wells	   for	   each	  concentration	  of	  mycobactin	  for	  each	  strain	  were	  used	  daily	  to	  determine	  the	  OD650	  at	  the	  spectrophotometer	  (Thermo-­‐Spectronic).	  
6.1.4.4 Uptake	  by	  Mtb	  Within	  Infected	  Macrophages	  To	   model	   the	   mycobactin-­‐mediated	   iron	   uptake	   in	   an	   actual	   infection	   model,	  uptake	   55Fe	   labelled	   siderophores	   by	  Mtb	   living	   within	   infected	   of	   macrophages	   was	  measured.	  Mtb	  cells	  were	  grown	  in	  GAST	  to	  an	  OD650	  of	  0.5-­‐0.6.	  The	  cultures	  were	  then	  washed	   once	   and	   resuspended	   in	   low	   iron	   GAST	   to	   an	   OD650	   0.1.	   After	   24	   hours	   the	  cultures	   were	   washed	   once	   with	   RPMI	  +	  foetal	   bovine	   serum	   (FBS)	   and	   diluted	   to	  8×107	  CFU/mL.	  THP-­‐1	  macrophages	  seeded	  in	  24	  well	  plates	  (1	  mL/well,	  106	  cells/mL),	  that	  had	  been	   activated	   48	   hours	   prior	   infection	   with	   PMA	   (50	   ng/ml),	   were	   infected	   with	   a	  multiplicity	  of	   infection	  (MOI)	  of	  20	  (250	  µL	  bacteria/well).	  The	  plates	  were	  incubated	  for	  2	  hours	  at	  37°C	  and	  then	  each	  well	  was	  washed	  three	  times	  with	  RPMI.	  Finally	  the	  cells	  were	  fed	  1	  mL	  of	  fresh	  RPMI	  +	  FBS	  and	  incubated	  again	  at	  37°C.	  24	  hours	  after	  the	  infection	  55Fe-­‐leaded	  siderophores	  (at	  a	  concentration	  of	  0.08	  µM)	  were	  added	  to	  each	  well.	   At	  2,	  7,	   and	  24	  hours	   the	  medium	  was	   removed,	   the	   supernatant	   collected	  and	  added	   to	   liquid	   scintillation	   vials	   for	   counting	  with	   a	   LSC	   (supernatant	   fraction).	   The	  wells	  of	   the	  24-­‐well	  plates	  were	  then	  washed	  2	  times	  with	  PBS	  and	  0.25	  mL	  PBS	  +	  1%	  Triton	   X-­‐100	   were	   added	   to	   each	   well	   to	   lyse	   the	   macrophages.	   The	   lysate	   was	  centrifuged	   for	   5	  min	   at	   14,000	   rpm	  and	   the	   supernatant	  was	   collected	   and	   added	   to	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scintillation	  tubes	  for	  counting	  (lysate	  fraction).	  The	  remaining	  pellet	  is	  washed	  3	  times	  with	  PBS	  +	  0.05%	  Tween	  80,	  resuspended	  into	  0.2	  mL	  of	  PBS	  and	  added	  to	  scintillation	  fluid	  for	  counting	  (pellet	  fraction).	  
6.1.5 Production	  of	  Anti-­Mycobactin	  Antibodies	  and	  Determination	  of	  Binding	  
Constants	  Mice	  were	  used	  to	  raise	  antibodies	  against	  SCM	  conjugated	  to	  the	  carrier	  protein	  bovine	   serum	   albumin	   (BSA)	   by	   linkage	   of	   the	   free	   acid.	  Monoclonal	   antibodies	  were	  isolated	   and	   their	   binding	   constants	   determined	   by	   Petr	   Čapek	   of	   Scripps	   Research	  Institute.	  Determination	   of	   the	   binding	   constants	   was	   done	   by	   competitive	   ELISA.	   The	  SCM-­‐BSA	   conjugate	   was	   used	   as	   the	   coating	   protein	   and	   the	   competing	   antigen	   was	  either	  SCM,	  SMT,	  a	  form	  of	  synthetic	  mycobactin	  T	  with	  a	  C6	  alkyl	  tail	  (SMT-­‐C6),	  or	  SMS	  in	  milk	  blocking	  buffer	  with	  1%	  DMSO.	  
6.2 Results	  and	  Discussion	  
6.2.1 Capture	  Ligand	  Development	  
6.2.1.1 Deposition	  of	  NTA	  onto	  the	  Electrode	  Surface	  The	   receptor	   immobilisation	   strategy	   depicted	   in	   Figure	   53B	   calls	   for	   the	  receptor	  protein	   to	  be	  anchored	  by	  means	  of	  an	  NTA-­‐functionalised	  electrode	  surface.	  The	   synthesis	   and	  diazonium	  salt	  deposition	  of	   an	  NTA	   ligand	  has	  been	  elucidated	  by	  Blankespoor	  et	  al.214	  NMR	  spectra	  of	  4-­‐aminophenyl-­‐NTA	  matched	  values	  given	   in	   the	  literature.	  After	   formation	  of	   the	  diazonium	  ion,	   it	  undergoes	  a	  two-­‐electron	  reduction	  to	   evolve	   gaseous	  N2	   and	   form	   a	   highly	   reactive	   aryl	   radical	   (Figure	   63).	   This	   radical	  rapidly	   forms	   a	   covalent	   bond	  with	   the	   nearby	   electrode	   surface	   to	   form	   a	   functional	  layer.	  Deposition	  of	   the	  diazonium	  salt	  of	  4-­‐aminophenyl-­‐NTA	  is	  shown	  in	  Figure	  64A.	  The	  deposition	  was	  quantified	  by	   integrating	   the	   charge	   transferred,	   assuming	   a	   two-­‐electron	   reduction.	   In	   this	   manner,	   the	   NTA	   surface	   coverage	   on	   the	   electrode	   was	  calculated	   to	   be	   5.2	  nmol/cm2.	   Attachment	   of	   the	  NTA	   ligand	   to	   the	   electrode	   surface	  was	  verified	  by	  monitoring	  the	  change	  in	  ferricyanide	  redox	  couple	  with	  pH	  as	  shown	  in	  Figure	  64B.	  At	  low	  pH	  (1.0)	  the	  three	  carboxylated	  arms	  of	  NTA	  become	  protonated,	  and	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the	   ferricyanide	   couple	   is	   observed	   normally.	   At	   neutral	   pH	   (7.5)	   NTA	   becomes	  deprotonated,	   thus	  creating	  a	   layer	  of	  negative	  charge	  on	   the	  surface	  of	   the	  electrode.	  This	   layer	   of	   negative	   charge	   inhibits	   the	   negatively	   charged	   ferricyanide	   ions	   from	  reaching	   the	  electrode	  surface,	  decreasing	   the	  amplitude	  of	   the	  observed	  redox	  peaks.	  This	  ligand	  is	  now	  ready	  for	  Lcn2	  attachment	  as	  proposed	  in	  Figure	  53B.	  	  
	  





Figure	  64A:	  Deposition	  of	  the	  diazonium	  ion	  onto	  a	  GCE	  surface	  at	  -­0.4	  V	  versus	  Ag/AgCl.	  B:	  CVs	  of	  
potassium	  ferricyanide	  at	  pH	  7.5	  and	  1.0	  indicate	  the	  successful	  functionalisation	  of	  the	  electrode	  
surface	  by	  slowing	  of	  the	  electrochemical	  process	  at	  pH	  7.5;	  0.1	  M	  potassium	  chloride,	  0.2	  V/s	  scan	  
rate.	  



























-0.2 0.0 0.2 0.4 0.6











[Fe(CN)  ]  , pH 7.5









Figure	  65A:	  SDS-­PAGE	  of	  insoluble	  and	  soluble	  fractions	  of	  Lcn2-­pET28b	  BL21	  E.	  coli	  cell	  lysate	  
after	  induction	  with	  IPTG.	  B:	  SDS-­PAGE	  of	  the	  Lcn2	  purification	  shows	  Lcn2	  with	  the	  expected	  
molecular	  weight	  of	  22.8	  kDa.	  
6.2.2 Synthetic	  Mycobactins	  Initially,	   synthesis	   of	   mycobactins	   was	   done	   following	   a	   minimal	   protecting	  group	   strategy	  developed	  by	  Hu	   and	  Miller152.	   Figure	  54	   shows	   the	   structures	   for	   the	  synthetic	   target	   compounds	   carboxymycobactin	   (SCM)	   and	   mycobactin	   T	   (SMT).	   To	  compare	   these	   with	   the	   natural	   structures	   described	   in	   Table	   8	   of	   Chapter	   2,	   SCM	  contains	  7	  carbons	  in	  its	  fatty	  acyl	  moiety,	  while	  the	  SMT	  fatty	  acyl	  contains	  19	  carbons.	  In	  addition	  to	  SCM	  and	  SMT,	  a	  synthetic	  version	  of	  mycobactin	  S	  (SMS)	  was	  made,	  which	  differs	  from	  SMT	  by	  only	  one	  chiral	  centre	  (see	  Table	  2).	  For	   clarification,	   the	   products	   of	   the	   minimal	   protecting	   group	   synthesis	   are	  labelled	   as	   mpSMT	   (for	   the	   mycobactin	   T	   version)	   and	   mpSCM	   (for	   the	  carboxymycobactin	  version).	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Further	   to	   this,	   it	  was	   noted	   that	   the	   ferric	   peak	   shifts	   to	   a	   longer	  wavelength	  upon	  addition	  of	  ferric	  chloride,	  as	  shown	  for	  mpSCM	  in	  Figure	  66B.	  The	  ferric	  peak	  is	  located	  at	  480	  nm	   in	   the	  presence	  of	  10	  µM	   ferric	   chloride,	  but	   shifts	   to	  510	  nm	  upon	  saturation	   with	   80	  µM	   ferric	   chloride.	   Addition	   of	   sodium	   hydroxide	   to	   the	   solution	  shifted	   the	   absorbance	  maxima	   back	   toward	   shorter	  wavelengths,	   followed	   by	   loss	   of	  the	  ferric	  peak,	  presumably	  due	  to	  degradation	  of	  the	  compound.	  This	  absorbance	  shift	  is	  consistent	  with	   the	  pH	  change	  accompanying	   ferric	  chloride	  addition	  and	  a	  reversal	  upon	  the	  addition	  of	  sodium	  hydroxide	  to	  again	  raise	  the	  pH.	  In	  contrast,	  authentic	  DFMJ	  does	   not	   exhibit	   any	   shift	   in	   position	   of	   the	  major	   absorbance	   peak	   with	   addition	   of	  ferric	  chloride.	  These	   data	   call	   into	   question	   the	   veracity	   of	   the	   products	   of	   the	   minimal	  protecting	  group	  synthesis.	  The	  shift	  in	  this	  peak,	  which	  corresponds	  to	  a	  chelated	  iron	  centre,	  indicates	  that	  iron	  coordination	  undergoes	  a	  gradual	  change	  with	  pH,	  which	  does	  not	   occur	   with	   the	   authentic	   mycobactin	   siderophores.	   Furthermore,	   aqueous	   cyclic	  voltammetry	   of	   the	   minimal	   protecting	   group	   products	   failed	   to	   produce	   the	  characteristic	   redox	   couple	  present	   in	  FeMJ	  as	   shown	   in	  Figure	  67	   (compare	  with	   the	  redox	   couple	   of	   authentic	   mycobactin	   reported	   in	   Figure	   24).	   Instead,	   mpSMT	   and	  mpSCM	   exhibit	   a	   single,	   irreversible	   reduction	   at	   -­‐0.85	  V	   in	   both	   the	   presence	   and	  absence	   of	   iron.	   Given,	   that	   this	   reduction	  wave	   is	   not	   dependent	   on	   the	   presence	   of	  iron,	   it	   must	   by	   a	   reduction	   of	   the	   compound	   itself	   and	   suggests	   that	   these	   minimal	  protecting	  group	  products	  have	  a	  reducible	   ligand,	  which	   is	  absent	   from	  the	  authentic	  siderophore.	  	  





Figure	  66A:	  Contrasting	  absorbance	  spectra	  of	  the	  minimal	  protecting	  group	  products,	  and	  
authentic	  FeMJ	  and	  FeMT.	  Spectra	  were	  normalised	  to	  their	  respective	  maxima	  at	  either	  450	  nm	  or	  
500	  nm.	  B:	  Desferri	  mpSCM	  was	  ferrated	  using	  ferric	  chloride,	  then	  sodium	  hydroxide	  was	  titrated	  
into	  the	  solution	  to	  observe	  the	  peak	  shift	  under	  re-­alkalinisation.	  
	  
Figure	  67:	  Cyclic	  voltammetric	  analysis	  of	  minimal	  protecting	  strategy	  products.	  All	  analytes	  at	  
1	  mM	  concentration,	  0.1	  M	  potassium	  chloride	  in	  50	  percent	  aqueous	  ethanol,	  0.2	  V/s	  scan	  rate.	  Due	   to	   the	   presence	   of	   trace	   amounts	   of	   iron	   in	   the	   synthetic	   process,	   the	  products	  were	  initially	  partially	  ferrated;	  the	  anticipated	  ionic	  mass	  of	  the	  SMT	  product	  is	   844.5	  amu	   without	   iron	   and	   897.5	  amu	   with	   iron	   bound.	   The	   addition	   of	   ferric	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chloride	   to	   the	   product	   unexpectedly	   produced	   a	   double	   elution	   peak	   of	   the	   ferric	  compound,	  as	  shown	  in	  Figure	  68.	  The	  doubling	  of	  the	  peak	  suggested	  that	  racemisation	  of	  a	  chiral	  centre	  was	  occurring	  at	  some	  point	  of	  the	  synthesis	  after	  the	  compound	  had	  already	  been	  exposed	  to,	  and	  chelated,	  trace	  amounts	  of	  iron.	  	  
	  
Figure	  68:	  HPLC	  chromatogram	  of	  mpSMT	  elution	  under	  the	  NM_MYCO3	  protocol	  (see	  Section	  
2.1.2.2).	  Addition	  of	  ferric	  chloride	  to	  mpSMT	  gave	  rise	  to	  a	  doubled	  elution	  peak;	  the	  elution	  of	  
authentic	  FeMJ	  is	  shown	  for	  comparison	  of	  elution	  times.	  Based	  upon	  these	  data,	  as	  well	  as	  additional	  NMR	  analysis	  performed	  at	  Scripps	  Institute,	   it	   was	   concluded	   that	   Miller’s	   minimal	   protecting	   group	   strategy	   was	   not	  producing	   the	   desired	   mycobactin	   target	   compound.	   Instead,	   these	   further	  investigations	  suggested	  the	   isomer	  shown	  in	  Figure	  69	  as	   the	  product	  of	  an	  alternate	  coupling	  between	  cobactin	  and	  mycobactic	  acid	  under	   the	  conditions	  described	  by	  Hu	  and	  Miller.	  This	  compound	  exhibited	  different	  iron-­‐binding	  properties	  from	  mycobactin,	  and	   hence	   was	   not	   suitable	   as	   a	   mycobactin	   standard.	   Additionally,	   this	   calls	   into	  question	   previously	   published	   findings	   that	   mycobactin	   S	   (MS)	   is	   a	   potent	   growth	  inhibitor	   of	   Mtb152,	   but	   rather,	   may	   indicate	   that	   mpSMT	   is	   the	   growth	   inhibitor.	  Although	   the	   compound	  did	  not	   exhibit	   a	   particularly	  potent	   affect,	  with	  99%	  growth	  inhibition	  at	  a	  concentration	  of	  12.5	  µg/mL152,	  the	  surprising	  element	  of	  the	  previously	  published	  data	  was	  the	  impression	  that	  such	  a	  nearly	  identical	  siderophore,	  differing	  by	  only	   one	   chiral	   centre,	   could	   be	   a	   growth	   inhibitor.	   Thus	   the	   finding	   that	   a	   different	  structure	  was	   responsible	   for	   growth	   inhibition	   regrettably	   lessens	   the	   impact	   of	   this	  discovery.	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Figure	  69:	  Structure	  of	  the	  minimal	  protecting	  group	  product	  mpSMT;	  not	  mycobactin.	  
6.2.2.2 Revised	  Synthetic	  Product	  A	   revised	   coupling	   strategy	   was	   able	   to	   produce	   a	   compound	   exhibiting	   the	  correct	  spectrophotometric	  properties	  as	  shown	  in	  Figure	  70	  and	  in	  contrast	  to	  Figure	  66A.	  The	  HPLC	  elution	  of	  this	  compound	  is	  shown	  in	  Figure	  71.	  Addition	  of	  ferric	  ion	  in	  the	   form	   of	   ferric	   acetylacetonate	   resulted	   in	   a	   single	   peak,	   indicating	   that	   no	  racemisation	   had	   taken	   place	   under	   the	   revised	   synthesis.	   Figure	   72	   shows	   FeSMT	  coeluting	  with	  natural	  FeMT	  compounds	  extracted	  from	  Mtb	  culture.	  The	  elution	  pattern	  is	  exactly	  as	  expected	  given	  the	  length	  of	  the	  hydrophobic	  tail.	  With	  a	  fatty	  acyl	  moiety	  containing	   19	   carbons,	   FeSMT	   eluted	   between	   the	   two	   major	   groups	   of	   natural	  mycobactins	  that	  contain	  18	  and	  20	  carbons	  in	  their	  fatty	  acyl	  moieties	  respectively.	  
	  
Figure	  70:	  UV-­visible	  spectra	  of	  FeSMT	  and	  FeSCM	  exhibited	  the	  same	  absorbance	  profile	  as	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Figure	  71:	  HPLC	  chromatogram	  of	  SMT	  elution	  under	  the	  NM_MYCO3	  protocol	  (see	  Section	  2.1.2.2).	  
Addition	  of	  ferric	  acetylacetonate	  (Fe(acac)3)	  produces	  only	  a	  single	  peak.	  
	  
Figure	  72:	  HPLC	  chromatogram	  of	  FeSMT	  eluting	  alongside	  mycobactins	  extracted	  from	  Mtb	  
culture	  (NM_MYCO3	  protocol,	  see	  Section	  2.1.2.2).	  Both	  the	  minimal	  protecting	  strategy	  product	  mpSMT	  and	  the	  revised	  synthesis	  product	  SMT	  were	  analysed	  via	  tandem	  mass	  spectrometry	  (MS/MS).	  The	  presence	  of	  a	  peak	  at	  758.5092	  	  m/z	  in	  the	  MS/MS	  spectra	  of	  the	  undesired	  product	  was	  particularly	  diagnostic	   (Figure	   73);	   this	   peak	   corresponds	   to	   the	   cleavage	   of	   the	   amide	   bond	  between	   the	   β-­‐hydroxy	   acid	   and	   azepinone	   fragments	   (C41H68N5O8+)	   and	   provides	  unequivocal	  evidence	  for	  the	  proposed	  connectivity	  of	  the	  minimal	  protecting	  strategy	  product	  shown	  in	  Figure	  69.	  In	  contrast	  to	  the	  product	  of	  the	  minimal	  protecting	  group	  strategy,	  fragmentation	  between	  building	  blocks	  C	  and	  D	  (Figure	  56)	  produced	  a	  species	  with	   717.4797	  m/z,	   corresponding	   to	   fragment	   A-­B-­C	   of	   the	   correctly	   coupled	  mycobactin,	  with	  no	  peak	  corresponding	  to	  the	  miscoupled	  product	  at	  758.5092	  m/z.	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Figure	  73:	  MS/MS	  spectra	  of	  the	  miscoupled	  product	  (mpSMT)	  (red,	  arrow	  points	  to	  m/z	  =	  
758.5092)	  and	  authentic	  mycobactin	  T	  (SMT)	  (blue,	  arrow	  points	  to	  m/z	  =	  717.4797).	  In	  both	  
cases,	  the	  parent	  peak	  has	  m/z	  =	  844.5432.	  Figure	  provided	  by	  Tobin	  J.	  Dickerson	  and	  Petr	  Čapek.	  
6.2.2.3 Biological	  Activity	  of	  Synthetic	  Mycobactins	  Biological	   activity	   analysis	   and	   evaluation	   were	   largely	   based	   upon	   raw	   data	  collected	  by	  Valentina	  Dona.	  
6.2.2.3.1 Uptake	  by	  Mtb	  in	  Liquid	  Culture	  and	  Growth	  Rescue	  Assay	  The	   mechanism	   of	   mycobactin-­‐mediated	   iron	   uptake	   remains	   shrouded	   in	  mystery.	   In	   order	   to	   gain	   some	   insight	   into	   this	   process	   and	   to	   test	   the	   biological	  effectiveness	   of	   the	   revised	   synthetic	   products,	   uptake	   of	   radioactive	   55Fe	   labelled	  mycobactins	  was	  measured	  both	  on	  the	  wild	  type	  Mtb	  strain	  H37Rv	  and	  the	  mycobactin	  deletion	  mutant	  ΔmbtB.	  The	  revised	  synthetic	  compounds	  FeSMT	  and	  FeSMS	  both	  show	  successful	  incorporation	  of	  their	  iron	  payloads	  into	  the	  mycobacterial	  cell	  pellet	  of	  both	  strains,	   as	   shown	   in	   Figure	   74.	   Again,	   note	   that	   FeSMT	   and	   FeSMS	   differ	   in	   structure	  only	  at	  one	  chiral	  centre.	  However,	  the	  FeSCM	  compound	  fails	  to	  efficiently	  incorporate	  its	   iron	  payload	  within	   the	  organism.	   It	   is	   evident	   that	   the	  organism	  does	  not	  need	   to	  produce	  endogenous	  mycobactin	   in	  order	   to	  utilise	   the	  exogenously	  added	  compound,	  however	   the	  presence	  of	   endogenously	  produced	  mycobactins	  or	   carboxymycobactins	  may	  aid	  in	  the	  transport	  and	  internalisation	  of	  iron	  and	  could	  explain	  why	  incorporation	  of	   iron	   is	   greater	   in	   the	   wild	   type	   strain	   than	   in	   the	   ΔmbtB	   strain	   that	   is	   unable	   to	  biosynthesise	  mycobactin.	  	  
!
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Figure	  74:	  Comparison	  of	  Mtb	  H37Rv	  and	  ΔmbtB	  uptake	  of	  80	  nM	  Fe55	  labelled	  FeSMT.	  Based	  on	  







Figure	  75:	  Growth	  rescue	  of	  ΔmbtB	  by	  FeSMT	  (A),	  FeSMS	  (B),	  or	  FeSCM	  (C).	  Based	  on	  data	  collected	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The	   failure	   of	   FeSCM	   to	   either	   incorporate	   iron	   into	   Mtb	   cultures	   or	   rescue	  growth	  of	   the	  ΔmbtB	  mutant	   could	  be	   explained	   in	   several	  different	  ways.	   First	   is	   the	  possibility	  that	  the	  biologically	  active	  compound	  is	  in	  fact	  the	  methyl	  ester	  rather	  than	  the	   carboxylic	   acid	   form	   of	   mycobactin.	   There	   has	   been	   debate	   regarding	   this	  proposition	   in	   the	   literature	   and	   it	   remains	   somewhat	   inconclusive	   as	   to	  which	   is	   the	  naturally	   produced	   compound46,	   47,	   119.	   In	   particular,	  Wong	   et	   al.	   have	   argued	   that	   the	  free-­‐acid	   form	   of	  mycobactin	   is	   likely	   just	   a	   degradation	   product,	   particularly	   as	   it	   is	  most	  readily	  obtained	  under	  acidic	  conditions,	  and	  that	  the	  methyl	  ester	  acts	  as	  the	  true	  siderophore51.	   A	   second	   intriguing	   possibility	   is	   that	   Mtb	   does	   not	   use	  carboxymycobactin	  as	  a	  means	  of	  extracellular	  iron	  acquisition.	  This	  would	  support	  the	  model	   proposed	   in	   Section	   2.3.1	   in	   which	   carboxymycobactin	   serves	   a	   role	   in	   iron	  trafficking	   primarily	  within	   the	   confines	   of	   the	  mycobacterial	   cell	   wall,	   and	   therefore	  there	  is	  no	  mechanism	  to	  facilitate	  transport	  of	  exogenous	  FeSCM	  into	  the	  cell.	  However,	  this	  interpretation	  would	  contradict	  results	  published	  elsewhere	  demonstrating	  uptake	  of	  exogenous	  carboxymycobactin-­‐bound	  iron122,	  125,	  217,	  218.	  
6.2.2.3.2 Uptake	  by	  Mtb	  Within	  Infected	  Macrophages	  In	  the	  macrophage	  infection	  model,	  it	  was	  observed	  that	  uptake	  was	  significantly	  higher	   for	   the	  ΔmbtB	  mutant	   at	   80	  nM	   (p	  <	  0.0001	  by	   two-­‐way	  ANOVA),	   however	   the	  difference	   was	   insignificant	   at	   400	  nM	   (p	  =	  0.26)	   (Figure	   76).	   This	   could	   be	   due	   to	  saturation	  of	  the	  uptake	  mechanism	  at	  the	  higher	  concentration.	  The	  reversal	  of	  relative	  uptake	   may	   indicate	   the	   more	   stringent	   iron-­‐restricted	   environment	   within	   the	  macrophage.	   Under	   these	   conditions,	   the	   ΔmbtB	   mutant	   is	   deprived	   of	   even	   trace	  quantities	  of	  iron	  that	  may	  be	  present	  in	  the	  culture	  medium,	  having	  to	  rely	  exclusively	  on	  the	  exogenously	  added	  mycobactin,	  while	  in	  the	  case	  of	  the	  wild	  type	  H37Rv	  strain,	  the	  exogenous	  mycobactin	  is	  competing	  with	  endogenously	  produced	  mycobactin.	  This	  effect	  could	  be	  compounded	  by	  the	  fact	  that	  exogenous	  mycobactin	  must	  first	  penetrate	  the	  macrophage,	  and	  thus	  is	  unable	  to	  fulfil	  the	  iron	  acquisition	  needs	  of	  the	  wild	  type	  stain	  as	  well	  as	  its	  own	  endogenously	  produced	  siderophores.	  	  





Figure	  76:	  80	  nM	  (A)	  or	  400	  nM	  (B)	  55Fe	  labelled	  FeSMT	  uptake	  into	  Mtb	  within	  macrophages	  
infected	  with	  strain	  H37Rv	  or	  ΔmbtB.	  Based	  on	  data	  collected	  by	  Valentina	  Dona.	  
6.2.3 Evaluation	  of	  Anti-­Mycobactin	  Antibodies	  Two	   monoclonal	   antibodies	   were	   successfully	   raised	   to	   a	   SCM-­‐BSA	   conjugate.	  The	   rationale	   for	   conjugating	   SCM	   by	   its	   free	   acid	   tail	   was	   to	   raise	   an	   antibody	   that	  would	  be	   specific	   to	   the	   iron-­‐chelating	  core	  of	  mycobactin	  T,	   rather	   than	  one	   that	  has	  specificity	  to	  a	  particular	  length	  of	  the	  fatty	  acyl	  tail.	  The	  binding	  constants	  for	  the	  two	  antibodies	  against	  various	  synthetic	   siderophores	   including	  a	  version	  of	  mycobactin	  T	  with	  a	  shortened	  C6	  acyl	  tail	  are	  reported	  in	  Table	  13.	  Antibody	  1	  exhibits	  a	  particularly	  high	  affinity	  for	  SCM	  and	  the	  shortened	  SMT-­‐C6	  over	   the	   lipophilic	   mycobactins	   with	   longer	   acyl	   chains.	   This	   preference	   is	   less	  pronounced	  with	  antibody	  2,	  however	   its	  overall	  weaker	  affinities	   for	   three	  out	  of	   the	  four	  siderophores	   indicate	  that	  antibody	  1	   is	   the	  more	  promising	  option.	  Although	  the	  specific	   epitopic	   regions	   of	   binding	  have	  not	   been	  determined,	   given	   the	   small	   size	   of	  mycobactin	   it	   is	   highly	   likely	   that	   the	   epitopes	   overlap	   each	   other	   to	   an	   extent	   that	  simultaneous	  binding	  by	  both	  antibodies	  would	  be	  sterically	  inhibited.	  
Table	  13:	  Binding	  constants	  for	  two	  monoclonal	  antibodies	  for	  different	  species	  of	  synthetic	  
mycobactin	  as	  measured	  by	  competitive	  ELISA.	  Data	  provided	  by	  Petr	  Čapek	  (personal	  
communication).	  
	   	   Binding	  Constant	  
Antibody	   Type	   SCM	   SMT	   SMT-­C6	   SMS	  
1	   Mouse	  IgG1	   1.3	  nM	   1190	  	  nM	   2.6	  	  nM	   2400	  	  nM	  
2	   Mouse	  IgG2a	   43	  nM	   1090	  	  nM	   222	  	  nM	   3400	  	  nM	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6.3 Conclusions	  In	   summary,	   the	   minimal	   protecting	   group	   strategy	   for	   mycobactin	   synthesis	  published	   by	   Hu	   and	   Miller152	   failed	   to	   produce	   the	   correct	   target	   compound.	   The	  revised	  synthetic	  method	  yielded	  a	  mycobactin	  representative	  of	  the	  natural	  compound	  in	   spectrophotometric	   absorbance,	   liquid	   chromatographic	   elution	   properties,	   and	  biological	  activity.	  The	  revised	  synthetic	  products	  FeSMT	  and	  FeSMS	  are	  biologically	  active	  and	  are	  able	   to	   transfer	   iron	   to	  Mtb	  without	   the	  need	   for	  direct	  mycobactin	  production	  by	   the	  organism,	   however	   endogenous	   mycobactin	   may	   aid	   in	   the	   process,	   at	   least	   in	   vitro.	  Furthermore,	  it	  has	  here	  been	  demonstrated	  that	  exogenous	  mycobactin	  T	  can	  be	  taken	  up	   by	  Mtb	   both	   in	   culture	   growth	   conditions	   and	  when	   infecting	   a	  macrophage.	   Both	  mycobactin	   T	   and	   mycobactin	   S,	   but	   not	   carboxymycobactin	   were	   able	   to	   promote	  growth	  of	  the	  ΔmbtB	  mutant.	  This	   revised	   synthetic	   product	  was	  used	   as	   a	   standard	   in	   the	  previous	   chapter	  investigating	  clinical	  samples	  for	  mycobactins	  and	  carboxymycobactins.	  However,	  these	  products	   now	   offer	   starting	   blocks	   for	   antibody	   production	   and	   alternative	  biorecognition	   and	   capture	   ligands	   to	   the	   Lcn2	   ligand	   proposed	   in	   Figure	   53.	   The	  development	  of	  these	  synthetic	  mycobactin	  compounds	  has	  allowed	  the	  first	  antibodies	  against	  mycobactin	   and	   carboxymycobactin	   to	   be	   raised.	   These	   antibodies	   could	   also	  serve	   the	   role	   as	   specific	   mycobactin	   binding	   agents,	   replacing	   Lcn2	   in	   a	   design.	  Alternatively,	   if	   it	   is	   possible	   to	   bind	   mycobactin	   simultaneously	   with	   two	   binding	  agents	   it	   would	   be	   possible	   to	   amplify	   the	   signal	   through	   the	   generation	   of	  enzymatically-­‐generated	  measurand	  by	  and	  enzyme	  conjugated	  to	  one	  binding	  agent,	  as	  in	  a	  traditional	  sandwich	  assay.	  Because	  of	  the	  deep	  binding	  pocket	  of	  Lcn2127	  and	  the	  small	  size	  of	  mycobactin,	  as	  discussed	  in	  Section	  6.2.3,	  this	  would	  be	  difficult	  to	  achieve.	  With	  the	  electrode	  now	  modified	  to	  accept	  either	  of	  these	  biorecognition	  ligands	  via	  a	  hexahistidine	  tag	  (Section	  6.1.2.2)	  further	  work	  can	  establish	  the	  best	  strategy	  for	  optimising	   such	   a	   ‘capture	   and	   report’	   electrode.	   Traditionally,	   protein-­‐modified	  electrodes	  have	  relied	  on	  the	  generation	  of	  a	  reporter	  molecule219	  or	  electron	  transfer	  through	   an	   intermediate	   to	   the	   electrode220.	   However	   more	   recent	   designs	   of	   ‘third	  generation’	   biosensors	   take	   advantage	   of	   direct	   electron	   transfer	   from	   the	   redox	  reaction	   of	   interest	   (usually	   catalysed	   within	   an	   enzyme)	   to	   the	   electrode221-­‐223.	  Improvements	   in	   the	   applicability	   of	   direct	   electron	   transfer	   to	   a	   wider	   variety	   of	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proteins	   have	   included	   the	   modification	   of	   the	   electrode	   surface	   with	   carbon	  nanotubes224,	   225	   or	   molecular	   wires223	   in	   order	   to	   reduce	   the	   distance	   of	   electron	  transfer	  from	  the	  catalytic	  pocket.	  In	  the	  case	  of	  mycobactin	  the	  reaction	  is	  not	  catalysed	  enzymatically,	  but	  is	  initiated	  directly	  by	  the	  potential	  drop	  near	  the	  electrode	  surface,	  so	   the	  specific	  catalytic	  activity	  of	   the	  enzyme	  is	  not	   important.	  This	  gives	  more	  scope	  for	  manipulation	  of	   the	  binding	  orientation	  to	  maintain	  mycobactin	  near	  the	  electrode	  surface	   for	   direct	   electron	   transfer.	   Direct	   electrochemistry	   has	   long	   been	   used	   for	  sensitive	  detection	  of	  non-­‐proteinaceous	  biomolecules,	  such	  as	  DNA226.	  Mycobactins	   and	   carboxymycobactins	   also	   offer	   a	   promising	   new	  modality	   for	  PET	  imaging	  of	  TB.	  The	  synthetic	  siderophores	  that	  have	  been	  developed	  in	  conjunction	  with	   this	  project	  have	  now	  been	  scaled	  up	   in	  production	  and	  offer	   the	  best	  option	   for	  testing	  the	  PET	  probe	  potential	  of	  siderophores	  for	  the	  visualisation	  of	  TB.	  The	  results	  from	   the	   mycobactin	   and	   carboxymycobactin	   uptake	   experiments	   indicate	   that	  mycobactin	   would	   offer	   superior	   labelling	   of	   Mtb	   cells	   themselves,	   however	   the	  divergent	   biodistribution	   profiles	   of	   carboxymycobactins	   and	   mycobactins	   will	   need	  further	   investigation	  to	  ascertain	  which	  one	  offers	  the	  best	  PET	  labelling	  strategy.	  The	  use	   of	   mycobactin	   as	   a	   PET	   probe,	   if	   it	   becomes	   a	   widespread	   technique,	   may	   also	  require	  the	  use	  of	  a	  companion	  diagnostic	  for	  safety	  purposes.	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7 Future	  Implications	  
Here	  the	  implications	  of	  this	  work	  for	  future	  research	  and	  the	  understanding	  of	  siderophores	   as	   potential	   diagnostic	   markers	   for	   TB	   are	   addressed.	   Other	   potential	  applications	  of	   the	   assay	   are	   explored,	   such	   as	   a	   biosensor	   for	   companion	  diagnostics	  and	  other	  industrial	  uses.	  Finally,	  some	  future	  possibilities	  for	  increasing	  the	  sensitivity	  of	  the	  assay	  are	  set	  forth.	  
7.1 Tuberculosis	  Diagnostic	  Potential	  of	  Mycobactin	  and	  
Carboxymycobactin	  There	   are	   two	   questions	   to	   be	   addressed	   regarding	   the	   possible	   use	   of	  mycobactins	  as	  diagnostic	  biomarkers	  for	  TB.	  One	  is	  a	  question	  of	  instrumentation	  and	  the	  creation	  of	  a	  biosensor	   for	  mycobactin/carboxymycobactin	  detection.	  The	  other	   is	  the	  question	  of	  the	  presence	  of	  these	  siderophores	  in	  significant	  enough	  quantities	  and	  with	  a	  biodistribution	  profile	  that	  is	  conducive	  to	  detection	  with	  such	  a	  biosensor.	  This	  work	   has	   sought	   to	   tackle	   the	   first	   question	   by	   developing	   a	   simple	   assay	   that	   could	  serve	  in	  the	  capacity	  of	  a	  diagnostic	  biosensor.	  Furthermore	  this	  study	  has	  established	  a	  low	   level	   of	   background	   signal	   interference	   when	   the	   assay	   is	   used	   to	   analyse	   urine	  samples.	  Unfortunately,	   the	   results	   are	   disappointing	   thus	   far	   in	   regard	   to	   the	   second	  question	   of	   siderophore	   biodistribution	   and	   empirical	   measurement	   of	   siderophores	  within	  the	  body	  tissues	  that	  have	  been	  tested	  here.	  If	  mycobactins	  are	  present,	  they	  are	  at	  very	  low	  levels	  within	  plasma	  and	  urine,	  but	  other	  tissues	  may	  hold	  better	  prospects	  for	  use	  with	   this	  assay.	  Further	  high-­‐sensitivity	   laboratory-­‐based	  testing	  of	  alternative	  tissues	  more	  proximal	  to	  the	  Mtb	  infection	  itself	  would	  provide	  the	  next	  step	  to	  establish	  the	  presence	  and	  levels	  of	  mycobactin	  in	  clinical	  samples.	  Only	  then	  will	  be	  possible	  to	  use	  this	  mycobactin	  assay	  as	  a	  novel	  TB	  diagnostic	  biosensor.	  
7.1.1 Bovine	  Tuberculosis	  Bovine	  TB,	  defined	  as	   infection	  of	  cattle	  by	  M.	  bovis	   rather	   then	  Mtb,	   is	  a	  major	  concern	   for	   cattle	   ranchers	   and	   is	   particularly	  widespread	   in	   the	   United	   Kingdom.	  M.	  
bovis	  is	  the	  only	  other	  mycobacterium	  to	  produce	  a	  siderophore	  structurally	  identical	  to	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that	   of	   Mtb50.	   As	   such,	   the	   simple	   assay	   could	   serve	   as	   a	   new	   diagnostic	   for	   this	  veterinary	   disease	   in	   addition	   to	   human	   TB.	   Diagnostics	   for	   animal	   and	   livestock	   use	  face	  fewer	  regulatory	  hurdles,	  reducing	  time-­‐to-­‐market,	  and,	  as	  the	  technology	  would	  be	  largely	  similar,	  could	  also	  serve	  as	  a	  way	  to	  gather	  more	  data	  for	  ongoing	  development	  of	  a	  human	  diagnostic.	  
7.2 Other	  Applications	  of	  the	  Mycobactin	  Assay	  
7.2.1 Companion	  Diagnostic	  for	  Therapeutic	  Administration	  of	  Mycobactins	  Mycobactin	   is	   an	   important	   natural	   product	   that	   has	   potential	   pharmaceutical	  uses	   for	   chelation	   and	   anti-­‐cancer	   therapy,	   as	   well	   as	   the	   basis	   for	   antimicrobial	  analogues,	  as	  discussed	  in	  Chapter	  1.	  The	  simple	  electrochemical	  assay	  for	  mycobactin	  could	   serve	   as	   a	   companion	   diagnostic	   for	   these	   therapeutic	   administrations	   of	  mycobactins	   and	   their	   analogues.	  Anti-­‐cancer	   applications	  of	  mycobactin	   in	  particular	  could	  benefit	   from	  a	   simple	  assay	   to	   serve	  as	  a	   companion	  diagnostic.	  Pharmaceutical	  companies	   have	   been	   increasingly	   turning	   to	   companion	   diagnostics	   as	   a	   means	   to	  improve	   safety	   and	   efficacy	   of	   new	   prospective	   pharmaceuticals,	   including	   cancer	  treatments227.	  Because	  of	   the	  disruption	   that	   aggressive	   iron	   chelation	  would	  have	  on	  iron	   homeostasis	   in	   the	   normal	   tissues	   of	   cancer	   patients,	   it	   would	   be	   desirable	   to	  closely	   monitor	   concentrations	   of	   the	   therapeutic	   mycobactin	   and	   its	   chelated	   iron	  content	  upon	  excretion.	  This	  dissertation	  has	  shown	  that	  a	  simple	  assay	  for	  mycobactin	  is	  able	  to	  detect	  and	  quantify	  mycobactin	  directly	  at	  concentrations	  of	  10	  µM	  and	  above.	  A	  streamlined	  concentration	  method	  that	  could	  potentially	  reduce	  the	  limit	  of	  detection	  to	  300	  pM	  has	  also	  been	  demonstrated.	  This	   limit	   of	   detection	   is	  well	  within	   the	   required	   sensitivity	  range	   for	   a	   sensor	   targeted	   as	   a	   companion	   diagnostic	   for	   mycobactin	   used	   as	   a	  chelation	   or	   anti-­‐cancer	   therapies.	   Typical	   therapeutic	   plasma	   concentrations	   for	   iron	  chelators	  are	  in	  the	  range	  of	  5-­‐450	  µM228-­‐231.	  Therefore	  it	  may	  be	  possible	  to	  directly	  use	  the	  assay	  without	  extensive	  sample	  processing	  and	  concentration.	  This	  depends	  on	  the	  levels	  of	  mycobactin	  that	  ultimately	  prove	  to	  be	  effective	  for	  therapeutic	  administration	  versus	  toxicity	  and	  on	  the	  rate	  of	  mycobactin	  filtration	  by	  the	  kidneys.	  In	  order	   to	  answer	   the	  next	  series	  of	  questions	   in	   regard	   to	   the	  applicability	  of	  the	   assay,	   the	   biodistribution	   and	   pharmacokinetic	   of	  mycobactin	   and	   its	   therapeutic	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analogues	  of	  interest	  must	  be	  investigated.	  The	  assay	  that	  has	  been	  developed	  here	  will	  serve	  as	  a	  useful	  tool	  that	  may	  undergo	  co-­‐development	  along	  with	  animal	  and	  clinical	  trials	  of	  mycobactin-­‐based	  therapeutics.	  
7.2.2 Biosensor	  for	  Industrial	  Siderophore	  Production	  In	   this	   study,	   Mtb	   grown	   in	   liquid	   culture	   produced	   siderophores	   at	   a	  concentration	   of	   8.6	  µM	   that	   would	   be	   accessible	   to	   a	   sensor	   exposed	   the	   culture	  medium,	  however	  much	  higher	  levels	  of	  production	  have	  been	  achieved	  under	  different	  conditions184.	  The	  CV	   limit	  of	  detection	   for	   the	  assay	  was	   in	   this	  same	  range	  at	  10	  µM.	  Strategies	  to	  concentrate	  the	  sample	  at	  the	  electrode	  surface,	  such	  as	  those	  set	  forth	  in	  Chapter	   6,	   would	   be	   necessary	   in	   order	   to	   allow	   real-­‐time	   monitoring	   of	   early-­‐stage	  siderophore	  production	  and	  accumulation.	  Such	   a	   real-­‐time	   sensor	   could	   have	   applications	   in	   monitoring	   commercial	  siderophore	  production.	  Mycobactin	  J	  is	  one	  industrially	  significant	  siderophore	  that	  is	  required	  for	  culturing	  M.	  avium	  subspecies	  paratuberculosis,	  which	  is	  routinely	  done	  to	  monitor	  cattle	  for	  Jöhne’s	  disease.	  Another	  application	  would	  be	  the	  ability	  of	  the	  assay	  to	   inexpensively	   identify	   an	   unknown	   organism	   as	   one	   that	   produces	   mycobactin.	  Monitoring	   of	   siderophore	   production	   within	   chemostats	   could	   provide	   information	  about	  the	  organisms’	  metabolic	  state,	  their	  need	  for	  iron,	  and	  could	  even	  reveal	  details	  about	   oxidative	   stress	   that	   the	   organism	   is	   experiencing.	   These	   are	   added	   to	   the	  usefulness	  of	  such	  a	  sensor	  in	  ongoing	  mycobacterial	  siderophore	  research.	  
7.3 The	  Role	  of	  In	  Vivo	  Mycobactin	  Reduction	  in	  Iron	  Trafficking	  It	  has	   long	  been	   thought	   that	  a	  putative	  reductase	  plays	  a	  role	   in	   the	  biological	  mechanism	  of	  iron	  dissociation	  from	  mycobactins	  or	  carboxymycobactins120.	  There	  are	  three	  different	  mechanisms	  that	  have	  been	  suggested	  by	  which	  bacteria	  may	  dissociate	  iron	   from	   their	   high-­‐affinity	   siderophores:	   reduction	   of	   Fe3+	   to	   Fe2+,	   cleavage	   of	   the	  siderophore,	   and	   protonation	   of	   the	   siderophore	   ligands197.	   While	   the	   cleavage	  mechanism	  has	   been	   observed	   in	   the	   case	   of	   catecholate	   siderophores	  with	   relatively	  simple	  structures232,	  it	  has	  been	  postulated	  that	  the	  chelation	  properties	  of	  hydroxamate	  siderophores	  are	  more	  conducive	  to	  dissociation	  by	  reduction	  of	  the	  ferric	  centre.	  This	  would	   also	   allow	   reuse	   of	   the	   siderophore,	   which	   in	   the	   case	   of	   mycobactin	   is	   quite	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complex	   and	   metabolically	   costly	   to	   produce.	   Recently	   Ryndak	   and	   colleagues	   found	  evidence	  of	  a	  flavin	  adenine	  dinucleotide	  (FAD)	  binding	  domain	  in	  the	  transmembrane	  IrtA	   transporter	   protein,	  which	   is	   necessary	   for	   iron	  uptake	   from	   carboxymycobactin.	  The	  presence	  of	  this	  FAD	  binding	  domain	  suggests	  that	  IrtA	  may	  serve	  not	  only	  as	  part	  of	   and	   ABC	   transported	   system	   together	  with	   IrtB,	   but	   also	   possesses	   FAD	   reductase	  functionality.	  In	  fact,	  mutations	  in	  the	  domain	  that	  prevented	  FAD	  binding	  reduced	  the	  organism’s	   ability	   to	   grow	   in	   conditions	   where	   iron	   is	   supplied	   solely	   chelated	   by	  carboxymycobactin218.	  This	  domain	  is	  thought	  to	  be	  on	  the	  cytoplasmic	  side	  of	  the	  cell	  membrane.	  This	  suggests	  an	  intimately	  linked	  siderophore	  import	  and	  reduction	  system	  for	  the	  utilisation	  of	  chelated	  ferric	  iron.	  This	   work	   has	   revealed	   the	   mechanism	   of	   mycobactin	   reduction	   (Chapter	   3),	  which	   likely	   has	   implications	   for	   how	   Mtb	   internalises	   and	   utilises	   uses	   iron	   from	  mycobactin	  in	  situ.	  Protonation	  of	  siderophore	  ligands	  has	  generally	  been	  dismissed	  as	  requiring	  pH	  values	  too	  low	  to	  be	  physiologically	  practical.	  However,	  protonation	  of	  the	  enzyme-­‐siderophore	   complex	   may	   not	   require	   such	   a	   low	   pH.	   As	   the	   proposed	  mechanism	  suggests,	  protonation	  of	  one	  or	  more	  of	  mycobactin’s	  chelation	  ligands	  can	  occur	  following	  reduction	  of	  the	  Fe3+	  centre	  under	  non-­‐acidic	  conditions.	  Facilitation	  of	  this	   protonation	   by	   an	   enzymatic	   process	  may	   help	   to	   thermodynamically	   favour	   the	  reduction,	  allowing	  both	  the	  low	  reduction	  potential	  and	  the	  low	  pH	  requirement	  to	  be	  overcome.	   Protonation	   of	   one	   or	  more	   of	   the	   chelation	   ligands	   could	   also	   prevent	   re-­‐oxidation	   of	   Fe2+	   while	   in	   the	   stabilising	   confines	   of	   the	   siderophore	   and	   facilitate	  dissociation	  of	  the	  Fe2+	  ion	  from	  the	  complex.	  
7.4 Electrode	  Surface	  Engineering	  The	   development	   of	   a	   novel	   biosensor	   is	   a	   long	   process	   that	   can	   take	   years,	  especially	   for	   medical	   diagnostic	   devices.	   The	   simple	   assay	   developed	   in	   this	  dissertation	  provides	  a	   foundation	   for	  such	  a	  biosensor.	  Here	  we	   look	   to	   the	   future	   to	  suggest	  some	  potential	  developments	  to	  further	  improve	  the	  sensor	  sensitivity.	  Mycobactin	   concentration	   at	   the	   electrode	   surface	   can	   be	   improved	   through	  modification	   of	   the	   surface	   itself	   to	   enhance	   the	   specific	   surface	   binding	   properties	  between	  the	  electrode	  and	  mycobactin	  through	  physical	  modification	  and	  patterning	  of	  the	  electrode	  surface.	  This	  is	  an	  alternative	  binding	  strategy	  that	  typically	  leads	  to	  less	  specific	   binding	   than	   the	  methods	   explored	   in	   Chapter	   6.	   There	   is	   a	   large	   and	   active	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body	   of	   research	   on	   the	   binding	   of	   analytes	   based	   upon	   molecular	   imprinting233,	   234,	  which	   can	  be	  applied	   to	   the	   surface	  of	   electrodes.	  The	   idea	  of	  molecular	   imprinting	   is	  that	  the	  analyte	  of	  interest	  is	  bound	  solely	  on	  the	  basis	  of	  its	  physical	  interactions	  with	  the	  substrate.	  Glassy	  carbon	  can	  also	  be	  imprinted	  with	  microstructures	  via	  mechanical	  machining,	   focused	   ion	   beam,	   and	   laser	   techniques235.	   The	   combination	   of	   these	  approaches	  would	  entail	  micropatterning	  of	  physical	   features	  on	   the	  electrode	  surface	  that	   to	   could	   interact	   with	   and	   preferentially	   adsorb	  mycobactin.	   Plasma	   etching	   can	  also	   be	   used	   to	   create	   patterned	   regions	   with	   differing	   hydrophilic/hydrophobic	  properties	   in	   order	   to	   give	   a	   combined	   physical/chemical	   approach	   to	   homing	   in	   on	  analyte-­‐specific	  binding	  morphologies236.	  This	  could	  be	  especially	  interesting	  to	  apply	  to	  the	  problem	  of	  mycobactin	  surface	  adsorption.	  	  Figure	   77	   shows	   a	   hypothetical	   molecular	   model	   of	   this	   scenario	   in	   which	   a	  hydrophobic	   groove	   has	   been	   etched	   in	   the	   surface	   of	   a	   graphite	   electrode	   with	  conformation	   designed	   to	   preferentially	   bind	  mycobactin.	   This	   hydrophobic	   groove	   is	  modelled	  after	  the	  hydrophobic	  pocket	  used	  to	  bind	  carboxymycobactin	  by	  Lcn2127.	  The	  groove	  shown	  in	  Figure	  77	  is	  6	  Å	  wide	  and	  the	  length	  of	  the	  groove	  that	  is	  occupied	  by	  mycobactin	   is	   42	  Å.	   Assuming	   equidistant	   groove	   spacing	   of	   6	  Å	   between	   groves,	   the	  area	  occupied	  by	  one	  molecule	  of	  mycobactin	  is	  therefore	  approximately	  42×12	  Å.	  Such	  a	   sensor	   would	   have	   a	   maximum	   total	   surface	   binding	   capacity	   of	   66	  pmol/cm2	   for	  mycobactin	  T,	  which	  would	  result	  in	  a	  charge	  transfer	  density	  of	  6.4	  µC/cm2	  for	  the	  one-­‐electron	  reduction	  of	  mycobactin.	  
	  
Figure	  77:	  Hypothetical	  molecular	  model	  of	  mycobactin	  T	  bound	  to	  a	  hydrophobic	  groove	  etched	  
in	  the	  surface	  of	  a	  graphite	  electrode.	  Molecular	  modelling	  and	  image	  were	  generously	  contributed	  
by	  Craig	  Saperstein	  using	  PyMOL	  version	  1.5.0.1237	  and	  Avogadro	  version	  1.0.3	  
(avogadro.openmolecules.net).	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7.5 Conclusions	  In	  this	  chapter	  the	  prospects	  of	  using	  the	  simple	  mycobactin	  assay	  developed	  in	  this	  dissertation	  for	  diagnosis	  of	  TB	  has	  been	  addressed,	  as	  well	  as	  a	  number	  of	  potential	  applications	  for	  the	  assay.	  The	  assay	  system	  has	  potential	  uses	  that	  run	  the	  gambit	  from	  TB	   and	   companion	   diagnostics	   to	   research	   utilisation	   and	   monitoring	   the	   industrial	  production	  of	  siderophores.	  These	  preliminary	  data	  also	  help	  to	  identify	  the	  direction	  of	  future	  research	  that	  may	  be	  done	  to	  further	  improve	  the	  sensitivity	  of	  the	  assay	  system	  for	   mycobactin.	   Furthermore,	   this	   dissertation	   has	   sought	   to	   elucidate	   what	   role	   the	  reduction	  of	   ferric	  mycobactin	  might	  play	  in	  the	  complex	  iron-­‐trafficking	  machinery	  of	  one	   of	   the	   world’s	   most	   deadly	   pathogens,	   Mycobacterium	   tuberculosis	   through	   the	  proposal	  of	  a	  novel,	  lipophilic	  mycobactin-­‐mediated	  iron	  acquisition	  pathway.	  Although	  mycobactin	  and	  carboxymycobactin	  were	  not	  detected	   in	   the	  clinical	   samples	  of	  urine	  and	  plasma	  tested	  here,	   future	   investigations	   into	  the	  biodistribution	  of	  mycobactin	   in	  other	  tissues	  of	  infected	  individuals	  may	  show	  that	  the	  goal	  of	  a	  low-­‐cost	  TB	  diagnostic	  device	   is	   still	  within	  reach.	  Ultimately,	   through	   the	  diligence	  of	   future	  endeavours,	   the	  simple	   assay	   for	   mycobacterial	   siderophores	   will	   serve	   to	   benefit	   science	   and	   the	  greater	  good	  of	  global	  health.	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Appendix	  1:	  Matlab	  Programs	  for	  Processing	  Electrochemical	  
Data	  
The	   following	   are	   Matlab	   programs	   that	   were	   written	   for	   analysis	   of	   the	  electrochemical	  data	  produced	  during	  this	  project.	  Note	  that	  hdrload.m	  is	  alo	  required	  for	   some	   of	   these	   programs	   and	   was	   downloaded	   form	   the	   Mathworks	   website	   at	  http://www.mathworks.com/support/tech-­‐notes/1400/1402.html.	  
High-­Speed	  Cyclic	  Voltammogram	  PicoScope	  Data	  Processing	  
‘PicoScope_binning_v11.m’	  
% This file was written by Nicholas McBride to process cyclic voltammetry 
% data acquired using the PicoScope 6 oscilloscope software. Please refer 




% Gets all the .mat file names in the specified directory and current range 
DirName = uigetdir('','Please select the direcory containing .mat files to 
be processed'); 
InputFiles = dir(fullfile(DirName, '*.mat')); 
CurrentRange = input('Current range (mA): ')/1000; 
BinSize = 4000; 
 
for FileNum = 1:length(InputFiles) 
 
    % Load data from PicoScope.mat file 
    % This file will contain the single column arrays 'A' and 'B' 
containing 
    % the channel A and B data and the variables 'Length' 'Tinterval' and 
'Tstart' 
    FileName = InputFiles(FileNum).name; 
    disp(' '); 
    disp(['Loading "', FileName, '"']); 
    load(fullfile(DirName, FileName)); 
 
    % Determine the number of binned untrimmed samples from the bin size 
    NumBins = floor(Length/BinSize); 
 
    % Seperates the bins into different columns 
    ColBinsA = zeros([BinSize, NumBins]); 
    ColBinsB = zeros([BinSize, NumBins]); 
    for BinNum = 1:NumBins 
        BinBottom = (BinNum-1)*BinSize+1; 
        BinTop = BinNum*BinSize; 
        ColBinsA(:, BinNum) = A(BinBottom:BinTop); 
        ColBinsB(:, BinNum) = B(BinBottom:BinTop); 
    end 
    clear('A', 'B'); 
     
    BinA = mean(ColBinsA)'; 
    BinB = mean(ColBinsB)'; 
    clear('ColBinsA', 'ColBinsB'); 
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    % Post-bin processing 
     
    % Scaling current range = 200mV for Solartron instrument 
    BinB = BinB.*(CurrentRange/0.2); 
     
    % Find minimum and maximum potentials to the nearest 10mV 
    MinPot = round(100*min(BinA))/100; 
    MaxPot = round(100*max(BinA))/100; 
     
    % Finds scan speed using linear fit 
    BinTinterval = Tinterval*BinSize; 
    Time = [0:BinTinterval:(NumBins-1)*BinTinterval]'; 
    Fit = 
polyfit(Time(round(0.35*NumBins):round(0.45*NumBins)),BinA(round(0.35*NumBi
ns):round(0.45*NumBins)),1); % Watch out for these numbers causing trouble 
    ScanSpeed = abs(Fit(1)); 
     
    % Determines whether vertex 2 is the minimum or maximum potential 
    if Fit(1) >= 0 
        Vertex1Pot = MinPot; 
        Vertex2Pot = MaxPot; 
        [unused, Vertex2Index] = 
max(BinA(round(0.45*NumBins):round(0.55*NumBins))); 
    else 
        Vertex1Pot = MaxPot; 
        Vertex2Pot = MinPot; 
        [unused, Vertex2Index] = 
min(BinA(round(0.45*NumBins):round(0.55*NumBins))); 
    end 
    Vertex2Index = Vertex2Index+round(0.45*NumBins)-1; % Corrects for 
limited range used to find vertex 2 index in previous line 
     
    % Trims the data to include only the center cycle from the data 
    % acquisition period and check if an entire cycle is included 
    SweepLengthBins = round((MaxPot-MinPot)/(ScanSpeed*BinTinterval)); 
    CycleStartIndex = Vertex2Index-SweepLengthBins; 
    if CycleStartIndex < 1 
        CycleStartIndex = 1; 
    end 
    CycleEndIndex = Vertex2Index+SweepLengthBins; 
    if CycleEndIndex > NumBins 
        CycleEndIndex = NumBins; 
    end 
         
    TrimA = BinA(CycleStartIndex:CycleEndIndex); 
    TrimB = BinB(CycleStartIndex:CycleEndIndex); 
     
    % Display statistics. The nasty was done by more than two elephants. 
    disp(['Vertex potential 1: ', num2str(Vertex1Pot), ' V']); 
    disp(['Vertex potential 2: ', num2str(Vertex2Pot), ' V']); 
    disp(['Calculated scan speed: ', num2str(ScanSpeed), ' V/s']); 
    disp(['Original data points: ', num2str(Length)]); 
    disp(['Bin size: ', num2str(BinSize)]); 
    disp(['Final resolution: ', num2str(SweepLengthBins/((MaxPot-MinPot))), 
' bins/V']); 
     
    % Write the stats and binned, trimmed data to a .csv file 
    NewFileName = regexprep(FileName,'.mat','_binned.csv'); 
    disp(['Writing 1 cycle of binned data to "', NewFileName, '"']); 
     
    dlmwrite(fullfile(DirName, NewFileName), {'Original file name,', 
FileName}, 'delimiter', ''); 
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    dlmwrite(fullfile(DirName, NewFileName), {'Modified,', 
InputFiles(FileNum).date}, '-append', 'delimiter', ''); 
     
    dlmwrite(fullfile(DirName, NewFileName), {'Processed file name,', 
NewFileName}, '-append', 'delimiter', '', 'roffset', 1); 
    dlmwrite(fullfile(DirName, NewFileName), {'Processed,', datestr(now)}, 
'-append', 'delimiter', ''); 
     
    dlmwrite(fullfile(DirName, NewFileName), {'Original data points,', 
num2str(Length)}, '-append', 'delimiter', '', 'roffset', 1); 
    dlmwrite(fullfile(DirName, NewFileName), {'Bin size,', 
num2str(BinSize)}, '-append', 'delimiter', ''); 
    dlmwrite(fullfile(DirName, NewFileName), {'Final resolution (bins/V),', 
num2str(SweepLengthBins/((MaxPot-MinPot)))}, '-append', 'delimiter', ''); 
    dlmwrite(fullfile(DirName, NewFileName), {'Vertex potential 1 (V),', 
num2str(Vertex1Pot)}, '-append', 'delimiter', ''); 
    dlmwrite(fullfile(DirName, NewFileName), {'Vertex potential 2 (V),', 
num2str(Vertex2Pot)}, '-append', 'delimiter', ''); 
    dlmwrite(fullfile(DirName, NewFileName), {'Calculated scan speed 
(V/s),', num2str(ScanSpeed)}, '-append', 'delimiter', ''); 
     
    dlmwrite(fullfile(DirName, NewFileName), 'Potential (V),Current (A)', 
'-append', 'delimiter', '', 'roffset', 1); % Write data headers 




% Seven more words to finish eights. 	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Appendix	  2:	  Mycobactin	  Masses	  for	  HRMS	  Screening	  
Table	  14:	  Carboxymycobactin	  masses.	  
ID	   C	   H	   N	   O	   Fe	  
C	  in	  Fatty	  
Acyl	   Unsat	  
Exact	  
Mass	   M	  +	  H+	  
M	  +	  H+	  
(Fe54)	  CM1	   28	   34	   5	   12	   1	   2	   0	   688.15533	   689.16261	   687.16728	  CM2	   29	   36	   5	   12	   1	   3	   0	   702.17098	   703.17826	   701.18293	  CM3	   30	   36	   5	   12	   1	   4	   1	   714.17098	   715.17826	   713.18293	  CM4	   30	   38	   5	   12	   1	   4	   0	   716.18663	   717.19391	   715.19858	  CM5	   31	   38	   5	   12	   1	   5	   1	   728.18663	   729.19391	   727.19858	  CM6	   31	   40	   5	   12	   1	   5	   0	   730.20228	   731.20956	   729.21423	  CM7	   32	   40	   5	   12	   1	   6	   1	   742.20228	   743.20956	   741.21423	  CM8	   32	   42	   5	   12	   1	   6	   0	   744.21793	   745.22521	   743.22988	  CM9	   33	   42	   5	   12	   1	   7	   1	   756.21793	   757.22521	   755.22988	  CM10	   33	   44	   5	   12	   1	   7	   0	   758.23358	   759.24086	   757.24553	  CM11	   34	   44	   5	   12	   1	   8	   1	   770.23358	   771.24086	   769.24553	  CM12	   34	   46	   5	   12	   1	   8	   0	   772.24923	   773.25651	   771.26118	  CM13	   35	   46	   5	   12	   1	   9	   1	   784.24923	   785.25651	   783.26118	  CM14	   35	   48	   5	   12	   1	   9	   0	   786.26488	   787.27216	   785.27683	  CM15	   36	   48	   5	   12	   1	   10	   1	   798.26488	   799.27216	   797.27683	  CM16	   36	   50	   5	   12	   1	   10	   0	   800.28053	   801.28781	   799.29248	  CM17	   37	   50	   5	   12	   1	   11	   1	   812.28053	   813.28781	   811.29248	  CM18	   37	   52	   5	   12	   1	   11	   0	   814.29618	   815.30346	   813.30813	  CM19	   38	   52	   5	   12	   1	   12	   1	   826.29618	   827.30346	   825.30813	  CM20	   38	   54	   5	   12	   1	   12	   0	   828.31183	   829.31911	   827.32378	  CM21	   39	   54	   5	   12	   1	   13	   1	   840.31183	   841.31911	   839.32378	  CM22	   39	   56	   5	   12	   1	   13	   0	   842.32748	   843.33476	   841.33943	  CM23	   40	   56	   5	   12	   1	   14	   1	   854.32748	   855.33476	   853.33943	  CM24	   40	   58	   5	   12	   1	   14	   0	   856.34313	   857.35041	   855.35508	  CM25	   41	   58	   5	   12	   1	   15	   1	   868.34313	   869.35041	   867.35508	  CM26	   41	   60	   5	   12	   1	   15	   0	   870.35878	   871.36606	   869.37073	  CM27	   42	   60	   5	   12	   1	   16	   1	   882.35878	   883.36606	   881.37073	  CM28	   42	   62	   5	   12	   1	   16	   0	   884.37443	   885.38171	   883.38638	  CM29	   43	   62	   5	   12	   1	   17	   1	   896.37443	   897.38171	   895.38638	  CM30	   43	   64	   5	   12	   1	   17	   0	   898.39009	   899.39736	   897.40203	  CM31	   44	   64	   5	   12	   1	   18	   1	   910.39009	   911.39736	   909.40203	  CM32	   44	   66	   5	   12	   1	   18	   0	   912.40574	   913.41301	   911.41768	  CM33	   45	   66	   5	   12	   1	   19	   1	   924.40574	   925.41301	   923.41768	  CM34	   45	   68	   5	   12	   1	   19	   0	   926.42139	   927.42866	   925.43333	  CM35	   46	   68	   5	   12	   1	   20	   1	   938.42139	   939.42866	   937.43333	  CM36	   46	   70	   5	   12	   1	   20	   0	   940.43704	   941.44431	   939.44898	  CM37	   47	   70	   5	   12	   1	   21	   1	   952.43704	   953.44431	   951.44898	  CM38	   47	   72	   5	   12	   1	   21	   0	   954.45269	   955.45996	   953.46463	  CM39	   48	   72	   5	   12	   1	   22	   1	   966.45269	   967.45996	   965.46463	  CM40	   48	   74	   5	   12	   1	   22	   0	   968.46834	   969.47561	   967.48028	  CM41	   49	   74	   5	   12	   1	   23	   1	   980.46834	   981.47561	   979.48028	  CM42	   49	   76	   5	   12	   1	   23	   0	   982.48399	   983.49126	   981.49593	  CM43	   50	   76	   5	   12	   1	   24	   1	   994.48399	   995.49126	   993.49593	  CM44	   50	   78	   5	   12	   1	   24	   0	   996.49964	   997.50691	   995.51158	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Table	  15:	  Mycobactin	  T	  masses.	  
ID	   C	   H	   N	   O	   Fe	  
C	  in	  Fatty	  
Acyl	   Unsat	  
Exact	  
Mass	   M	  +	  H+	  
M	  +	  H+	  
(Fe54)	  MT1	   29	   36	   5	   10	   1	   3	   1	   670.18115	   671.18843	   669.19310	  MT2	   29	   38	   5	   10	   1	   3	   0	   672.19680	   673.20408	   671.20875	  MT3	   30	   38	   5	   10	   1	   4	   1	   684.19680	   685.20408	   683.20875	  MT4	   30	   40	   5	   10	   1	   4	   0	   686.21246	   687.21973	   685.22440	  MT5	   31	   40	   5	   10	   1	   5	   1	   698.21246	   699.21973	   697.22440	  MT6	   31	   42	   5	   10	   1	   5	   0	   700.22811	   701.23538	   699.24005	  MT7	   32	   42	   5	   10	   1	   6	   1	   712.22811	   713.23538	   711.24005	  MT8	   32	   44	   5	   10	   1	   6	   0	   714.24376	   715.25103	   713.25570	  MT9	   33	   44	   5	   10	   1	   7	   1	   726.24376	   727.25103	   725.25570	  MT10	   33	   46	   5	   10	   1	   7	   0	   728.25941	   729.26668	   727.27135	  MT11	   34	   46	   5	   10	   1	   8	   1	   740.25941	   741.26668	   739.27135	  MT12	   34	   48	   5	   10	   1	   8	   0	   742.27506	   743.28233	   741.28700	  MT13	   35	   48	   5	   10	   1	   9	   1	   754.27506	   755.28233	   753.28700	  MT14	   35	   50	   5	   10	   1	   9	   0	   756.29071	   757.29798	   755.30265	  MT15	   36	   50	   5	   10	   1	   10	   1	   768.29071	   769.29798	   767.30265	  MT16	   36	   52	   5	   10	   1	   10	   0	   770.30636	   771.31363	   769.31830	  MT17	   37	   52	   5	   10	   1	   11	   1	   782.30636	   783.31363	   781.31830	  MT18	   37	   54	   5	   10	   1	   11	   0	   784.32201	   785.32928	   783.33395	  MT19	   38	   54	   5	   10	   1	   12	   1	   796.32201	   797.32928	   795.33395	  MT20	   38	   56	   5	   10	   1	   12	   0	   798.33766	   799.34493	   797.34960	  MT21	   39	   56	   5	   10	   1	   13	   1	   810.33766	   811.34493	   809.34960	  MT22	   39	   58	   5	   10	   1	   13	   0	   812.35331	   813.36058	   811.36526	  MT23	   40	   58	   5	   10	   1	   14	   1	   824.35331	   825.36058	   823.36526	  MT24	   40	   60	   5	   10	   1	   14	   0	   826.36896	   827.37623	   825.38091	  MT25	   41	   60	   5	   10	   1	   15	   1	   838.36896	   839.37623	   837.38091	  MT26	   41	   62	   5	   10	   1	   15	   0	   840.38461	   841.39188	   839.39656	  MT27	   42	   62	   5	   10	   1	   16	   1	   852.38461	   853.39188	   851.39656	  MT28	   42	   64	   5	   10	   1	   16	   0	   854.40026	   855.40753	   853.41221	  MT29	   43	   64	   5	   10	   1	   17	   1	   866.40026	   867.40753	   865.41221	  MT30	   43	   66	   5	   10	   1	   17	   0	   868.41591	   869.42318	   867.42786	  MT31	   44	   66	   5	   10	   1	   18	   1	   880.41591	   881.42318	   879.42786	  MT32	   44	   68	   5	   10	   1	   18	   0	   882.43156	   883.43883	   881.44351	  MT33	   45	   68	   5	   10	   1	   19	   1	   894.43156	   895.43883	   893.44351	  MT34	   45	   70	   5	   10	   1	   19	   0	   896.44721	   897.45448	   895.45916	  MT35	   46	   70	   5	   10	   1	   20	   1	   908.44721	   909.45448	   907.45916	  MT36	   46	   72	   5	   10	   1	   20	   0	   910.46286	   911.47013	   909.47481	  MT37	   47	   72	   5	   10	   1	   21	   1	   922.46286	   923.47013	   921.47481	  MT38	   47	   74	   5	   10	   1	   21	   0	   924.47851	   925.48578	   923.49046	  MT39	   48	   74	   5	   10	   1	   22	   1	   936.47851	   937.48578	   935.49046	  MT40	   48	   76	   5	   10	   1	   22	   0	   938.49416	   939.50143	   937.50611	  MT41	   49	   76	   5	   10	   1	   23	   1	   950.49416	   951.50143	   949.50611	  MT42	   49	   78	   5	   10	   1	   23	   0	   952.50981	   953.51708	   951.52176	  MT43	   50	   78	   5	   10	   1	   24	   1	   964.50981	   965.51708	   963.52176	  MT44	   50	   80	   5	   10	   1	   24	   0	   966.52546	   967.53273	   965.53741	  MT45	   51	   80	   5	   10	   1	   25	   1	   978.52546	   979.53273	   977.53741	  	  
